

**UNITED STATES DISTRICT COURT  
SOUTHERN DISTRICT OF NEW YORK**

In re:

PURDUE PHARMA L.P., *et al.*,  
BANKRUPTCY APPEALS

This Filing Relates to

ALL MATTERS

21 cv 7532 (CM)

21 cv 7585 (CM)

21 cv 7961 (CM)

21 cv 7962 (CM)

21 cv 7966 (CM)

21 cv 7969 (CM)

21 cv 8034 (CM)

21 cv 8042 (CM)

21 cv 8049 (CM)

21 cv 8055 (CM)

21 cv 8139 (CM)

21 cv 8258 (CM)

21 cv 8271 (CM)

21 cv 8548 (CM)

21 cv 8566 (CM)

On Appeal from the United  
States Bankruptcy Court for the  
Southern District of New York

**AD HOC COMMITTEE OF NAS CHILDREN'S APPENDIX**

**LEVENFELD PEARLSTEIN, LLC**

Harold D. Israel  
2 North LaSalle St., Suite 1300  
Chicago, Illinois 60602  
Telephone: 312-346-8380  
Facsimile: 312-346-8434  
hisrael@lplegal.com

**MARTZELL, BICKFORD & CENTOLA**

Scott R. Bickford (LA 1165)  
338 Lafayette Street  
New Orleans, LA 70130  
Telephone: 504-581-9065  
Facsimile: 504-581-7635  
sbickford@mbfirm.com

## TABLE OF CONTENTS

### **Bankruptcy Court Filings**

Schedules of Assets and Liabilities for Purdue Pharma L.P.....	NAS0001
NAS Ad Hoc Committee’s Limited Objection to Disclosure Statement and Solicitation Procedures Motion.....	NAS1583
Disclosure Statement for Fifth Amended Joint Chapter 11 Plan of Reorganization of Purdue Pharma L.P. and its Affiliated Debtors.....	NAS1683
Mediator’s Report .....	NAS2182
Final Declaration of Christina Pullo of Prime Clerk LLC Regarding the Solicitation of Votes and Tabulation of Ballots Cast on the Fifth Amended Joint Chapter 11 Plan of Reorganization of Purdue Pharma L.P. and its Affiliated Debtors.....	NAS2188
Declaration of Jesse DelConte .....	NAS2253
Declaration of Timothy J. Martin .....	NAS2323
Statement of the Raymond Sackler Family in Support of Confirmation of Debtors' Sixth Amended Plan of Reorganization and in Reply to Plan Objections .....	NAS3048
Declaration of Jonathan Greville White. ....	NAS3186
Modified Bench Ruling on Request for Confirmation of Eleventh Amended Joint Chapter 11 Plan .....	NAS3230
Declaration of Cheryl Juaire in Support of the Opposition of the Official Committee of Unsecured Creditors To Motions for Stay Pending Appeal .....	NAS3389
Declaration of Kara Trainor in Support of the Opposition of the Official Committee .....	NAS3399

### **Appeal Filings**

Memorandum in Support of Ad Hoc Committee of NAS Children’s Motion for Leave to Intervene as Appellee Pursuant to Rule 8013(g) of the Federal Rules of Bankruptcy Procedure .....	NAS3408
Order on the Pending Motions to Intervene by the Ad Hoc Committee of NAS Children, the Multi-State Government Entities Group, and the Ad Hoc Group of Individual Victims of Purdue Pharma L.P., et al.....	NAS3437
Brief of Appellant, William K. Harrington, United States Trustee .....	NAS3439

**Bankruptcy Court Transcripts**

August 23, 2021 Transcript of Proceedings.....NAS3510

November 9, 2021 Transcript of Proceedings .....NAS3898

# AJ Irrevocable Trust (1)

(\$ in Millions)	Total		Total
<b>Assets</b>		<b>Liabilities</b>	
Cash and Cash Equivalents	\$ 60.7	Accounts Payable	\$ -
Accounts Receivable and Prepaid Expenses	0.9	Long-Term Debt	-
Marketable Securities and Hedge Funds	752.1	Mortgage Debt	-
Independent Associated Companies (IAC's)	-	Short-Term Debt	-
Notes Receivable	64.6 (2)	Est. Tax Liability: IAC's	-
Other Investments	-	Est. Tax Liability: Unrealized Gains	64.2 (3)
Private Equity Investments	468.1		
Real Estate Investments	151.8	<b>Total Liabilities</b>	<b>\$ 64.2</b>
Residential Real Estate	-		
Life Insurance -Surrender Value	-	<b>Net Assets (Equity)</b>	<b>\$ 1,434.1</b>
Retirement Accounts	-		
Artwork (including Jewelry)	-	<b>Less: Net IACs</b>	<b>\$ -</b>
<b>Total Assets</b>	<b>\$ 1,498.3</b>	<b>Net Assets Excluding Net IACs</b>	<b>\$ 1,434.1</b>

(1) This page reflects the value of AJ Irrevocable Trust's beneficial interest in all assets (subject to any previously described adjustments), even where legal title is still held by 74-AJ Trust. See page 65, note (1) for further details.

(2) Includes \$107.2M due from Investment Trust which was reduced to \$64.6M in accordance with the previously described methodology.

(3) The hypothetical tax liability results from unrealized gains of \$194.5M.



# Additional Trusts That Directly and/or Indirectly Own Interests in IACs

# Beverly Sackler Trust 1 f/b/o David Alex Sackler 12/20/1989 ("Gallo Trust 1")

(\$ in Millions)	Total		Total
<b>Assets</b>		<b>Liabilities</b>	
Cash and Cash Equivalents	\$ 0.0	Accounts Payable	\$ -
Accounts Receivable and Prepaid Expenses	-	Long-Term Debt	-
Marketable Securities and Hedge Funds	-	Mortgage Debt	-
Independent Associated Companies (IAC's)	0.0	Short-Term Debt	-
Notes Receivable	-	Est. Tax Liability: IAC's	0.0
Other Investments	0.7 (1)	Est. Tax Liability: Unrealized Gains	-
Private Equity Investments	-		
Real Estate Investments	-	<b>Total Liabilities</b>	<b>\$ 0.0</b>
Residential Real Estate	-		
Life Insurance -Surrender Value	-	<b>Net Assets (Equity)</b>	<b>\$ 0.7</b>
Retirement Accounts	-		
Artwork (including Jewelry)	-	<b>Less: Net IACs</b>	<b>\$ (0.0)</b>
<b>Total Assets</b>	<b>\$ 0.7</b>	<b>Net Assets Excluding Net IACs</b>	<b>\$ 0.7</b>

(1) Includes an investment of \$1.0M to a non-Initial Covered Sackler Person which was reduced to \$0.7M in accordance with previously described methodology.

# Beverly Sackler Trust 2 f/b/o David Alex Sackler 12/20/1989 ("Gallo Trust 2")

(\$ in Millions)	Total		Total
<b>Assets</b>		<b>Liabilities</b>	
Cash and Cash Equivalents	\$ 0.0	Accounts Payable	\$ -
Accounts Receivable and Prepaid Expenses	-	Long-Term Debt	-
Marketable Securities and Hedge Funds	-	Mortgage Debt	-
Independent Associated Companies (IAC's)	-	Short-Term Debt	-
Notes Receivable	-	Est. Tax Liability: IAC's	-
Other Investments	2.5 (1)	Est. Tax Liability: Unrealized Gains	-
Private Equity Investments	-		
Real Estate Investments	-	<b>Total Liabilities</b>	<b>\$ -</b>
Residential Real Estate	-		
Life Insurance -Surrender Value	-	<b>Net Assets (Equity)</b>	<b>\$ 2.5</b>
Retirement Accounts	-		
Artwork (including Jewelry)	-	<b>Less: Net IACs</b>	<b>\$ -</b>
<b>Total Assets</b>	<b>\$ 2.5</b>	<b>Net Assets Excluding Net IACs</b>	<b>\$ 2.5</b>

(1) Includes \$2.5M investment in a non-Initial Covered Sackler Person.

# Beverly Sackler Trust 3 f/b/o David Alex Sackler 12/20/1989 ("Gallo Trust 3")

Pg 219 of 725

(\$ in Millions)	Total		Total
<b>Assets</b>		<b>Liabilities</b>	
Cash and Cash Equivalents	\$ 0.3	Accounts Payable	\$ -
Accounts Receivable and Prepaid Expenses	-	Long-Term Debt	-
Marketable Securities and Hedge Funds	-	Mortgage Debt	-
Independent Associated Companies (IAC's)	24.4	Short-Term Debt	-
Notes Receivable	-	Est. Tax Liability: IAC's	8.1
Other Investments	9.0 (1)	Est. Tax Liability: Unrealized Gains	-
Private Equity Investments	-		
Real Estate Investments	-	<b>Total Liabilities</b>	<b>\$ 8.1</b>
Residential Real Estate	-		
Life Insurance -Surrender Value	-	<b>Net Assets (Equity)</b>	<b>\$ 25.7</b>
Retirement Accounts	-		
Artwork (including Jewelry)	-	<b>Less: Net IACs</b>	<b>\$ (16.4)</b>
<b>Total Assets</b>	<b>\$ 33.7</b>	<b>Net Assets Excluding Net IACs</b>	<b>\$ 9.3</b>

(1) Includes an investment of \$27.0M to an investment in a non-Initial Covered Sackler Person, which was reduced to \$9.0M in accordance with previously described methodology.

NAS2541

# Other Trusts

# Richard S. Sackler Life Insurance Trust

19-23649-2 Doc-87322-EM 08/05/21 15:56 Filed 08/05/21 Page 14 of 71  
 Case 1:21-cv-00001 Document 1-1 Filed 08/05/21 Page 14 of 71

(\$ in Millions)	Total		Total
<b>Assets</b>		<b>Liabilities</b>	
Cash and Cash Equivalents	\$ 0.0	Accounts Payable	\$ -
Accounts Receivable and Prepaid Expenses	-	Long-Term Debt	-
Marketable Securities and Hedge Funds	-	Mortgage Debt	-
Independent Associated Companies (IAC's)	-	Short-Term Debt	-
Notes Receivable	-	Est. Tax Liability: IAC's	-
Other Investments	-	Est. Tax Liability: Unrealized Gains	-
Private Equity Investments	-		
Real Estate Investments	-	<b>Total Liabilities</b>	<b>\$ -</b>
Residential Real Estate	-		
Life Insurance -Surrender Value	1.2	<b>Net Assets (Equity)</b>	<b>\$ 1.2</b>
Retirement Accounts	-		
Artwork (including Jewelry)	-	<b>Less: Net IACs</b>	<b>\$ -</b>
<b>Total Assets</b>	<b>\$ 1.2</b>	<b>Net Assets Excluding Net IACs</b>	<b>\$ 1.2</b>

# Jonathan D. Sackler Life Insurance Trust

(\$ in Millions)	Total		Total
<b>Assets</b>		<b>Liabilities</b>	
Cash and Cash Equivalents	\$ 0.0	Accounts Payable	\$ -
Accounts Receivable and Prepaid Expenses	-	Long-Term Debt	-
Marketable Securities and Hedge Funds	-	Mortgage Debt	-
Independent Associated Companies (IAC's)	-	Short-Term Debt	-
Notes Receivable	-	Est. Tax Liability: IAC's	-
Other Investments	-	Est. Tax Liability: Unrealized Gains	-
Private Equity Investments	-		
Real Estate Investments	-	<b>Total Liabilities</b>	<b>\$ -</b>
Residential Real Estate	-		
Life Insurance -Surrender Value	2.6	<b>Net Assets (Equity)</b>	<b>\$ 2.6</b>
Retirement Accounts	-		
Artwork (including Jewelry)	-	<b>Less: Net IACs</b>	<b>\$ -</b>
<b>Total Assets</b>	<b>\$ 2.6</b>	<b>Net Assets Excluding Net IACs</b>	<b>\$ 2.6</b>

# Irrevocable Trust under Declaration dated as of September 19, 1995 f/b/o Issue of Richard S. Sackler

11-21-2023 11:04:57 AM Document ID: 15875666 Pg 223 of 725

(\$ in Millions)	Total		Total
<b>Assets</b>		<b>Liabilities</b>	
Cash and Cash Equivalents	\$ 0.0	Accounts Payable	\$ -
Accounts Receivable and Prepaid Expenses	-	Long-Term Debt	-
Marketable Securities and Hedge Funds	-	Mortgage Debt	-
Independent Associated Companies (IAC's)	-	Short-Term Debt	-
Notes Receivable	-	Est. Tax Liability: IAC's	-
Other Investments	1.3 (1)	Est. Tax Liability: Unrealized Gains	-
Private Equity Investments	-		
Real Estate Investments	-	<b>Total Liabilities</b>	<b>\$ -</b>
Residential Real Estate	-		
Life Insurance -Surrender Value	-	<b>Net Assets (Equity)</b>	<b>\$ 1.3</b>
Retirement Accounts	-		
Artwork (including Jewelry)	-	<b>Less: Net IACs</b>	<b>\$ -</b>
<b>Total Assets</b>	<b>\$ 1.3</b>	<b>Net Assets Excluding Net IACs</b>	<b>\$ 1.3</b>

(1) Includes \$1.3M investment in non-Initial Covered Sackler Person.



# David A. Sackler 2012 Trust

19-23649-2 Doc 87-22 Filed 08/05/21 Entered 08/05/21 15:28:38 Page 148  
 Case 7:21-cv-01514 Document 158-5 Filed 05/21/24 Page 148 of 224  
 Pg 224 of 725

(\$ in Millions)	Total		Total
<b>Assets</b>		<b>Liabilities</b>	
Cash and Cash Equivalents	\$ 0.1	Accounts Payable	\$ -
Accounts Receivable and Prepaid Expenses	-	Long-Term Debt	-
Marketable Securities and Hedge Funds	-	Mortgage Debt	-
Independent Associated Companies (IAC's)	-	Short-Term Debt	-
Notes Receivable	0.3 (1)	Est. Tax Liability: IAC's	-
Other Investments	-	Est. Tax Liability: Unrealized Gains	-
Private Equity Investments	0.4		
Real Estate Investments	-	<b>Total Liabilities</b>	<b>\$ -</b>
Residential Real Estate	-		
Life Insurance -Surrender Value	-	<b>Net Assets (Equity)</b>	<b>\$ 0.8</b>
Retirement Accounts	-		
Artwork (including Jewelry)	-	<b>Less: Net IACs</b>	<b>\$ -</b>
<b>Total Assets</b>	<b>\$ 0.8</b>	<b>Net Assets Excluding Net IACs</b>	<b>\$ 0.8</b>

(1) Includes an amount of \$0.5M due from David Sackler which was reduced to \$0.3M in accordance with the previously described methodology.

# Irrevocable Trust under Declaration dated as of April 25, 1991

(\$ in Millions)	Total		Total
<b>Assets</b>		<b>Liabilities</b>	
Cash and Cash Equivalents	\$ 0.2	Accounts Payable	\$ -
Accounts Receivable and Prepaid Expenses	-	Long-Term Debt	0.0
Marketable Securities and Hedge Funds	0.6	Mortgage Debt	-
Independent Associated Companies (IAC's)	-	Short-Term Debt	8.0
Notes Receivable	-	Est. Tax Liability: IAC's	-
Other Investments	-	Est. Tax Liability: Unrealized Gains	-
Private Equity Investments	0.0		
Real Estate Investments	-	<b>Total Liabilities</b>	<b>\$ 8.0</b>
Residential Real Estate	-		
Life Insurance -Surrender Value	-	<b>Net Assets (Equity)</b>	<b>\$ -</b>
Retirement Accounts	-		
Artwork (including Jewelry)	-	<b>Less: Net IACs</b>	<b>\$ -</b>
<b>Total Assets</b>	<b>\$ 0.8</b>	<b>Net Assets Excluding Net IACs</b>	<b>\$ -</b>

# Irrevocable Trust under Declaration dated as of August 25, 1992

(\$ in Millions)	Total		Total
<b>Assets</b>		<b>Liabilities</b>	
Cash and Cash Equivalents	\$ 4.4	Accounts Payable	\$ -
Accounts Receivable and Prepaid Expenses	-	Long-Term Debt	-
Marketable Securities and Hedge Funds	3.0	Mortgage Debt	-
Independent Associated Companies (IAC's)	-	Short-Term Debt	-
Notes Receivable	-	Est. Tax Liability: IAC's	-
Other Investments	-	Est. Tax Liability: Unrealized Gains	0.1 (1)
Private Equity Investments	-		
Real Estate Investments	-	<b>Total Liabilities</b>	<b>\$ 0.1</b>
Residential Real Estate	-		
Life Insurance -Surrender Value	-	<b>Net Assets (Equity)</b>	<b>\$ 7.3</b>
Retirement Accounts	-		
Artwork (including Jewelry)	-	<b>Less: Net IACs</b>	<b>\$ -</b>
<b>Total Assets</b>	<b>\$ 7.4</b>	<b>Net Assets Excluding Net IACs</b>	<b>\$ 7.3</b>

(1) The hypothetical tax liability results from unrealized gains of \$0.4M.

# The RSS 2012 Family Trust

19-23649-21 Doc 87822-EM Filed 08/05/21 Entered 08/05/21 14:28:38 Page 148  
Pg 227 of 725

(\$ in Millions)	Total		Total
<b>Assets</b>		<b>Liabilities</b>	
Cash and Cash Equivalents	\$ 3.5	Accounts Payable	\$ -
Accounts Receivable and Prepaid Expenses	-	Long-Term Debt	-
Marketable Securities and Hedge Funds	1.1	Mortgage Debt	-
Independent Associated Companies (IAC's)	-	Short-Term Debt	-
Notes Receivable	-	Est. Tax Liability: IAC's	-
Other Investments	-	Est. Tax Liability: Unrealized Gains	0.0 (1)
Private Equity Investments	0.4		
Real Estate Investments	2.0	<b>Total Liabilities</b>	<b>\$ 0.0</b>
Residential Real Estate	-		
Life Insurance -Surrender Value	-	<b>Net Assets (Equity)</b>	<b>\$ 6.9</b>
Retirement Accounts	-		
Artwork (including Jewelry)	-	<b>Less: Net IACs</b>	<b>\$ -</b>
<b>Total Assets</b>	<b>\$ 7.0</b>	<b>Net Assets Excluding Net IACs</b>	<b>\$ 6.9</b>

(1) The hypothetical tax liability results from unrealized gains of \$0.1M.

# Raymond R. Sackler Credit Shelter Trust u/a 3/29/2012

(\$ in Millions)	Total		Total
<b>Assets</b>		<b>Liabilities</b>	
Cash and Cash Equivalents	\$ 0.1	Accounts Payable	\$ -
Accounts Receivable and Prepaid Expenses	-	Long-Term Debt	-
Marketable Securities and Hedge Funds	-	Mortgage Debt	-
Independent Associated Companies (IAC's)	-	Short-Term Debt	-
Notes Receivable	-	Est. Tax Liability: IAC's	-
Other Investments	-	Est. Tax Liability: Unrealized Gains	-
Private Equity Investments	-		
Real Estate Investments	-	<b>Total Liabilities</b>	<b>\$ -</b>
Residential Real Estate	-		
Life Insurance -Surrender Value	-	<b>Net Assets (Equity)</b>	<b>\$ 0.1</b>
Retirement Accounts	-		
Artwork (including Jewelry)	-	<b>Less: Net IACs</b>	<b>\$ -</b>
<b>Total Assets</b>	<b>\$ 0.1</b>	<b>Net Assets Excluding Net IACs</b>	<b>\$ 0.1</b>

# Raymond R. Sackler GST Exempt Marital Trust u/a 3/29/2012

(\$ in Millions)	Total		Total
<b>Assets</b>		<b>Liabilities</b>	
Cash and Cash Equivalents	\$ 8.6	Accounts Payable	\$ -
Accounts Receivable and Prepaid Expenses	-	Long-Term Debt	-
Marketable Securities and Hedge Funds	2.0	Mortgage Debt	-
Independent Associated Companies (IAC's)	-	Short-Term Debt	-
Notes Receivable	-	Est. Tax Liability: IAC's	-
Other Investments	-	Est. Tax Liability: Unrealized Gains	0.2 (1)
Private Equity Investments	4.6		
Real Estate Investments	-	<b>Total Liabilities</b>	<b>\$ 0.2</b>
Residential Real Estate	-		
Life Insurance -Surrender Value	-	<b>Net Assets (Equity)</b>	<b>\$ 15.0</b>
Retirement Accounts	-		
Artwork (including Jewelry)	-	<b>Less: Net IACs</b>	<b>\$ -</b>
<b>Total Assets</b>	<b>\$ 15.3</b>	<b>Net Assets Excluding Net IACs</b>	<b>\$ 15.0</b>

(1) The hypothetical tax liability results from unrealized gains of \$0.8M.

# Appendix A: Entities

# Rosebay Medical Company L.P.

19-23649-2 Doc-87822-EM-08/05/21 15:56 Filed 08/05/21 Page 20 of 725  
 19-23649-2 Doc-87822-EM-08/05/21 15:56 Filed 08/05/21 Page 20 of 725

(\$ in Millions)	Total		Total
<b>Assets</b>		<b>Liabilities</b>	
Cash and Cash Equivalents	\$ 39.1	Accounts Payable	\$ 0.6
Accounts Receivable and Prepaid Expenses	0.0	Long-Term Debt	39.0 (4)
Marketable Securities and Hedge Funds	0.0	Mortgage Debt	-
Independent Associated Companies (IAC's)	552.9	Short-Term Debt	-
Notes Receivable	- (1)	Est. Tax Liability: IAC's	182.5
Other Investments	0.0 (2)	Est. Tax Liability: Unrealized Gains	-
Private Equity Investments	7.8		
Real Estate Investments	- (3)	<b>Total Liabilities</b>	<b>\$ 222.1</b>
Residential Real Estate	-		
Life Insurance -Surrender Value	-	<b>Net Assets (Equity)</b>	<b>\$ 377.8</b>
Retirement Accounts	-		
Artwork (including Jewelry)	-	<b>Less: Net IACs</b>	<b>\$ (370.5)</b>
<b>Total Assets</b>	<b>\$ 599.9</b>	<b>Net Assets Excluding Net IACs</b>	<b>\$ 7.4</b>

(1) \$7.8M was reclassified from Notes Receivable to IAC's.

(2) \$0.0M other investment is in a non-Initial Covered Sackler Person.

(3) A real estate investment of -\$0.2 was restated to zero.

(4) \$21.0M is due to 74A Trust and \$18.0M is due to Rosebay Medical Company Inc. (see pages 23 and 77 of November 22 Presentation respectively).

NAS2553

PROFESSIONALS' EYES ONLY/HIGHLY CONFIDENTIAL—SUBJECT TO PROPOSED PROTECTIVE ORDER AND FRE 408

This presentation may only be viewed by the professionals identified on page 2, and it may not be shared.



(\$ in Millions)	Total		Total
<b>Assets</b>		<b>Liabilities</b>	
Cash and Cash Equivalents	\$ 0.2	Accounts Payable	\$ -
Accounts Receivable and Prepaid Expenses	-	Long-Term Debt	-
Marketable Securities and Hedge Funds	-	Mortgage Debt	-
Independent Associated Companies (IAC's)	11.1	Short-Term Debt	-
Notes Receivable	18.0 (1)	Est. Tax Liability: IAC's	3.6
Other Investments	-	Est. Tax Liability: Unrealized Gains	-
Private Equity Investments	-		
Real Estate Investments	-	<b>Total Liabilities</b>	<b>\$ 3.6</b>
Residential Real Estate	-		
Life Insurance -Surrender Value	-	<b>Net Assets (Equity)</b>	<b>\$ 25.6</b>
Retirement Accounts	-		
Artwork (including Jewelry)	-	<b>Less: Net IACs</b>	<b>\$ (7.4)</b>
<b>Total Assets</b>	<b>\$ 29.3</b>	<b>Net Assets Excluding Net IACs</b>	<b>\$ 18.2</b>

(1) Relates to an amount due from Rosebay Medical Company LP (see page 75 in November 22 Presentation).

(\$ in Millions)	Total		Total
<b>Assets</b>		<b>Liabilities</b>	
Cash and Cash Equivalents	\$ -	Accounts Payable	\$ -
Accounts Receivable and Prepaid Expenses	-	Long-Term Debt	-
Marketable Securities and Hedge Funds	-	Mortgage Debt	-
Independent Associated Companies (IAC's)	-	Short-Term Debt	-
Notes Receivable	-	Est. Tax Liability: IAC's	-
Other Investments	-	Est. Tax Liability: Unrealized Gains	-
Private Equity Investments	-		
Real Estate Investments	-	<b>Total Liabilities</b>	<b>\$ -</b>
Residential Real Estate	-		
Life Insurance -Surrender Value	-	<b>Net Assets (Equity)</b>	<b>\$ -</b>
Retirement Accounts	-		
Artwork (including Jewelry)	-	<b>Less: Net IACs</b>	<b>\$ -</b>
<b>Total Assets</b>	<b>\$ -</b>	<b>Net Assets Excluding Net IACs</b>	<b>\$ -</b>

(\$ in Millions)	Total		Total
<b>Assets</b>		<b>Liabilities</b>	
Cash and Cash Equivalents	\$ -	Accounts Payable	\$ -
Accounts Receivable and Prepaid Expenses	-	Long-Term Debt	-
Marketable Securities and Hedge Funds	-	Mortgage Debt	-
Independent Associated Companies (IAC's)	-	Short-Term Debt	-
Notes Receivable	-	Est. Tax Liability: IAC's	-
Other Investments	-	Est. Tax Liability: Unrealized Gains	-
Private Equity Investments	-		
Real Estate Investments	-	<b>Total Liabilities</b>	<b>\$ -</b>
Residential Real Estate	-		
Life Insurance -Surrender Value	-	<b>Net Assets (Equity)</b>	<b>\$ -</b>
Retirement Accounts	-		
Artwork (including Jewelry)	-	<b>Less: Net IACs</b>	<b>\$ -</b>
<b>Total Assets</b>	<b>\$ -</b>	<b>Net Assets Excluding Net IACs</b>	<b>\$ -</b>

(\$ in Millions)	Total		Total
<b>Assets</b>		<b>Liabilities</b>	
Cash and Cash Equivalents	\$ -	Accounts Payable	\$ -
Accounts Receivable and Prepaid Expenses	-	Long-Term Debt	-
Marketable Securities and Hedge Funds	-	Mortgage Debt	-
Independent Associated Companies (IAC's)	-	Short-Term Debt	-
Notes Receivable	-	Est. Tax Liability: IAC's	-
Other Investments	-	Est. Tax Liability: Unrealized Gains	-
Private Equity Investments	-		
Real Estate Investments	-	<b>Total Liabilities</b>	<b>\$ -</b>
Residential Real Estate	-		
Life Insurance -Surrender Value	-	<b>Net Assets (Equity)</b>	<b>\$ -</b>
Retirement Accounts	-		
Artwork (including Jewelry)	-	<b>Less: Net IACs</b>	<b>\$ -</b>
<b>Total Assets</b>	<b>\$ -</b>	<b>Net Assets Excluding Net IACs</b>	<b>\$ -</b>

(\$ in Millions)	Total		Total
<b>Assets</b>		<b>Liabilities</b>	
Cash and Cash Equivalents	\$ -	Accounts Payable	\$ -
Accounts Receivable and Prepaid Expenses	-	Long-Term Debt	-
Marketable Securities and Hedge Funds	-	Mortgage Debt	-
Independent Associated Companies (IAC's)	-	Short-Term Debt	-
Notes Receivable	-	Est. Tax Liability: IAC's	-
Other Investments	-	Est. Tax Liability: Unrealized Gains	-
Private Equity Investments	-		
Real Estate Investments	-	<b>Total Liabilities</b>	<b>\$ -</b>
Residential Real Estate	-		
Life Insurance -Surrender Value	-	<b>Net Assets (Equity)</b>	<b>\$ -</b>
Retirement Accounts	-		
Artwork (including Jewelry)	-	<b>Less: Net IACs</b>	<b>\$ -</b>
<b>Total Assets</b>	<b>\$ -</b>	<b>Net Assets Excluding Net IACs</b>	<b>\$ -</b>

## Appendix B: General Description of Categories

# General Description of Asset Categories

Category	General Description
Cash and Cash Equivalents	Deposits and money market mutual funds.
Accounts Receivable and Prepaid Expenses	Tax refunds receivable, receivables from hedge fund redemptions, and prepaid expenses.
Notes Receivable and Loans	Debt financing in the form of notes and loans.
Independent Associated Companies (IACs)	Direct and indirect investments in II-way non-U.S. based pharmaceutical and health related assets, not including investments in joint-ventures.
Marketable Securities and Hedge Funds	Investments made directly or through various pooling investment vehicles investing in stocks, other marketable securities and hedge funds managed by either a third-party manager or family office.
Private Equity Investments	Investments made directly or indirectly in private companies, private equity funds, venture funds, joint ventures or private credit funds managed by either a third-party manager or family office.

# General Description of Asset Categories (cont'd)

Category	General Description
Real Estate Investments	Investments made directly or through various pooling investment vehicles in real estate managed either by a third-party manager or family office.
Life Insurance - Surrender Value	Cash surrender value of life insurance policies.
Retirement Accounts	IRA, 401(k) or other similar type of account.
Residential Real Estate	Direct or indirect ownership in residential real estate held principally for the purpose of inhabitation.
Artwork (including Jewelry)	Paintings, jewelry, and other collectibles.
Other Investments	Investments made directly or indirectly that either fall into multiple categories or do not fall into reported categories.
Net IACs	IACs less Est. Tax Liability: IAC



# General Description of Liability Categories

Category	General Description
Accounts Payable	Money owed for services provided.
Short-Term Debt	Note payable that has a maturity of less than 12 months.
Long-Term Debt	Note payable that has a maturity of greater than 12 months.
Mortgage Debt	A long-term loan used to finance the purchase of residential real estate.
Est. Tax Liability: IAC	For illustrative and directional purposes only, the liability reflects a 33% tax obligation applied to the value of each entity's interest in IACs.
Est. Tax Liability: Unrealized Gains	For illustrative and directional purposes only, the liability reflects a 33% tax obligation on the unrealized gains related to the estimated unrealized gains associated with assets on the balance sheet.

## Appendix C: Attestation of Timothy J. Martin

UNITED STATES BANKRUPTCY COURT  
SOUTHERN DISTRICT OF NEW YORK

In re:

PURDUE PHARMA L.P., *et al.*,  
  
Debtors.

Chapter 11

Case No. 19-23649 (RDD)  
  
(Jointly Administered)

**ATTESTATION OF TIMOTHY J. MARTIN WITH RESPECT TO  
RAYMOND SACKLER-SIDE NET ASSETS REPORT**

I, Timothy J. Martin, hereby attest that the following is true to the best of my knowledge, information and belief:

**Qualifications**

1. I am a managing director at Huron Consulting Services LLC (“Huron”), which was founded in 2002 and whose parent, Huron Consulting Group Inc. (“Huron Consulting Group”), is publicly traded on the NASDAQ Global Select Market under the symbol “HURN”. Huron Consulting Group and its subsidiaries employ in excess of 3,000 full time employees in offices across the United States, including in Chicago, New York, and Boston, and abroad in Canada, India, Singapore, Switzerland, and the United Kingdom. Huron Consulting Group and its subsidiaries provide a range of professional services primarily through three operating segments: healthcare, business advisory, and education.

2. I have more than two decades of experience providing forensic, investigative and financial advisory consulting services to companies, boards of directors, creditors, equity holders and the legal community. I have been engaged by trustees and receivers in bankruptcy cases to conduct investigations into some of the largest known frauds, including Ponzi and pyramid schemes, securities fraud, fraudulent conveyances and financial statement fraud. I am

a Certified Insolvency and Restructuring Advisor (CIRA), Certified Turnaround Professional (CTP) and Certified Fraud Examiner (CFE).

**Compensation Disclosure**

3. Huron has been retained by Milbank LLP and Joseph Hage Aaronson LLC in their capacity as counsel to the Raymond-side Initial Covered Sackler Persons,<sup>1</sup> including Rosebay Medical Company L.P. (“RMLP”). Huron is being compensated for its work on this matter at its standard hourly rates. No part of Huron’s compensation is presently contingent on any particular outcome or resolution of this matter.

**Scope of Report**

4. On November 5, 2019, Purdue Pharma L.P. and certain of its affiliates that are debtors in possession in the above-captioned chapter 11 cases (collectively, the “Debtors”), the Official Committee of Unsecured Creditors Committee appointed in the Debtors’ chapter 11 cases (the “UCC”), Beacon Company and RMLP entered into that certain *Amended and Restated Case Stipulation Among the Debtors, the Official Committee of Unsecured Creditors and Certain Related Parties* (the “Amended Stipulation”) [Docket No. 518].

5. The Amended Stipulation contemplates that the Shareholder Parties will provide the following to the legal and financial advisors to the Debtors and the UCC:

- (i) a report setting forth the net assets of the Initial Covered Sackler Persons, which report will set forth the approximate aggregate value of the assets owned by category (e.g., cash, securities, real estate, private and other investments, etc.) and the approximate liabilities, also by category, and
- (ii) an attestation from a responsible person or independent third party as to the accuracy of the report.

<sup>1</sup> All capitalized terms used herein that are not otherwise defined shall have the meanings ascribed to them in the Amended Stipulation (as defined below).

See Amended Stipulation ¶ 17(a).

6. Huron prepared a report with respect to each Raymond-side Initial Covered Sackler Persons (the “Net Assets Report”). This attestation is annexed to the Net Asset Report as Appendix C.

#### **Information Considered**

7. I, or others working under my direction, received from North Bay Associates (“North Bay”) balance sheets as of October 31, 2019 relating to the forty-seven Raymond-side Initial Covered Sackler Persons set forth on Schedule A. It has been represented to Huron by North Bay that these balance sheets were prepared by North Bay in the ordinary course of business and that these balance sheets represent all of the Initial Covered Sackler Persons as prepared by North Bay.

8. North Bay does not, in the ordinary course of business, prepare balance sheets relating to thirteen of the Raymond-side Initial Covered Sackler Persons, which are described below:

- (i) For six of such Initial Covered Sackler Persons,<sup>2</sup> Huron obtained the values of their respective assets and liabilities through discussion with North Bay and review of available records which are reflected in the Net Assets Report.
- (ii) For six of such Initial Covered Sackler Persons,<sup>3</sup> North Bay provided Huron with balance sheets prepared by a third party.

<sup>2</sup> These six Initial Covered Sackler Persons are: the RSS Revocable Pourover Trust; JDS Revocable Pourover Trust; Trust under Declaration of Trust dated August 23, 1988 f/b/o Richard S. Sackler and Issue of Richard S. Sackler; Trust under Declaration of Trust dated December 17, 1991 f/b/o Richard S. Sackler and Issue of Richard S. Sackler; Trust under Declaration of Trust dated August 23, 1988 f/b/o Jonathan D. Sackler and Issue of Jonathan D. Sackler; and Trust under Declaration of Trust dated December 17, 1991 f/b/o Jonathan D. Sackler and Issue of Jonathan D. Sackler.

<sup>3</sup> These six Initial Covered Sackler Persons are: RSS Fiduciary Management Trust, Crystal Trust, MCM Fiduciary Management Trust, Data Trust, Cornice Trust, and Cedar Cliff Trust, all of which were formed to hold interests in Wyoming entities that serve as trustees for certain Raymond-side trusts. Balance sheets for these Wyoming entities were collected by North Bay and provided to Huron.

- (iii) For the remaining Initial Covered Sackler Person,<sup>4</sup> Huron ascertained the values of its respective assets and liabilities by reviewing its balance sheet.

9. North Bay also provided additional contextual information, through written and oral communications, relating to the information described in paragraphs 7 and 8 (such contextual information, together with the information described in paragraphs 7 and 8, the “Balance Sheet Information”). The Balance Sheet Information constitutes the entire set of information relied on by Huron in preparing the Net Assets Report, except as described in paragraph 14 below.

10. Huron has, for the purpose of the Net Assets Report, placed each asset referenced in the Balance Sheet Information into one of the following categories based on information provided by North Bay:

- (i) Cash and Cash Equivalents: Deposits and money market mutual funds.
- (ii) Accounts Receivable and Prepaid Expenses: Tax refunds receivable, receivables from hedge fund redemptions, and prepaid expenses.
- (iii) Notes Receivable and Loans: Debt financing in the form of notes and loans.
- (iv) Independent Associated Companies (IACs): Direct and indirect investments in II-way non-U.S. based pharmaceutical and health related assets, not including investments in joint-ventures.
- (v) Marketable Securities and Hedge Funds: Investments made directly or through various pooling investment vehicles investing in stocks, other marketable securities and hedge funds managed by either a third-party manager or family office.
- (vi) Private Equity Investments: Investments made directly or indirectly in private companies, private equity funds, venture funds, joint ventures or private credit funds managed by either a third-party manager or family office.

<sup>4</sup> The remaining one such Initial Covered Sackler Person is the DABB Trust.

- (vii) Real Estate Investments: Investments made directly or through various pooling investment vehicles in real estate managed either by a third-party manager or family office.
- (viii) Life Insurance - Surrender Value: Cash surrender value of life insurance policies.
- (ix) Retirement Accounts: IRA, 401(k) or other similar type of account.
- (x) Residential Real Estate: Direct or indirect ownership in residential real estate held principally for the purpose of inhabitation.
- (xi) Artwork (including Jewelry): Paintings, jewelry, and other collectibles.
- (xii) Other Investments: Investments made directly or indirectly that either fall into multiple categories or do not fall into reported categories.

11. Huron has, also for the purpose of the Net Asset Report, placed each liability referenced in the Balance Sheet Information into one of the following categories based on information provided by North Bay:

- (i) Accounts Payable: Money owed for services provided.
- (ii) Short-Term Debt: Note payable that has a maturity of less than 12 months.
- (iii) Long-Term Debt: Note payable that has a maturity of greater than 12 months.
- (iv) Mortgage Debt: A long-term loan used to finance the purchase of residential real estate.

12. If a balance sheet line item represented an interest in a holding company, Huron classified the asset consistent with its underlying investment. For example, several of the Initial Covered Sackler Persons have an interest in a Delaware general partnership that serves as a vehicle for making investments. This entity holds various private equity, hedge fund, and marketable securities investments. For presentation purposes, each Initial Covered Sackler Person's interest in this entity was classified consistent with its underlying assets.

13. It was necessary to create a category for "Other Investments" because the character of certain investments were not able to be easily classified using another enumerated category, particularly in cases where an asset is a holding company that holds many different types of investments (for which investment detail was not readily available) or a service provider such as North Bay. For each Initial Covered Sackler Person, descriptions for each asset classified as Other Investments are provided throughout.

14. The value of the net assets as presented in the Net Assets Report for each of the Raymond-side Initial Covered Sackler Persons is consistent with the value of its underlying net assets as set forth in the Balance Sheet Information relating to the applicable Initial Covered Sackler Person, with the following exceptions to more appropriately reflect the value of those net assets:

- (i) The values of assets reflecting direct or indirect ownership in the Debtors were eliminated from the Net Assets Report, such as RMLP's indirect interest in the Debtors.
- (ii) Where a more representative realizable value of an asset was available (e.g., third-party appraisal, tax assessment, oil and gas reserve report, etc.) the balance sheet value of the asset was adjusted to that amount and the adjustment was disclosed in the notes for the relevant Initial Covered Sackler Person.
- (iii) Illustrative values were substituted for the balance sheet values related to the IACs, all of which IACs are contemplated to be sold under the settlement framework set out in the *Summary Term Sheet with Ad Hoc Committee* filed by the Debtors (the "Proposed Settlement Framework") [Docket No. 257]. An illustrative aggregate value of \$4.5 billion is ascribed to the IACs and value is allocated among the various IACs according to their respective management's projections for the years 2020 – 2024 using the methodology described in the "Allocation of Independent Associated Companies" section of the Net Assets Report. Applying an illustrative blended tax rate of 33% to the aggregate value of the IACs, the sale of the IACs generates \$3 billion in net proceeds, which is the amount guaranteed under the Proposed Settlement Framework. Neither the \$4.5 billion aggregate value nor the 33% blended tax rate are projections of

actual value or tax liability; they are applied solely for illustrative purposes.<sup>5</sup>

- (iv) In instances where the net asset value for an Initial Covered Sackler Person would otherwise be negative (a “Obligor Person”), the net asset would be adjusted to zero. Where an Obligor Person’s net asset value was negative in part due to debt owed to other Initial Covered Sackler Persons (each an “Obligee Person”), for the purpose of this presentation, the value of the assets of the Obligee Person are reduced by the amount by which the face amount of the debt in question exceeded the assets of the Obligor Person. This was done to reflect the net recoverable value relating to the debt. For example, if liabilities exceeded assets for an Obligor Person by \$50 and the Obligor Person has a \$100 note payable to an Obligee Person, the net assets of the Obligor Person would be reflected as \$0.0 and the value of the Obligee Person’s note receivable would be reduced by \$50, thus balancing in the aggregate. In one case, where an Obligor Person had issued both secured and unsecured debt, the associated asset of the Obligor Person was reduced before the secured debt.
- (v) Certain of the balance sheets prepared for individual Initial Covered Sackler Persons by North Bay in the ordinary course of business include line items in the asset column relating to trusts that are themselves Initial Covered Sackler Persons. The net asset values of such trusts are not reflected as assets of such individuals, but are instead presented independently, consistent with the presentation of Initial Covered Sackler Persons generally.
- (vi) Solely in instances where a third party provides an estimate or statement of value (such assets, “Third-Party Valued Assets”), “unrealized gain/loss” refers to the difference between that value and the tax basis of the Third-Party Valued Asset in question. An illustrative 33% blended tax rate (for presentation purposes only) was applied to the estimated unrealized gains to illustrate the hypothetical tax obligation that would result from a sale of such Third-Party Valued Assets.

15. Although Huron expresses no opinion with respect to the value of any specific asset, Huron believes that with the adjustments made, excluding the value ascribed to the IAC’s which was done for illustrative purposes only, the Net Assets Report represents a reasonable approach to approximate the total net asset values of the Raymond-side Initial Covered Sackler

<sup>5</sup> In many cases, Initial Covered Sackler Person’s interests in IAC are held through interests in I-way holding companies. Where an entity reflected on an Initial Covered Sackler Person’s balance directly or indirectly held interests in IACs in addition to other assets, North Bay provided to Huron a description of the assets and liabilities not associated with the IACs.

Persons. The Net Asset Report is not intended to estimate the proceeds that would be realized from a forced sale of underlying assets.

16. To the extent Huron discovers any information that would lead it to conclude that presentation made in the Net Asset Report were materially inaccurate as of the date of this attestation, Huron will promptly supplement the Net Asset Report accordingly and provide such supplemented report to the parties to the Amended Stipulation.

  
Timothy J. Martin  
Managing Director  
Huron Consulting Services LLC

# Appendix D: Attestation of Stephen A. Ives



UNITED STATES BANKRUPTCY COURT  
SOUTHERN DISTRICT OF NEW YORK

In re:

PURDUE PHARMA L.P., *et al.*,  
  
Debtors.

Chapter 11

Case No. 19-23649 (RDD)  
  
(Jointly Administered)

**ATTESTATION OF STEPHEN A. IVES WITH RESPECT TO  
RAYMOND SACKLER-SIDE NET ASSETS REPORT**

I, Stephen A. Ives, hereby attest that the following is true to the best of my knowledge,  
information and belief:

**Background and Qualifications**

1. I am the vice president of North Bay Associates (“North Bay”). North Bay provides tax and accounting services to members of the Raymond Sackler family, trusts established for their benefit and certain entities directly or indirectly owned by such family members or trusts.

2. I supervise all accountants and others who provide services through North Bay Associates. I have served in this capacity for over 25 years.

3. Since 1975, I have been a certified public accountant and I am in good standing with the accounting licensing authority in Oklahoma.

**Huron’s Report**

4. On November 5, 2019, Purdue Pharma L.P. and certain of its affiliates that are debtors in possession in the above-captioned chapter 11 cases (collectively, the “Debtors”), the Official Committee of Unsecured Creditors Committee appointed in the Debtors’ chapter 11 cases (the “UCC”), Beacon Company and Rosebay Medical Company L.P. entered into that certain

*Amended and Restated Case Stipulation Among the Debtors, the Official Committee of Unsecured Creditors and Certain Related Parties* (the “Amended Stipulation”) [Docket No. 518].

5. The Amended and Restated Stipulation contemplates that the Shareholder Parties will provide the following to the legal and financial advisors to the Debtors and the UCC:

- (i) a report setting forth the net assets of the Initial Covered Sackler Persons,<sup>1</sup> which report will set forth the approximate aggregate value of the assets owned by category (e.g., cash, securities, real estate, private and other investments, etc.) and the approximate liabilities, also by category, and
- (ii) an attestation from a responsible person or independent third party as to the accuracy of the report.

*See Amended Stipulation*, ¶ 17(a).

6. Huron Consulting Services, LLC (“Huron”) has prepared a report with respect to each of the Raymond-side Initial Covered Sackler Persons (the “Net Assets Report”). North Bay assisted Huron in the preparation of the Net Assets Report by providing the information on which the Net Assets Report is based, as described herein. This attestation is annexed to the Net Asset Report as Appendix D.

**Information Provided**

7. In connection with providing the services described above, North Bay, in the ordinary course of business, maintains the books and records of, and prepares monthly financial statements relating to, each of the Initial Covered Sackler Persons set forth on Schedule A attached hereto. Generally, the balance sheets present the assets as follows:

- (i) Cash and Cash Equivalents: Book but reconciled to account statement balances.
- (ii) Accounts Receivable and Prepaid Investments: Expected receivables and amounts paid.

<sup>1</sup> All capitalized terms used herein that are not otherwise defined shall have the meanings ascribed to them in the Amended Stipulation.



- (iii) Notes Receivable and Loans: Principal amounts outstanding.
- (iv) Marketable Securities and Hedge Funds: Closing prices for publicly-traded securities, valuations provided by fund managers or, in the absence of the foregoing, tax bases (e.g., cost bases).
- (v) Private Equity Investments: Valuations provided by fund managers, when available. Otherwise tax bases.
- (vi) Real Estate Investments: Valuations provided by fund managers, when available; otherwise, tax bases.
- (vii) Life Insurance – Surrender Value: Statement balances.
- (viii) Retirement Accounts: Statement balances.
- (ix) Residential Real Estate: Tax bases.
- (x) Artwork: Cost.
- (xi) Other Investments: Tax bases.

8. Generally, the balance sheets present the liabilities as follows:

- (i) Accounts Payable: Actual amounts owed and expected payments.
- (ii) Short-Term Debt: Principal amounts outstanding.
- (iii) Long-Term Debt: Principal amounts outstanding.
- (iv) Mortgage Debt: Principal amounts outstanding.

9. In connection with Huron's preparation of the Net Assets Report, North Bay provided to Huron forty-seven balance sheets as of October 31, 2019 relating to the Initial Covered Sackler Persons. These balance sheets were prepared in the ordinary course of business consistent with past practices, i.e., in the manner described in paragraph 7 above. None of the balance sheets provided to Huron were altered for the purposes of the Net Assets Report. The balance sheets are the most recent available as of the date hereof and, to the best of my knowledge,

accurately present the assets and liabilities of each of the applicable Initial Covered Sackler Persons as of the above-mentioned date.

10. To the best of my knowledge, there are no material transactions that have not been properly recorded in the accounting records underlying the balance sheets.

11. I have no knowledge of any error, fraud or suspected error or fraud where the fraud or error could have a material effect on the balance sheets.

12. North Bay does not, in the ordinary course of business, prepare balance sheets relating to thirteen of the Initial Covered Sackler Persons, which consist of:

- (i) Two trusts,<sup>2</sup> whose assets are reflected on the balance sheets of their respective beneficiaries;
- (ii) Four trusts,<sup>3</sup> whose only assets are remainder interests in residential real estate;
- (iii) Six trusts,<sup>4</sup> whose only assets are interests in companies that serve as trustees for other Raymond-side trusts, the books and records of which companies are maintained by a Wyoming service company;
- (iv) One trust,<sup>5</sup> whose only assets are real estate investments.

13. In connection with Huron's preparation of the Net Assets Report, North Bay collected and provided to Huron, in addition to the balance sheets described at paragraph 9 above, balance sheets prepared by third persons, as well as valuation assessments from public bodies.

<sup>2</sup> These two Initial Covered Sackler Persons are: the RSS Revocable Pourover Trust and JDS Revocable Pourover Trust.

<sup>3</sup> These four Initial Covered Sackler Persons are: the Trust under Declaration of Trust dated August 23, 1988 f/b/o Richard S. Sackler and Issue of Richard S. Sackler; Trust under Declaration of Trust dated December 17, 1991 f/b/o Richard S. Sackler and Issue of Richard S. Sackler; Trust under Declaration of Trust dated August 23, 1988 f/b/o Jonathan D. Sackler and Issue of Jonathan D. Sackler; and Trust under Declaration of Trust dated December 17, 1991 f/b/o Jonathan D. Sackler and Issue of Jonathan D. Sackler.

<sup>4</sup> These six Initial Covered Sackler Persons are: the RSS Fiduciary Management Trust, Crystal Trust, MCM Fiduciary Management Trust, Data Trust, Cornice Trust and the Cedar Cliff Trust.

<sup>5</sup> This Initial Covered Sackler Person is: the DABB Trust.

14. In connection with Huron's preparation of the Net Assets Report, North Bay also provided Huron with the following information prepared by third parties relating to the Initial Covered Sackler Persons:

- (i) Appraisals: Third-party appraisals of artwork and jewelry.
- (ii) Reserve Report Results: Summarized results of third party engineer's petroleum reserve report dated May 2019.
- (iii) Connecticut Residence Tax Assessment: 2015 estimate of the fair market value of residential real estate for the purpose of assessing tax liability on the real estate.

15. North Bay has provided Huron all information, such as financial records and related data, which Huron requested in connection with the preparation of the Net Assets Report.

16. This attestation is limited to the matters expressly set forth herein. I express no opinion as to the fair market value of the assets or the value of the proceeds that may be derived from the forced sale of the assets.

  
\_\_\_\_\_  
Stephen A. Ives

#### Schedule A

- Richard Sackler
- RSS Revocable Pourover Trust
- Trust under agreement dated December 3, 1979 f/b/o Richard S. Sackler ("RSS BRP Trust")
- Trust under agreement dated June 16, 1980 f/b/o Richard S. Sackler ("RSS FPC Trust")
- Trust under agreement dated December 23, 1980 f/b/o Richard S. Sackler ("RSS XPC Trust")
- Trust Agreement dated August 29, 2003 f/b/o Issue of Richard S. Sackler
- Richard S. Sackler Trust U/A 9/30/04
- RSS Fiduciary Management Trust
- Jonathan Sackler
- JDS Revocable Pourover Trust
- Trust under agreement dated December 3, 1979 f/b/o Jonathan D. Sackler ("JDS BRP Trust")
- Trust under agreement dated June 16, 1980 f/b/o Jonathan D. Sackler ("JDS FPC Trust")
- Trust under agreement dated December 23, 1980 f/b/o Jonathan D. Sackler ("JDS XPC Trust")
- Trust Agreement dated August 29, 2003 f/b/o Issue of Jonathan D. Sackler
- David Sackler
- Richard S. Sackler Trust f/b/o David A. Sackler 3/8/90
- The Estate of Beverly Sackler (d. October 14, 2019)
- Beverly Sackler Revocable Trust
- Trust U/A fbo Beverly Sackler ("74 Trust")
- Raymond R. Sackler Trust 1 dtd 12/23/89 ("1A Trust")
- Raymond R. Sackler Trust 2 dtd 12/23/89 ("2A Trust")
- Raymond R. Sackler Trust 1B dtd 12/23/89 ("1B Trust")
- Raymond R. Sackler Trust 2B dtd 12/23/89 ("2B Trust")
- Trust B U/A fbo Beverly Sackler ("74B Trust")
- The 1974 Irrevocable Investment Trust ("Investment Trust")
- 1974 Irrevocable Trust fbo BS and RSS ("74-AR Trust")
- 1974 Irrevocable Trust fbo BS and JDS ("74-AJ Trust")
- AR Irrevocable Trust
- AJ Irrevocable Trust
- Beverly Sackler Trust 1 f/b/o David A. Sackler 12/20/1989 ("Gallo Trust 1")
- Beverly Sackler Trust 2 f/b/o David A. Sackler 12/20/1989 ("Gallo Trust 2")
- Beverly Sackler Trust 3 f/b/o David A. Sackler 12/20/1989 ("Gallo Trust 3")
- Richard S. Sackler Life Insurance Trust
- Jonathan D. Sackler Life Insurance Trust

- Irrevocable Trust under Declaration dated as of September 19, 1995 f/b/o Issue of Richard S. Sackler
- David A. Sackler 2012 Trust
- Irrevocable Trust under Declaration dated as of April 25, 1991
- Irrevocable Trust under Declaration dated as of August 25, 1992
- The RSS 2012 Family Trust
- Raymond R. Sackler Credit Shelter Trust u/a 3/29/2012
- Raymond R. Sackler GST Exempt Marital Trust u/a 3/29/2012
- Rosebay Medical Company L.P.
- Rosebay Medical Company, Inc
- Linarite Holdings LLC
- Perthlite Holdings LLC
- Moonstone Holdings LLC
- Roselite Holdings LLC

# Exhibit C

# Raymond-Side Cash & Non-Cash Activity Summary (January 2008 – March 2020)

*August 13, 2020*

- This report ("Report") is provided under the conditions set forth for Professionals' Eyes Only / Highly Confidential Information in the Proposed Protective Order filed with the Court on January 9, 2020, as amended. All capitalized terms used on this page (and only this page) have the same meanings as the terms are defined in the Proposed Protective Order.
- By viewing this report and the accompanying presentation (whether in-person or by remote access) you are agreeing to the terms of the Proposed Protective Order governing Professionals' Eyes Only/Confidential Information, including, without limitation, the following provisions:
  - Attendance to this Report and presentation is restricted to Outside Counsel and Professionals retained by the Debtors, Committee, Consenting Ad Hoc Committee, and the Ad Hoc Group of Non-Consenting States; Member Outside Counsel for Members of the Committee; and View-Only Designees for Members of the Committee, Consenting Ad Hoc Committee, and the Ad Hoc Group of Non-Consenting States.
  - The name of each View-Only Designee in attendance has been provided in advance to Counsel to the Family Members and Family Entities.
  - No View-Only Designee will engage in behavior that would render the purpose of view-only access a nullity.
  - This Report or the presentation of this Report shall be used solely for purposes of the proceeding, and the contents in this Report or the presentation of this Report shall not be disclosed to any person or entity that is not in attendance.

# Definition of Top-Level Entities

19-23649 and 19-23649-2 Doc-87822-ENL Dtd 08/05/21 Entered 08/05/21 14:28 Page 48 of 725  
Case 1:21-cv-01514 Document 1-1 Filed 08/05/21 Page 48 of 725

- The thirteen Top-Level Entities referenced throughout this presentation are listed below (“the Top-Level Entities”)

## Top-Level Entities

Rosebay Medical Company L.P.	RMLP
Trust U/A 11/5/74 fbo Beverly Sackler	74A
Rosebay Medical Company, Inc.	RMCI
1974 Irrevocable Trust A fbo BS and RSS	74-AR
1974 Irrevocable Trust A fbo BS and JDS	74-AJ
Trust B U/A dtd 11/5/74 fbo Beverly Sackler	74B
1974 Irrevocable Investment Trust	Inv. Trust
Raymond R. Sackler Trust 1 dtd 12/23/89	1A Trust
Raymond R. Sackler Trust 2 dtd 12/23/89	2A Trust
Raymond R. Sackler Trust 1B dtd 12/23/89	1B Trust
Raymond R. Sackler Trust 2B dtd 12/23/89	2B Trust
AR Irrevocable Trust	74-AR IR
AJ Irrevocable Trust	74-AJ IR

- *Huron Consulting Services LLC (“Huron”) was retained by Milbank LLP and Joseph Hage Aaronson LLC (together “Counsel”) to provide certain services as set forth in the engagement letter dated May 20, 2019 (“Engagement Letter”).*
- Huron is a management consulting firm and not a CPA firm. Huron does not provide attest services, audits, or other engagements in accordance with standards established by the American Institute of Certified Public Accountants (“AICPA”) or promulgated by the Public Company Accounting Oversight Board (“PCAOB”). The procedures Huron performed were for the purposes of responding to the services outlined in the Engagement Letter noted above and did not include independent verification of information provided by management, financial statement balances or internal controls, the performance of which might have revealed additional information that could affect the findings of this Report. Accordingly, we express no opinion or other form of assurance on any financial statements, management representations of other derived data accompanying or included in this Report.
- Any analytical, forecasting or other model that we create as part of our services will be unique to this engagement, based on specific circumstances and assumptions, and may not be appropriate for use when those circumstances and assumptions change.



# Table of Contents

---

# Table of Contents

19-23649-2 Doc-87822-0 Filed 08/05/21 Entered 08/05/21 14:28:38 Page 46 of 148  
Case 7:21-cv-01511 Document 158-5 Filed 08/05/21 Page 46 of 148  
Pg 257 of 725

Section	Page
Executive Summary	7
Methodology	17
Sources and Uses of Cash	22
Equity Rollforward	31
Significant Transactions	33
Appendix A: 2008 – 2019 Annual Sources & Uses	42
Appendix B: 2008 – 2020 Equity Rollforward	55
Appendix C: 2008 – 2020 Statements of Operations	69
Appendix D: 2008 – 2020 Balance Sheets	83
Appendix E: 2008 – 2020 ICSP Wage and Consulting Income	97

# Executive Summary

# Executive Summary

- This presentation has been prepared for the limited purpose of illustrating the flow of funds from Purdue Pharma, L.P. and related entities ("Purdue") to the Top-Level Entities, transfers among the Top-Level Entities, and subsequent transfers to other parties. This presentation utilizes "book value" as maintained in the applicable books and records of the Top-Level Entities and does not contain adjustments to the fair market value of any entity or assets referenced. Accordingly, this presentation is not a representation of the net worth of any Top-Level entity, nor the fair market of any asset held by a Top-Level Entity.
- The Top-Level Entities received cash of approximately \$4.1B originating from Purdue from January 2008 through March 31, 2020. Substantially all cash receipts from Purdue were received by RMLP and subsequently distributed to its two partners (74A and RMCI).
- Other cash receipts during this period included approximately \$688M generated from IAC distributions (\$540.4M) and net proceeds from lending by third party financial institutions (\$142.4M).
- The distributions from Purdue, along with the other net cash receipts of \$688M, total approximately \$4.8B. These funds, together with the opening balance of \$19.4M, were primarily used as set forth below.

(\$ in millions)	Sources	Uses	Net
<b>Beginning January 1, 2008 Cash Balance</b>			<b>\$ 19.4</b>
Purdue Pharma, LP et al.	\$ 4,096.1	\$ (0.0)	\$ 4,096.1
Independent Associated Companies (IACs)	634.1	(93.6)	540.4
Bank Loans	250.4	(108.0)	142.4
Other (inclusive of transactions between the Top-Level Entities)	8,164.3	(8,159.3)	5.0
			<b>\$ 4,784.0</b>
Taxes	92.4	(2,206.4)	(2,114.0)
Family Owned Entity Holding Third Party Investments	3,719.3	(4,700.2)	(981.0)
Third Party Investments	866.9	(1,395.4)	(528.5)
Family Owned Business Investments	25.0	(548.4)	(523.4)
Consulting / Professional Fees	-	(289.1)	(289.1)
Third Party - Other	1.9	(39.4)	(37.5)
Payments to Sackler Family Members	-	(19.2)	(19.2)
			<b>\$ (4,492.7)</b>
<b>Net Sources and Uses of Cash</b>			<b>\$ 291.3</b>
<b>Ending March 31, 2020 Cash Balance</b>			<b>\$ 310.7</b>

- On a combined basis, net cash increased by \$291.3 million.

# Executive Summary

- During this period, limited cash payments were made by the Top-Level Entities to certain Sackler family members, either as distributions or as compensation for services rendered.
- These payments totaled \$19.2 million and were comprised of the following:
  - Distributions from the 1A Trust totaled \$13.2 million.
  - Distributions from the 2A Trust totaled \$2.6 million.
  - Directors' Fee payments made by RMCI totaled approximately \$3.4 million.
  - No distributions or director's fees payments were made to Sackler family members after 2016.

Payor	Recipient	Totals	2008	2009	2010	2011	2012	2013	2014	2015	2016
(\$ in millions)											
<b>Distributions:</b>											
1A Trust	Marianna Sackler	\$ 4.4	\$ -	\$ -	\$ 4.4	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 0.1
1A Trust	Rebecca Sackler	4.4	-	-	4.4	-	-	-	-	-	-
1A Trust	David Sackler	4.4	-	-	-	-	-	4.4	-	-	-
2A Trust	Clare Sackler	2.1	-	-	-	-	-	2.1	-	-	-
2A Trust	Miles Sackler	0.5	-	-	-	-	-	0.5	-	-	-
		15.8	-	-	8.7	-	-	7.0	-	-	0.1
<b>Director's Fees:</b>											
RMCI	Richard Sackler	0.6	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.0
RMCI	Jonathan Sackler	2.0	0.1	0.1	0.3	0.1	0.1	0.1	0.1	0.6	0.3
RMCI	David Sackler	0.8	-	-	-	-	-	-	-	0.5	0.3
		3.4	0.2	0.2	0.4	0.2	0.2	0.2	0.2	1.2	0.6
		\$ 19.2	\$ 0.2	\$ 0.2	\$ 9.1	\$ 0.2	\$ 0.2	\$ 7.2	\$ 0.2	\$ 1.2	\$ 0.7

- In addition to the cash payments above, in 2009 1A Trust distributed approximately \$10 million of publicly traded securities to two of its beneficiaries, Marianna and Rebecca Sackler. Each of them received securities which, at the time, were valued at approximately \$4.9 million.
- Due to rounding, numbers presented above and throughout this document, may not add up precisely to the totals provided.

- **Non-Cash “Book” Activity:**

In addition to cash activity, various non-cash transfers of value were made to, among, and from the Top-Level Entities.

Examples of these activities include the division of 74A Trust, the decanting of 74-AR and 74-AJ Trusts and taxes paid directly by Purdue for the benefit of the Top-Level Entities.

This activity is presented on a book value basis. No attempt to adjust the historical basis of the underlying assets or liabilities to their fair market value was undertaken. The description of Significant Transactions is captured later in the presentation.

- **Equity Rollforward:**

An equity rollforward has been prepared to identify on a combined cash and non-cash basis what and when, if any, value has been transferred to entities other than among the Top-Level Entities, i.e., “outside the system.” Substantially all cash received by the Top-Level Entities and the cash and non-cash proceeds of such cash, remains within the Top-Level Entities.

# Top-Level Equity Rollforward

January 1, 2008 through March 31, 2020

19-30497-21 Doc 02522-01 Filed 05/21/24 Entered 05/21/24 23:38:51 Page 148  
Pg 262 of 725

(\$ in millions)	Notes	Total	RMLP	74A	RMCI	74-AR	74-AJ	74B	Inv. Trust	1A Trust	2A Trust	1B Trust	2B Trust	74-AR IR	74-AJ IR
<b>Beginning Equity 2008</b>			\$ 379.7	\$ 391.9	\$ 7.6	\$ -	\$ -	\$ 95.5	\$ 99.2	\$ 68.8	\$ 70.9	\$ 0.2	\$ 0.2	\$ -	\$ -
<b>Sources of Cash:</b>															
Receipts from Purdue		\$ 4,096.1	\$ 4,090.0	\$ 0.1	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 3.0	\$ 3.0	\$ -	\$ -
74A Division	<b>1</b>	313.4	-	-	-	149.1	164.3	-	-	-	-	-	-	-	-
74-AR & 74-AJ Decanting	<b>2</b>	156.2	-	-	-	-	-	-	-	-	-	-	-	118.0	38.2
Partnership Contributions		16.4	16.4	-	-	-	-	-	-	-	-	-	-	-	-
Partnership Distributions		4,302.4	1.2	4,215.2	86.0	-	-	-	-	-	-	-	-	-	-
Dividends		35.0	-	-	-	-	-	-	-	17.5	17.5	-	-	-	-
Top-Level Entity Transfers		404.8	-	-	-	25.0	10.2	-	-	131.9	155.8	-	-	39.5	42.4
Loan Activity between Top-Level Entities		2,676.5	39.0	350.0	-	177.4	229.5	-	488.9	650.9	740.9	-	-	-	-
Interest Income from Top-Level Entity		144.8	-	111.9	0.3	12.0	13.6	2.1	0.0	-	-	-	-	2.6	2.2
Loan Repayment from Sackler Family Members		39.7	-	-	-	-	0.8	-	30.9	8.0	-	-	-	-	-
Loan Repayment from Family Owned Entities (non-Top-Level Entity)		39.6	0.4	-	0.2	-	-	-	-	38.0	1.0	-	-	-	-
Interest Income from Sackler Family Members		6.4	-	-	-	-	0.0	-	5.7	0.6	-	-	-	-	-
Interest Income from Family Owned Entities (non-Top-Level Entity)		6.4	0.0	0.0	0.0	-	-	1.2	4.5	0.3	0.3	-	-	0.0	-
Independent Associated Companies (IACs)		634.1	85.5	-	-	-	-	-	-	274.3	274.3	-	-	-	-
Loan Proceeds from Bank		250.4	-	-	-	248.0	-	-	-	2.4	-	-	-	-	-
Interest and Dividends		22.8	0.3	4.8	0.6	3.1	5.6	0.7	0.5	1.5	3.5	0.1	0.1	0.6	1.2
Third Party - Other		1.9	0.2	(0.0)	0.1	0.3	0.1	0.0	0.0	0.1	0.2	0.0	0.0	(0.0)	1.0
Family Owned Business Investments		25.0	-	-	-	25.0	-	-	-	-	-	-	-	-	-
Third Party Investments	<b>3</b>	866.9	222.0	99.3	-	112.2	50.2	36.6	11.6	181.2	154.1	-	-	0.0	(0.3)
Family Owned Entity Holding Third Party Investments		3,719.3	15.6	417.3	-	790.4	551.9	94.3	97.4	641.7	733.6	-	-	242.9	134.2
Tax Refunds		92.4	2.7	72.2	1.9	0.8	0.8	0.0	1.5	6.8	5.5	0.0	0.0	-	-
		\$ 17,890.5	\$ 4,473.3	\$ 5,270.8	\$ 89.3	\$ 1,543.3	\$ 1,026.9	\$ 135.0	\$ 641.2	\$ 1,955.2	\$ 2,086.6	\$ 3.2	\$ 3.2	\$ 403.7	\$ 218.9
<b>Uses of Cash:</b>															
Payments to Purdue		\$ (0.0)	\$ (0.0)	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ (0.0)	\$ (0.0)	\$ -	\$ -	\$ -	\$ -
74A Division	<b>1</b>	(313.4)	-	(313.4)	-	-	-	-	-	-	-	-	-	-	-
74-AR & 74-AJ Decanting	<b>2</b>	(156.2)	-	-	-	(118.0)	(38.2)	-	-	-	-	-	-	-	-
Partnership Contributions		(16.4)	-	(16.1)	(0.3)	-	-	-	-	-	-	-	-	-	-
Partnership Distributions		(4,301.2)	(4,301.2)	-	-	-	-	-	-	-	-	-	-	-	-
Dividends		(35.0)	-	-	(35.0)	-	-	-	-	-	-	-	-	-	-
Top-Level Entity Transfers		(404.8)	-	(287.7)	-	(39.5)	(42.4)	-	-	-	-	-	-	(25.0)	(10.2)
Loan Activity between Top-Level Entities		(2,676.5)	-	(1,909.7)	(18.0)	(26.9)	(11.9)	(30.0)	-	(271.4)	(408.7)	-	-	-	-
Interest Payments to Top-Level Entity		(144.8)	(0.7)	-	-	(0.6)	(1.0)	-	(42.7)	(48.2)	(51.6)	-	-	-	-
Loans to Sackler Family Members		(59.7)	-	-	-	(0.8)	-	-	(38.9)	(20.0)	-	-	-	-	-
Loan Payments to Family Owned Entities (non-Top-Level Entities)		(27.3)	-	-	(0.1)	-	-	-	(7.0)	(13.6)	(6.6)	-	-	-	-
Interest Payments to Family Owned Entities (non-Top-Level Entity)		(0.1)	-	-	-	-	-	-	-	(0.0)	(0.0)	-	-	-	-
Independent Associated Companies (IACs)		(93.6)	(85.1)	-	-	-	-	-	-	(4.2)	(4.2)	(0.0)	(0.0)	-	-
Repayment of Bank Debt		(108.0)	-	-	-	(8.0)	-	-	-	-	-	-	-	(100.0)	-
Interest		(24.0)	-	-	-	(19.5)	-	-	-	-	-	-	-	(4.5)	-
Directors' Fees - Sackler Family		(3.4)	-	-	(3.4)	-	-	-	-	-	-	-	-	-	-
Distributions to Sackler Family Beneficiaries		(15.8)	-	-	-	-	-	-	-	(13.2)	(2.6)	-	-	-	-
Third Party - Other		(39.4)	(38.0)	(0.1)	(0.2)	(0.0)	(0.0)	(0.1)	(0.0)	(0.8)	(0.2)	(0.0)	(0.0)	-	-
Family Owned Business Investments		(548.4)	-	-	-	(24.6)	-	-	(521.5)	(0.9)	-	-	-	(1.3)	-
Consulting and Professional Fees		(289.1)	(38.8)	(16.6)	(1.5)	(64.5)	(27.2)	(4.4)	(2.8)	(38.1)	(41.8)	(0.0)	(0.0)	(30.4)	(22.9)
Third Party Investments		(1,395.4)	-	(144.7)	-	(425.5)	(127.2)	(19.1)	(3.9)	(356.7)	(318.3)	-	-	-	-
Family Owned Entity Holding Third Party Investments		(4,700.2)	(7.5)	(806.6)	-	(716.5)	(710.7)	(60.7)	(22.2)	(1,079.7)	(992.6)	-	-	(195.0)	(108.6)
Tax Payments		(2,206.4)	(2.6)	(1,758.8)	(30.5)	(97.5)	(67.1)	(16.8)	(5.9)	(102.3)	(123.8)	(0.5)	(0.5)	-	-
		\$ (17,559.1)	\$ (4,474.1)	\$ (5,253.6)	\$ (89.0)	\$ (1,541.1)	\$ (1,026.5)	\$ (131.1)	\$ (644.9)	\$ (1,949.2)	\$ (1,950.5)	\$ (0.6)	\$ (0.6)	\$ (356.2)	\$ (141.8)
<b>Net Sources and Uses of Cash</b>		\$ 291.3	\$ (0.9)	\$ 17.2	\$ 0.2	\$ 2.2	\$ 0.5	\$ 3.9	\$ (3.7)	\$ 6.0	\$ 136.0	\$ 2.6	\$ 2.6	\$ 47.5	\$ 77.1
<b>Non-Cash Book Activity:</b>															
74A Division	<b>1</b>	\$ -	\$ (2,228.8)	\$ -	\$ 1,122.2	\$ 1,106.5	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
74-AR & 74-AJ Decanting	<b>2</b>	-	-	-	(1,545.8)	(1,499.7)	-	-	-	-	-	-	-	1,545.8	1,499.7
Intra-Trust Activity	<b>4</b>	-	-	-	379.0	332.0	-	-	-	(379.0)	(332.0)	-	-	-	-
Distribution of Publicly Traded Stock to Sackler Family Mer	<b>5</b>	-	-	-	-	-	-	-	-	(12.6)	-	-	-	-	-
Other Contributions	<b>6</b>	39.0	-	-	-	-	-	-	-	-	-	-	-	-	0.2
Other Withdrawals	<b>7</b>	-	(0.2)	-	(8.0)	-	-	-	-	(2.5)	(1.6)	-	-	(10.8)	(17.7)
Receipt of Non Cash Taxes Paid Directly by Purdue Pharma	<b>8</b>	385.1	-	-	-	-	-	-	-	-	-	-	-	-	-
Distribution of Tax Benefit by RMLP	<b>8</b>	(385.1)	377.4	7.7	-	-	-	-	-	-	-	-	-	-	-
Income Tax Expense	<b>8</b>	-	(377.4)	(7.7)	-	-	-	-	-	-	-	-	-	-	-
Net Change of Other Assets & Liabilities	<b>9</b>	204.6	2,723.4	22.1	67.3	75.6	45.9	(570.2)	1,162.5	1,137.6	0.0	0.0	0.0	4.1	(77.3)
<b>Net Non-Cash Book Activity</b>		\$ 243.7	\$ 494.4	\$ 22.1	\$ 14.8	\$ 14.4	\$ 45.9	\$ (570.2)	\$ 768.5	\$ 804.0	\$ 0.0	\$ 0.0	\$ 1,539.1	\$ 1,404.9	
<b>Ending Equity March 2020</b>	<b>10</b>	\$ 622.5	\$ 903.5	\$ 29.9	\$ 17.0	\$ 14.9	\$ 145.3	\$ (474.7)	\$ 843.3	\$ 1,011.0	\$ 2.8	\$ 2.8	\$ 1,586.6	\$ 1,482.0	
<b>Ending Equity March 2020 (Net of Pharma Assets)</b>	<b>11</b>	\$ (0.1)	\$ 899.0	\$ 29.9	\$ 17.0	\$ 14.9	\$ 145.3	\$ (474.7)	\$ 366.3	\$ 533.6	\$ 2.8	\$ 2.8	\$ 1,586.6	\$ 1,482.0	

- As captured in the Executive Summary, between 2008 and 2020, the Top-Level Entities received \$4.1B from Purdue. Substantially all cash proceeds were received by RMLP and then distributed to its two partners (74A and RMCI).
- A consolidated equity position was not presented as it would have required elimination adjustments to be taken into consideration when aggregating the equity position of each of the trusts.
- Refer to slides 21 to 23 for descriptions of each category.
- Footnotes explanations are captured on the following slides.

NAS2584

PROFESSIONALS' EYES ONLY/HIGHLY CONFIDENTIAL—SUBJECT TO PROPOSED PROTECTIVE ORDER AND FRE 408

This presentation may only be viewed by the professionals identified on page 2, and it may not be shared.

# Top-Level Equity Rollforward Footnotes

Case 1:19-cv-02522-ONE Document 156-1 Filed 11/15/21 Page 52 of 148  
Pg 263 of 725

January 1, 2008 through March 31, 2020

- 1 In 2015, 74-AR and 74-AJ were created by the division of 74-A (See Significant Transactions Section).
- 2 In 2019, 74-AR and 74-AJ decanted substantially all assets to 74-AR IR and 74-AJ IR, respectively (See Significant Transactions Section).
- 3 In 2013, RMLP received approximately \$219.0 million in connection with the sale of its holdings of Infinity Pharmaceuticals Inc. ("Infinity") publicly-traded stock. Purdue Pharma acquired Infinity shares at various times and distributed such shares to the A-Side and B-Side families in equal proportions in 2008, 2009, and 2013.
- 4 In 2015, 1A and 2A transferred assets to 74-AR and 74-AJ (See Significant Transactions Section).
- 5 In 2009, 1A distributed securities of a publicly traded company to certain Sackler family members (See Significant Transactions Section).
- 6 RMLP: Includes \$36.5 million in legal fees paid by other entities on behalf of RMLP.
- 7 1A: In 2009, 1A distributed securities of a publicly traded company to certain Sackler family members (See Significant Transactions Section).  
2A: In 2013, 2A distributed approximately \$1.6 million of non-cash assets to certain Sackler family members.  
74-AR, 74-AR IR, and 74-AJ IR: Includes legal fees of approximately \$36.5 million paid on behalf of RMLP.
- 8 Reflects the distribution of benefits associated with taxes paid directly by Purdue Pharma, *et al.* from RMLP to 74A and RMCI (See Significant Transactions Section).
- 9 Reflects the remaining net change in non-cash assets and liabilities, primarily consisting of unrealized gains and losses including those related to the value of investments in Purdue and the IACs.
- 10 North Bay's accounting for the Top-Level Entities 2019 and Q1 2020 is not finalized. For this reason, the March 2020 Ending Equity Balance is subject to change.
- 11 Ending Equity less investments in Purdue Pharma, LP et al. and IACs



# Top-Level Entities Activity Summary – Cash Sources

January 1, 2008 through March 31, 2020

(\$ in millions)	Notes	Total	RMLP	74A	RMCI	74-AR	74-AJ	74B	Inv. Trust	1A Trust	2A Trust	1B Trust	2B Trust	74-AR IR	74-AJ IR
<b>Beginning Equity 2008</b>			\$ 379.7	\$ 391.9	\$ 7.6	\$ -	\$ -	\$ 95.5	\$ 99.2	\$ 68.8	\$ 70.9	\$ 0.2	\$ 0.2	\$ -	\$ -
<b>Sources of Cash:</b>															
Receipts from Purdue		\$ 4,096.1	\$ 4,090.0	\$ 0.1	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 3.0	\$ 3.0	\$ -	\$ -
74A Division	<b>1</b>	313.4	-	-	-	149.1	164.3	-	-	-	-	-	-	-	-
74-AR & 74-AJ Decanting	<b>2</b>	156.2	-	-	-	-	-	-	-	-	-	-	-	118.0	38.2
Partnership Contributions		16.4	16.4	-	-	-	-	-	-	-	-	-	-	-	-
Partnership Distributions		4,302.4	1.2	4,215.2	86.0	-	-	-	-	-	-	-	-	-	-
Dividends		35.0	-	-	-	-	-	-	-	17.5	17.5	-	-	-	-
Top-Level Entity Transfers		404.8	-	-	-	25.0	10.2	-	-	131.9	155.8	-	-	39.5	42.4
Loan Activity between Top-Level Entities		2,676.5	39.0	350.0	-	177.4	229.5	-	488.9	650.9	740.9	-	-	-	-
Interest Income from Top-Level Entity		144.8	-	111.9	0.3	12.0	13.6	2.1	0.0	-	-	-	-	2.6	2.2
Loan Repayment from Sackler Family Members		39.7	-	-	-	-	0.8	-	30.9	8.0	-	-	-	-	-
Loan Repayment from Family Owned Entities (non-Top-Level Entity)		39.6	0.4	-	0.2	-	-	-	-	38.0	1.0	-	-	-	-
Interest Income from Sackler Family Members		6.4	-	-	-	-	0.0	-	5.7	0.6	-	-	-	-	-
Interest Income from Family Owned Entities (non-Top-Level Entity)		6.4	0.0	0.0	0.0	-	-	1.2	4.5	0.3	0.3	-	-	0.0	-
Independent Associated Companies (IACs)		634.1	85.5	-	-	-	-	-	-	274.3	274.3	-	-	-	-
Loan Proceeds from Bank		250.4	-	-	-	248.0	-	-	-	2.4	-	-	-	-	-
Interest and Dividends		22.8	0.3	4.8	0.6	3.1	5.6	0.7	0.5	1.5	3.5	0.1	0.1	0.6	1.2
Third Party - Other		1.9	0.2	(0.0)	0.1	0.3	0.1	0.0	0.0	0.1	0.2	0.0	0.0	(0.0)	1.0
Family Owned Business Investments		25.0	-	-	-	25.0	-	-	-	-	-	-	-	-	-
Third Party Investments	<b>3</b>	866.9	222.0	99.3	-	112.2	50.2	36.6	11.6	181.2	154.1	-	-	0.0	(0.3)
Family Owned Entity Holding Third Party Investments		3,719.3	15.6	417.3	-	790.4	551.9	94.3	97.4	641.7	733.6	-	-	242.9	134.2
Tax Refunds		92.4	2.7	72.2	1.9	0.8	0.8	0.0	1.5	6.8	5.5	0.0	0.0	-	-
		<u>\$ 17,850.5</u>	<u>\$ 4,473.3</u>	<u>\$ 5,270.8</u>	<u>\$ 89.3</u>	<u>\$ 1,543.3</u>	<u>\$ 1,026.9</u>	<u>\$ 135.0</u>	<u>\$ 641.2</u>	<u>\$ 1,955.2</u>	<u>\$ 2,086.6</u>	<u>\$ 3.2</u>	<u>\$ 3.2</u>	<u>\$ 403.7</u>	<u>\$ 218.9</u>

- 1 In 2015, 74-AR and 74-AJ were created by the division of 74-A (See Significant Transactions Section).
- 2 In 2019, 74-AR and 74-AJ decanted substantially all assets to 74-AR IR and 74-AJ IR, respectively (See Significant Transactions Section).
- 3 In 2013, RMLP received approximately \$219.0 million in connection with the sale of its holdings of Infinity Pharmaceuticals Inc. ("Infinity") publicly-traded stock. Purdue Pharma acquired Infinity shares at various times and distributed such shares to the A-Side and B-Side families in equal proportions in 2008, 2009, and 2013.

Refer to the slides 24 – 25 for descriptions of the above categories.

**NAS2586**

PROFESSIONALS' EYES ONLY/HIGHLY CONFIDENTIAL—SUBJECT TO PROPOSED PROTECTIVE ORDER AND FRE 408

This presentation may only be viewed by the professionals identified on page 2, and it may not be shared.

# Top-Level Entities Activity Summary – Cash Uses

January 1, 2008 through March 31, 2020

(\$ in millions)	Notes	Total	RMLP	74A	RMCI	74-AR	74-AJ	74B	Inv. Trust	1A Trust	2A Trust	1B Trust	2B Trust	74-AR IR	74-AJ IR
<b>Uses of Cash:</b>															
Payments to Purdue		\$ (0.0)	\$ (0.0)	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ (0.0)	\$ (0.0)	\$ -	\$ -	\$ -	\$ -
74A Division	<b>1</b>	(313.4)	-	(313.4)	-	-	-	-	-	-	-	-	-	-	-
74-AR & 74-AJ Decanting	<b>2</b>	(156.2)	-	-	-	(118.0)	(38.2)	-	-	-	-	-	-	-	-
Partnership Contributions		(16.4)	-	(16.1)	(0.3)	-	-	-	-	-	-	-	-	-	-
Partnership Distributions		(4,301.2)	(4,301.2)	-	-	-	-	-	-	-	-	-	-	-	-
Dividends		(35.0)	-	-	(35.0)	-	-	-	-	-	-	-	-	-	-
Top-Level Entity Transfers		(404.8)	-	(287.7)	-	(39.5)	(42.4)	-	-	-	-	-	-	(25.0)	(10.2)
Loan Activity between Top-Level Entities		(2,676.5)	-	(1,909.7)	(18.0)	(26.9)	(11.9)	(30.0)	-	(271.4)	(408.7)	-	-	-	-
Interest Payments to Top-Level Entity		(144.8)	(0.7)	-	-	(0.6)	(1.0)	-	(42.7)	(48.2)	(51.6)	-	-	-	-
Loans to Sackler Family Members		(59.7)	-	-	-	-	(0.8)	-	(38.9)	(20.0)	-	-	-	-	-
Loan Payments to Family Owned Entities (non-Top-Level Entities)		(27.3)	-	-	(0.1)	-	-	-	(7.0)	(13.6)	(6.6)	-	-	-	-
Interest Payments to Family Owned Entities (non-Top-Level Entities)		(0.1)	-	-	-	-	-	-	-	(0.0)	(0.0)	-	-	-	-
Independent Associated Companies (IACs)		(93.6)	(85.1)	-	-	-	-	-	-	(4.2)	(4.2)	(0.0)	(0.0)	-	-
Repayment of Bank Debt		(108.0)	-	-	-	(8.0)	-	-	-	-	-	-	-	(100.0)	-
Interest		(24.0)	-	-	-	(19.5)	-	-	-	-	-	-	-	(4.5)	-
Directors' Fees – Sackler Family		(3.4)	-	-	(3.4)	-	-	-	-	-	-	-	-	-	-
Distributions to Sackler Family Beneficiaries		(15.8)	-	-	-	-	-	-	-	(13.2)	(2.6)	-	-	-	-
Third Party - Other		(39.4)	(38.0)	(0.1)	(0.2)	(0.0)	(0.0)	(0.1)	(0.0)	(0.8)	(0.2)	(0.0)	(0.0)	-	-
Family Owned Business Investments		(548.4)	-	-	-	(24.6)	-	-	(521.5)	(0.9)	-	-	-	(1.3)	-
Consulting and Professional Fees		(289.1)	(38.8)	(16.6)	(1.5)	(64.5)	(27.2)	(4.4)	(2.8)	(38.1)	(41.8)	(0.0)	(0.0)	(30.4)	(22.9)
Third Party Investments		(1,395.4)	-	(144.7)	-	(425.5)	(127.2)	(19.1)	(3.9)	(356.7)	(318.3)	-	-	-	-
Family Owned Entity Holding Third Party Investments		(4,700.2)	(7.5)	(806.6)	-	(716.5)	(710.7)	(60.7)	(22.2)	(1,079.7)	(992.6)	-	-	(195.0)	(108.6)
Tax Payments		(2,206.4)	(2.6)	(1,758.8)	(30.5)	(97.5)	(67.1)	(16.8)	(5.9)	(102.3)	(123.8)	(0.5)	(0.5)	-	-
		<u>\$ (17,559.1)</u>	<u>\$ (4,474.1)</u>	<u>\$ (5,253.6)</u>	<u>\$ (89.0)</u>	<u>\$ (1,541.1)</u>	<u>\$ (1,026.5)</u>	<u>\$ (131.1)</u>	<u>\$ (644.9)</u>	<u>\$ (1,949.2)</u>	<u>\$ (1,950.5)</u>	<u>\$ (0.6)</u>	<u>\$ (0.6)</u>	<u>\$ (356.2)</u>	<u>\$ (141.8)</u>
<b>Net Sources and Uses of Cash</b>		<u>\$ 291.3</u>	<u>\$ (0.9)</u>	<u>\$ 17.2</u>	<u>\$ 0.2</u>	<u>\$ 2.2</u>	<u>\$ 0.5</u>	<u>\$ 3.9</u>	<u>\$ (3.7)</u>	<u>\$ 6.0</u>	<u>\$ 136.0</u>	<u>\$ 2.6</u>	<u>\$ 2.6</u>	<u>\$ 47.5</u>	<u>\$ 77.1</u>

1 In 2015, 74-AR and 74-AJ were created by the division of 74-A (See Significant Transactions Section).

2 In 2019, 74-AR and 74-AJ decanted substantially all assets to 74-AR IR and 74-AJ IR, respectively (See Significant Transactions Section).

Refer to the slides 26 – 27 for descriptions of the above categories.

**NAS2587**

PROFESSIONALS' EYES ONLY/HIGHLY CONFIDENTIAL—SUBJECT TO PROPOSED PROTECTIVE ORDER AND FRE 408

This presentation may only be viewed by the professionals identified on page 2, and it may not be shared.

# Top-Level Entities Activity Summary – Non-Cash

January 1, 2008 through March 31, 2020

(\$ in millions)	Notes	Total	RMLP	74A	RMCI	74-AR	74-AJ	74B	Inv. Trust	1A Trust	2A Trust	1B Trust	2B Trust	74-AR IR	74-AJ IR
<b>Non-Cash Book Activity:</b>															
74A Division	1		\$ -	\$ (2,228.8)	\$ -	\$ 1,122.2	\$ 1,106.5	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
74-AR & 74-AJ Decanting	2		-	-	-	(1,545.8)	(1,499.7)	-	-	-	-	-	-	1,545.8	1,499.7
Intra-Trust Activity	4		-	-	-	379.0	332.0	-	-	(379.0)	(332.0)	-	-	-	-
Distribution of Publicly Traded Stock to Sackler Family Mer	5		-	-	-	-	-	-	-	(12.6)	-	-	-	-	-
Other Contributions	6		39.0	-	-	-	-	-	-	-	-	-	-	-	0.2
Other Withdrawals	7		-	(0.2)	-	(8.0)	-	-	-	(2.5)	(1.6)	-	-	(10.8)	(17.7)
Receipt of Non Cash Taxes Paid Directly by Purdue Pharma	8		385.1	-	-	-	-	-	-	-	-	-	-	-	-
Distribution of Tax Benefit by RMLP	8		(385.1)	377.4	7.7	-	-	-	-	-	-	-	-	-	-
Income Tax Expense	8		-	(377.4)	(7.7)	-	-	-	-	-	-	-	-	-	-
Net Change of Other Assets & Liabilities	9		204.6	2,723.4	22.1	67.3	75.6	45.9	(570.2)	1,162.5	1,137.6	0.0	0.0	4.1	(77.3)
<b>Net Non-Cash Book Activity</b>			<b>\$ 243.7</b>	<b>\$ 494.4</b>	<b>\$ 22.1</b>	<b>\$ 14.8</b>	<b>\$ 14.4</b>	<b>\$ 45.9</b>	<b>\$ (570.2)</b>	<b>\$ 768.5</b>	<b>\$ 804.0</b>	<b>\$ 0.0</b>	<b>\$ 0.0</b>	<b>\$ 1,539.1</b>	<b>\$ 1,404.9</b>
<b>Ending Equity March 2020</b>	10		<b>\$ 622.5</b>	<b>\$ 903.5</b>	<b>\$ 29.9</b>	<b>\$ 17.0</b>	<b>\$ 14.9</b>	<b>\$ 145.3</b>	<b>\$ (474.7)</b>	<b>\$ 843.3</b>	<b>\$ 1,011.0</b>	<b>\$ 2.8</b>	<b>\$ 2.8</b>	<b>\$ 1,586.6</b>	<b>\$ 1,482.0</b>
<b>Ending Equity March 2020 (Net of Pharma Assets)</b>	11		<b>\$ (0.1)</b>	<b>\$ 899.0</b>	<b>\$ 29.9</b>	<b>\$ 17.0</b>	<b>\$ 14.9</b>	<b>\$ 145.3</b>	<b>\$ (474.7)</b>	<b>\$ 366.3</b>	<b>\$ 533.6</b>	<b>\$ 2.8</b>	<b>\$ 2.8</b>	<b>\$ 1,586.6</b>	<b>\$ 1,482.0</b>

- 1 In 2015, 74-AR and 74-AJ were created by the division of 74-A (See Significant Transactions Section).
- 2 In 2019, 74-AR and 74-AJ decanted substantially all assets to 74-AR IR and 74-AJ IR, respectively (See Significant Transactions Section).
- 4 In 2015, 1A and 2A transferred assets to 74-AR and 74-AJ (See Significant Transactions Section).
- 5 In 2009, 1A distributed securities of a publicly traded company to certain Sackler family members (See Significant Transactions Section).
- 6 RMLP: Includes \$36.5 million in legal fees paid by other entities on behalf of RMLP.
- 7 1A: In 2009, 1A distributed securities of a publicly traded company to certain Sackler family members (See Significant Transactions Section).  
2A: In 2013, 2A distributed approximately \$1.6 million of non-cash assets to certain Sackler family members.  
74-AR, 74-AR IR, and 74-AJ IR: Includes legal fees of approximately \$36.5 million paid on behalf of RMLP.
- 8 Reflects the distribution of benefits associated with taxes paid directly by Purdue Pharma, *et al.* from RMLP to 74A and RMCI (See Significant Transactions Section).
- 9 Reflects the remaining net change in non-cash assets and liabilities, primarily consisting of unrealized gains and losses including those related to the value of investments in Purdue and the IACs.
- 10 North Bay's accounting for the Top-Level Entities 2019 and Q1 2020 is not finalized. For this reason, the March 2020 Ending Equity Balance is subject to change.
- 11 Ending Equity less investments in Purdue Pharma, LP et al. and IACs

NAS2588

PROFESSIONALS' EYES ONLY/HIGHLY CONFIDENTIAL—SUBJECT TO PROPOSED PROTECTIVE ORDER AND FRE 408

This presentation may only be viewed by the professionals identified on page 2, and it may not be shared.

Summary financial information related to each of the analyses described on the previous page are included in the following appendices:

- **Appendix A:** 2008 – 2019 Annual Sources and Uses of Cash
- **Appendix B:** 2008 – 2020 Equity Rollforward
- **Appendix C:** 2008 – 2020 Annual Statement of Operations
- **Appendix D:** 2008 – 2020 Annual Balance Sheets
- **Appendix E:** 2008 – 2020 ICSP Sources of Wage and Consulting Income

# Methodology

**The following procedures were employed to prepare the categorized Sources and Uses schedules contained herein:**

1. The financial information for the Raymond-side Initial Covered Sackler Persons (“ICSPs”) was prepared by North Bay Associates (“North Bay”), an entity that provides accounting and tax services for Raymond-side individuals, entities and trusts. In the ordinary course of business, North Bay maintains the books and records of, and prepares monthly financial statements relating to, nearly all these ICSPs.
2. Monthly cash flow statements were obtained for each of the thirteen entities listed below (the “Top-Level Entities”) for January 2008 through March 2020.

**Top-Level Entities**

Rosebay Medical Company L.P.	RMLP
Trust U/A 11/5/74 fbo Beverly Sackler	74A
Rosebay Medical Company, Inc.	RMCI
1974 Irrevocable Trust A fbo BS and RSS	74-AR
1974 Irrevocable Trust A fbo BS and JDS	74-AJ
Trust B U/A dtd 11/5/74 fbo Beverly Sackler	74B
1974 Irrevocable Investment Trust	Inv. Trust
Raymond R. Sackler Trust 1 dtd 12/23/89	1A Trust
Raymond R. Sackler Trust 2 dtd 12/23/89	2A Trust
Raymond R. Sackler Trust 1B dtd 12/23/89	1B Trust
Raymond R. Sackler Trust 2B dtd 12/23/89	2B Trust
AR Irrevocable Trust	74-AR IR
AJ Irrevocable Trust	74-AJ IR

# Methodology – Sources and Uses of Cash

3. Each cash flow item was classified into one of the sources and uses categories described on pages 24-27 of this Report. These categories were selected to be as descriptive as possible while still providing a meaningful summary.
4. Transactions between the Top-Level Entities (including loans and related debt service - principal and interest, transfers, etc.) were reconciled to show the impact of transactions.

# Methodology – Equity Rollforward

## **The following procedures were employed to prepare the Equity Rollforward contained herein:**

1. Monthly balance sheets, income statements, and general ledgers were obtained for each of the Top-Level Entities for January 2008 through March 2020.
2. The change in each Top-Level Entity's equity accounts was analyzed on an annual basis for the years 2008 through 2019 and for the first quarter of 2020.
3. The equity accounts activity for each of the periods was classified into the categories described on the following slide.



### Contributions:

- Partnership Contributions (Cash): Cash received by a partnership entity from its partners. Amounts corresponds with Partnership Contributions category in Sources and Uses analysis.
- Other Cash: Cash transactions between Top-Level Entities, including transfers related to the division and decanting of trusts for which there was an impact on equity.
- Non-Cash: Non-cash transactions between Top-Level Entities, including transfers related to the division and decanting of trusts.

### Withdrawals:

- Partnership Distributions (Cash): Distributions of cash by partnership entities to their partners. Amounts correspond with Partnership Distributions category description in Sources and Uses analysis.
- Other Cash: Cash transactions between Top-Level Entities, payments of dividends by RMCI, and trust distributions of cash made directly to Sackler family members for which there was an impact on equity.
- Non-Cash Taxes Paid Directly by Purdue Pharma, et al.: Non-cash distribution of funds by partnership entities paid directly to tax authorities on behalf of its partners.
- Other Non-Cash: Non-cash transfers between Top-Level Entities.

### Net Income / (Loss):

- Receipts from Purdue (Cash): Receipts of cash from Purdue Pharma, LP, *et al.* Amounts correspond with Receipts from Purdue category description in Sources and Uses analysis.
- Partnership Distributions (Cash): Receipts of cash from a partnership entity by its partners. Amounts corresponds with Partnership Distributions category in Sources and Uses analysis.
- Other Net Cash: Net remaining cash receipts and distributions (including receipt of dividends).
- Net Non-Cash: Net remaining non-cash transactions.

# Sources and Uses of Cash

For presentation purposes only the sources and uses of cash were aggregated into the following categories:

### Sources

- Receipts from Purdue
- 74A Division
- 74-AR & 74-AJ Decanting
- Partnership Contributions
- Partnership Distributions
- Dividends
- Top-Level Entity Transfers
- Loan Activity between Top-Level Entities
- Interest Income from Top-Level Entity
- Loan Repayments from Sackler Family Members
- Loan Repayments from Family Owned Entities (non-Top-Level Entities)
- Interest Income from Sackler Family Members
- Interest Income from Family Owned Entities (non-Top-Level Entities)
- Independent Associated Companies (IACs)
- Loan Proceeds from Bank
- Interest and Dividends
- Third Party - Other
- Family Owned Business Investments
- Third Party Investments
- Family Owned Entity Holding Third Party Investments
- Tax Refunds

### Uses

- Payments to Purdue
- 74A Division
- 74-AR & 74-AJ Decanting
- Partnership Contributions
- Partnership Distributions
- Dividends
- Top-Level Entity Transfers
- Loan Activity between Top-Level Entities
- Interest Payments to Top-Level Entity
- Loan Payments to Sackler Family Members
- Loan Payments to Family Owned Entities (non-Top-Level)
- Interest Payments to Top-Level Entity
- Independent Associated Companies (IACs)
- Repayment of Bank Debt
- Interest
- Directors' Fees – Sackler Family
- Distributions to Sackler Family Beneficiaries
- Third Party - Other
- Family Owned Business Investments
- Consulting and Professional Fees
- Third Party Investments
- Family Owned Entity Holding Third Party Investments
- Tax Payments

# Category Descriptions – Cash Sources

- **Receipts from Purdue:** Cash receipts from Purdue Pharma, LP, *et al.*
- **74A Division:** Cash receipts by 74-AR and 74-AJ related to the division of 74A (see Significant Transactions Section for further description)
- **74-AR & 74-AJ Decanting:** Cash receipts related to the decanting of 74-AR and 74AJ (see Significant Transactions Section for further description)
- **Partnership Contributions:** Cash received by a partnership entity from its partners
- **Partnership Distributions:** Cash distributed to a partnership entity to its partners
- **Dividends:** Receipts of dividends paid by RMCI to its equity holders
- **Top-Level Entity Transfers:** Cash proceeds from transfers other Top-Level Entities
- **Loan Activity between Top-Level Entities:** Cash receipts from loans between Top-Level Entities (principal only)
- **Interest Income from Top-Level Entity:** Cash receipts from interest income associated with loans to Top-Level Entities
- **Loans Repayment from Sackler Family Members:** Cash received from Sackler family members for repayment of loan principal
- **Loan Repayment from Family Owned Entities (non-Top-Level Entities):** Cash received from family owned entities for repayment of loan principal
- **Interest Income from Sackler Family Members:** Receipts of interest income associated with loans to Sackler family members

# Category Descriptions – Cash Sources

- **Interest Income from Family Owned Entities (non-Top-Level Entities):** Receipts of interest income associated with loans to non-Top-Level Entities
- **Independent Associated Companies (IACs):** Cash receipts from Ex-US pharmaceutical companies
- **Loan Proceeds from Bank:** Cash proceeds advanced from bank loans
- **Interest and Dividends:** Receipts of bank interest, sweep account proceeds, and dividends paid to Top-Level Entities by banks and other third parties
- **Third Party – Other:** Cash receipts from third parties not captured by other categories
- **Family Owned Business Investments:** Receipts of funds from investments in family owned entities, (e.g., Cheyenne Petroleum, etc.).
- **Third Party Investments:** Cash proceeds generated from investments with third party financial institutions (hedge funds, etc.) made directly to the Top-Level Entities
- **Family Owned Entity Holding Third Party Investments:** Cash proceeds generated from family owned entities established to hold third party investments, (e.g., Poco Bay, etc.)
- **Tax Refunds:** Cash proceeds generated from tax refunds from both foreign and domestic sources.

# Category Descriptions – Cash Uses

- **Payments to Purdue:** Cash disbursements made to Purdue Pharma, LP, *et al.*
- **74A Division:** Cash disbursements to 74-AR and 74-AJ related to the division of 74A (see Significant Transactions Section for further description)
- **74-AR & 74-AJ Decanting:** Cash disbursements resulting from the decanting of 74-AR and 74AJ (see Significant Transactions Section for further description)
- **Partnership Contributions:** Cash contributed to a partnership from its partners
- **Partnership Distributions:** Cash disbursed by the partnership entities to their partners
- **Dividends:** Payments of dividends by RMCI to its equity holders
- **Top-Level Entity Transfers:** Cash disbursed among the Top-Level Entities
- **Loan Activity between Top-Level Entities:** Cash transferred through lending relationship among the Top-Level Entities (principal only)
- **Interest Payments to Top-Level Entity:** Interest paid to a Top-Level Entity from a borrower.
- **Loan Payments to Sackler Family Members:** Loan proceeds paid to Sackler Family Members
- **Loan Payments to Family Owned Entities (non-Top-Level):** Loan proceeds to Family owned Entities (non-Top-Level)
- **Independent Associated Companies (IACs):** Cash disbursed to Ex-US pharmaceutical companies
- **Repayment of Bank Debt:** Repayments of bank loans or lines of credit.

# Category Descriptions – Cash Uses

- **Interest:** Interest paid to service loans from banking institutions
- **Directors’ Fees – Sackler Family:** Payments of consulting/directors’ fees by RMCI to the Sackler Family members
- **Distributions to Sackler Family Beneficiaries:** Trust cash distributions made directly to the Sackler family members
- **Third Party – Other:** Payments to third parties not captured by another category
- **Family Owned Business Investments:** Cash disbursed for investments in family owned entities, (e.g., Cheyenne Petroleum, etc.)
- **Consulting and Professional Fees:** Payments made to professional advisors (e.g., legal advisors), third-party investment advisors, consultants and other service providers.
- **Third Party Investments:** Cash disbursed to third party financial institutions (e.g., hedge funds, etc.) made by directly by Top-Level Entities
- **Family Owned Entity Holding Third Party Investments:** Cash disbursed to family owned entities from to hold third party investments, (e.g., Poco Bay, etc.)
- **Tax Payments:** Cash disbursed to foreign and domestic taxing authorities.

# Flow of Funds Summary

January 1, 2008 through March 31, 2020

10-14958-12 Licor 4232-Eyed 08/05/21 15:55 Filed 08/05/21 Page 18 of 28  
Pg 279 of 725

(\$ in millions)	Notes	Total	RMLP	74A	RMCI	74-AR	74-AJ	74B	Inv. Trust	1A Trust	2A Trust	1B Trust	2B Trust	74-AR IR	74-AJ IR
<b>Beginning January 1, 2008 Balance</b>		\$ 19.4	\$ 2.0	\$ 7.5	\$ 0.0	\$ -	\$ -	\$ 2.3	\$ 4.3	\$ 2.1	\$ 1.1	\$ 0.0	\$ 0.0	\$ -	\$ -
<b>Sources of Cash:</b>															
Receipts from Purdue		\$ 4,096.1	\$ 4,090.0	\$ 0.1	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 3.0	\$ 3.0	\$ -	\$ -
74A Division	1	313.4	-	-	-	149.1	164.3	-	-	-	-	-	-	-	-
74-AR & 74-AJ Decanting	2	156.2	-	-	-	-	-	-	-	-	-	-	-	118.0	38.2
Partnership Contributions		16.4	16.4	-	-	-	-	-	-	-	-	-	-	-	-
Partnership Distributions		4,302.4	1.2	4,215.2	86.0	-	-	-	-	-	-	-	-	-	-
Dividends		35.0	-	-	-	-	-	-	-	17.5	17.5	-	-	-	-
Top-Level Entity Transfers		404.8	-	-	-	25.0	10.2	-	-	131.9	155.8	-	-	39.5	42.4
Loan Activity between Top-Level Entities		2,676.5	39.0	350.0	-	177.4	229.5	-	488.9	650.9	740.9	-	-	-	-
Interest Income from Top-Level Entity		144.8	-	111.9	0.3	12.0	13.6	2.1	0.0	-	-	-	-	2.6	2.2
Loan Repayment from Sackler Family Members		39.7	-	-	-	-	0.8	-	30.9	8.0	-	-	-	-	-
Loan Repayment from Family Owned Entities (non-Top-Level Entities)		39.6	0.4	-	0.2	-	-	-	-	38.0	1.0	-	-	-	-
Interest Income from Sackler Family Members		6.4	-	-	-	-	0.0	-	5.7	0.6	-	-	-	-	-
Interest Income from Family Owned Entities (non-Top-Level Entities)		6.4	0.0	0.0	0.0	-	-	1.2	4.5	0.3	0.3	-	-	0.0	-
Independent Associated Companies (IACs)		634.1	85.5	-	-	-	-	-	-	274.3	274.3	-	-	-	-
Loan Proceeds from Bank		250.4	-	-	-	248.0	-	-	-	2.4	-	-	-	-	-
Interest and Dividends		22.8	0.3	4.8	0.6	3.1	5.6	0.7	0.5	1.5	3.5	0.1	0.1	0.6	1.2
Third Party - Other		1.9	0.2	(0.0)	0.1	0.3	0.1	0.0	0.0	0.1	0.2	0.0	0.0	(0.0)	1.0
Family Owned Business Investments		25.0	-	-	-	25.0	-	-	-	-	-	-	-	-	-
Third Party Investments		866.9	222.0	99.3	-	112.2	50.2	36.6	11.6	181.2	154.1	-	-	0.0	(0.3)
Family Owned Entity Holding Third Party Investments		3,719.3	15.6	417.3	-	790.4	551.9	94.3	97.4	641.7	733.6	-	-	242.9	134.2
Tax Refunds		92.4	2.7	72.2	1.9	0.8	0.8	0.0	1.5	6.8	5.5	0.0	0.0	-	-
		\$ 17,850.45	\$ 4,473.28	\$ 5,270.83	\$ 89.28	\$ 1,543.31	\$ 1,026.93	\$ 135.00	\$ 641.18	\$ 1,955.18	\$ 2,086.55	\$ 3.16	\$ 3.16	\$ 403.70	\$ 218.90
<b>Uses of Cash:</b>															
Payments to Purdue		\$ (0.03)	\$ (0.01)	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ (0.01)	\$ (0.01)	\$ -	\$ -	\$ -	\$ -
74A Division	1	(313.4)	-	(313.4)	-	-	-	-	-	-	-	-	-	-	-
74-AR & 74-AJ Decanting	2	(156.2)	-	-	-	(118.0)	(38.2)	-	-	-	-	-	-	-	-
Partnership Contributions		(16.4)	-	(16.1)	(0.3)	-	-	-	-	-	-	-	-	-	-
Partnership Distributions		(4,301.2)	(4,301.2)	-	-	-	-	-	-	-	-	-	-	-	-
Dividends		(35.0)	-	-	(35.0)	-	-	-	-	-	-	-	-	-	-
Top-Level Entity Transfers		(404.8)	-	(287.7)	-	(39.5)	(42.4)	-	-	-	-	-	-	(25.0)	(10.2)
Loan Activity between Top-Level Entities		(2,676.5)	-	(1,909.7)	(18.0)	(26.9)	(11.9)	(30.0)	-	(271.4)	(408.7)	-	-	-	-
Interest Payments to Top-Level Entity		(144.8)	(0.7)	-	-	(0.6)	(1.0)	-	(42.7)	(48.2)	(51.6)	-	-	-	-
Loans to Sackler Family Members		(59.7)	-	-	-	-	(0.8)	-	(38.9)	(20.0)	-	-	-	-	-
Loan Payments to Family Owned Entities (non-Top-Level Entities)		(27.3)	-	-	(0.1)	-	-	-	(7.0)	(13.6)	(6.6)	-	-	-	-
Interest Payments to Family Owned Entities (non-Top-Level Entities)		(0.1)	-	-	-	-	-	-	-	(0.0)	(0.0)	-	-	-	-
Independent Associated Companies (IACs)		(93.6)	(85.1)	-	-	-	-	-	-	(4.2)	(4.2)	(0.0)	(0.0)	-	-
Repayment of Bank Debt		(108.0)	-	-	-	(8.0)	-	-	-	-	-	-	-	(100.0)	-
Interest		(24.0)	-	-	-	(19.5)	-	-	-	-	-	-	-	(4.5)	-
Directors' Fees - Sackler Family		(3.4)	-	-	(3.4)	-	-	-	-	-	-	-	-	-	-
Distributions to Sackler Family Beneficiaries		(15.8)	-	-	-	-	-	-	-	(13.2)	(2.6)	-	-	-	-
Third Party - Other		(39.4)	(38.0)	(0.1)	(0.2)	(0.0)	(0.0)	(0.1)	(0.0)	(0.8)	(0.2)	(0.0)	(0.0)	-	-
Family Owned Business Investments		(548.4)	-	-	-	(24.6)	-	-	(521.5)	(0.9)	-	-	-	(1.3)	-
Consulting and Professional Fees		(289.1)	(38.8)	(16.6)	(1.5)	(64.5)	(27.2)	(4.4)	(2.8)	(38.1)	(41.8)	(0.0)	(0.0)	(30.4)	(22.9)
Third Party Investments		(1,395.4)	-	(144.7)	-	(425.5)	(127.2)	(19.1)	(3.9)	(356.7)	(318.3)	-	-	-	-
Family Owned Entity Holding Third Party Investments		(4,700.2)	(7.5)	(806.6)	-	(716.5)	(710.7)	(60.7)	(22.2)	(1,079.7)	(992.6)	-	-	(195.0)	(108.6)
Tax Payments		(2,206.4)	(2.6)	(1,758.8)	(30.5)	(97.5)	(67.1)	(16.8)	(5.9)	(102.3)	(123.8)	(0.5)	(0.5)	-	-
		\$ (17,559.1)	\$ (4,474.1)	\$ (5,253.6)	\$ (89.0)	\$ (1,541.1)	\$ (1,026.5)	\$ (131.1)	\$ (644.9)	\$ (1,949.2)	\$ (1,950.5)	\$ (0.6)	\$ (0.6)	\$ (356.2)	\$ (141.8)
<b>Total Cash Flow</b>		\$ 291.3	\$ (0.9)	\$ 17.2	\$ 0.2	\$ 2.2	\$ 0.5	\$ 3.9	\$ (3.7)	\$ 6.0	\$ 136.0	\$ 2.6	\$ 2.6	\$ 47.5	\$ 77.1
<b>Ending March 31, 2020 Balance</b>		\$ 310.7	\$ 1.1	\$ 24.7	\$ 0.3	\$ 2.2	\$ 0.5	\$ 6.2	\$ 0.6	\$ 8.1	\$ 137.2	\$ 2.6	\$ 2.6	\$ 47.5	\$ 77.1

1 In 2015, 74-AR and 74-AJ were created by the division of 74-A (See Significant Transactions Section).

2 In 2019, 74-AR and 74-AJ decanted substantially all assets to 74-AR IR and 74-AJ IR, respectively (See Significant Transactions Section).

**NAS2601**

PROFESSIONALS' EYES ONLY/HIGHLY CONFIDENTIAL—SUBJECT TO PROPOSED PROTECTIVE ORDER AND FRE 408

This presentation may only be viewed by the professionals identified on page 2, and it may not be shared.



January 1, 2008 through March 31, 2020

(\$ in millions)	Notes	Total	RMLP	74A	RMCI	74-AR	74-AJ	74B	Inv. Trust	1A Trust	2A Trust	1B Trust	2B Trust	74-AR IR	74-AJ IR
<b>Beginning January 1, 2008 Balance</b>		\$ 19.4	\$ 2.0	\$ 7.5	\$ 0.0	\$ -	\$ -	\$ 2.3	\$ 4.3	\$ 2.1	\$ 1.1	\$ 0.0	\$ 0.0	\$ -	\$ -
<b>Sources of Cash:</b>															
Receipts from Purdue		\$ 4,096.1	\$ 4,090.0	\$ 0.1	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 3.0	\$ 3.0	\$ -	\$ -
74A Division	<b>1</b>	313.4	-	-	-	149.1	164.3	-	-	-	-	-	-	-	-
74-AR & 74-AJ Decanting	<b>2</b>	156.2	-	-	-	-	-	-	-	-	-	-	-	118.0	38.2
Partnership Contributions		16.4	16.4	-	-	-	-	-	-	-	-	-	-	-	-
Partnership Distributions		4,302.4	1.2	4,215.2	86.0	-	-	-	-	-	-	-	-	-	-
Dividends		35.0	-	-	-	-	-	-	-	17.5	17.5	-	-	-	-
Top-Level Entity Transfers		404.8	-	-	-	25.0	10.2	-	-	131.9	155.8	-	-	39.5	42.4
Loan Activity between Top-Level Entities		2,676.5	39.0	350.0	-	177.4	229.5	-	488.9	650.9	740.9	-	-	-	-
Interest Income from Top-Level Entity		144.8	-	111.9	0.3	12.0	13.6	2.1	0.0	-	-	-	-	2.6	2.2
Loan Repayment from Sackler Family Members		39.7	-	-	-	-	0.8	-	30.9	8.0	-	-	-	-	-
Loan Repayment from Family Owned Entities (non-Top-Level Entities)		39.6	0.4	-	0.2	-	-	-	-	38.0	1.0	-	-	-	-
Interest Income from Sackler Family Members		6.4	-	-	-	-	0.0	-	5.7	0.6	-	-	-	-	-
Interest Income from Family Owned Entities (non-Top-Level Entities)		6.4	0.0	0.0	0.0	-	-	1.2	4.5	0.3	0.3	-	-	0.0	-
Independent Associated Companies (IACs)		634.1	85.5	-	-	-	-	-	-	274.3	274.3	-	-	-	-
Loan Proceeds from Bank		250.4	-	-	-	248.0	-	-	-	2.4	-	-	-	-	-
Interest and Dividends		22.8	0.3	4.8	0.6	3.1	5.6	0.7	0.5	1.5	3.5	0.1	0.1	0.6	1.2
Third Party - Other		1.9	0.2	(0.0)	0.1	0.3	0.1	0.0	0.0	0.1	0.2	0.0	0.0	(0.0)	1.0
Family Owned Business Investments		25.0	-	-	-	25.0	-	-	-	-	-	-	-	-	-
Third Party Investments		866.9	222.0	99.3	-	112.2	50.2	36.6	11.6	181.2	154.1	-	-	0.0	(0.3)
Family Owned Entity Holding Third Party Investments		3,719.3	15.6	417.3	-	790.4	551.9	94.3	97.4	641.7	733.6	-	-	242.9	134.2
Tax Refunds		92.4	2.7	72.2	1.9	0.8	0.8	0.0	1.5	6.8	5.5	0.0	0.0	-	-
		\$ 17,850.45	\$ 4,473.28	\$ 5,270.83	\$ 89.28	\$ 1,543.31	\$ 1,026.93	\$ 135.00	\$ 641.18	\$ 1,955.18	\$ 2,086.55	\$ 3.16	\$ 3.16	\$ 403.70	\$ 218.90

1 In 2015, 74-AR and 74-AJ were created by the division of 74-A (See Significant Transactions Section).

2 In 2019, 74-AR and 74-AJ decanted substantially all assets to 74-AR IR and 74-AJ IR, respectively (See Significant Transactions Section).

January 1, 2008 through March 31, 2020

(\$ in millions)	Notes	Total	RMLP	74A	RMCI	74-AR	74-AJ	74B	Inv. Trust	1A Trust	2A Trust	1B Trust	2B Trust	74-AR IR	74-AJ IR
<b>Uses of Cash:</b>															
Payments to Purdue		\$ (0.03)	\$ (0.01)	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ (0.01)	\$ (0.01)	\$ -	\$ -	\$ -	\$ -
74A Division	1	(313.4)	-	(313.4)	-	-	-	-	-	-	-	-	-	-	-
74-AR & 74-AJ Decanting	2	(156.2)	-	-	-	(118.0)	(38.2)	-	-	-	-	-	-	-	-
Partnership Contributions		(16.4)	-	(16.1)	(0.3)	-	-	-	-	-	-	-	-	-	-
Partnership Distributions		(4,301.2)	(4,301.2)	-	-	-	-	-	-	-	-	-	-	-	-
Dividends		(35.0)	-	-	(35.0)	-	-	-	-	-	-	-	-	-	-
Top-Level Entity Transfers		(404.8)	-	(287.7)	-	(39.5)	(42.4)	-	-	-	-	-	-	(25.0)	(10.2)
Loan Activity between Top-Level Entities		(2,676.5)	-	(1,909.7)	(18.0)	(26.9)	(11.9)	(30.0)	-	(271.4)	(408.7)	-	-	-	-
Interest Payments to Top-Level Entity		(144.8)	(0.7)	-	-	(0.6)	(1.0)	-	(42.7)	(48.2)	(51.6)	-	-	-	-
Loans to Sackler Family Members		(59.7)	-	-	-	-	(0.8)	-	(38.9)	(20.0)	-	-	-	-	-
Loan Payments to Family Owned Entities (non-Top-Level Entities)		(27.3)	-	-	(0.1)	-	-	-	(7.0)	(13.6)	(6.6)	-	-	-	-
Interest Payments to Family Owned Entities (non-Top-Level Entities)		(0.1)	-	-	-	-	-	-	-	(0.0)	(0.0)	-	-	-	-
Independent Associated Companies (IACs)		(93.6)	(85.1)	-	-	-	-	-	-	(4.2)	(4.2)	(0.0)	(0.0)	-	-
Repayment of Bank Debt		(108.0)	-	-	-	(8.0)	-	-	-	-	-	-	-	(100.0)	-
Interest		(24.0)	-	-	-	(19.5)	-	-	-	-	-	-	-	(4.5)	-
Directors' Fees – Sackler Family		(3.4)	-	-	(3.4)	-	-	-	-	-	-	-	-	-	-
Distributions to Sackler Family Beneficiaries		(15.8)	-	-	-	-	-	-	-	(13.2)	(2.6)	-	-	-	-
Third Party - Other		(39.4)	(38.0)	(0.1)	(0.2)	(0.0)	(0.0)	(0.1)	(0.0)	(0.8)	(0.2)	(0.0)	(0.0)	-	-
Family Owned Business Investments		(548.4)	-	-	-	(24.6)	-	-	(521.5)	(0.9)	-	-	-	(1.3)	-
Consulting and Professional Fees		(289.1)	(38.8)	(16.6)	(1.5)	(64.5)	(27.2)	(4.4)	(2.8)	(38.1)	(41.8)	(0.0)	(0.0)	(30.4)	(22.9)
Third Party Investments		(1,395.4)	-	(144.7)	-	(425.5)	(127.2)	(19.1)	(3.9)	(356.7)	(318.3)	-	-	-	-
Family Owned Entity Holding Third Party Investments		(4,700.2)	(7.5)	(806.6)	-	(716.5)	(710.7)	(60.7)	(22.2)	(1,079.7)	(992.6)	-	-	(195.0)	(108.6)
Tax Payments		(2,206.4)	(2.6)	(1,758.8)	(30.5)	(97.5)	(67.1)	(16.8)	(5.9)	(102.3)	(123.8)	(0.5)	(0.5)	-	-
		\$ (17,559.1)	\$ (4,474.1)	\$ (5,253.6)	\$ (89.0)	\$ (1,541.1)	\$ (1,026.5)	\$ (131.1)	\$ (644.9)	\$ (1,949.2)	\$ (1,950.5)	\$ (0.6)	\$ (0.6)	\$ (356.2)	\$ (141.8)
<b>Total Cash Flow</b>		\$ 291.3	\$ (0.9)	\$ 17.2	\$ 0.2	\$ 2.2	\$ 0.5	\$ 3.9	\$ (3.7)	\$ 6.0	\$ 136.0	\$ 2.6	\$ 2.6	\$ 47.5	\$ 77.1
<b>Ending March 31, 2020 Balance</b>		\$ 310.7	\$ 1.1	\$ 24.7	\$ 0.3	\$ 2.2	\$ 0.5	\$ 6.2	\$ 0.6	\$ 8.1	\$ 137.2	\$ 2.6	\$ 2.6	\$ 47.5	\$ 77.1

1 In 2015, 74-AR and 74-AJ were created by the division of 74-A (See Significant Transactions Section).

2 In 2019, 74-AR and 74-AJ decanted substantially all assets to 74-AR IR and 74-AJ IR, respectively (See Significant Transactions Section).

# Equity Rollforward

# Equity Rollforward Summary

January 1, 2008 through March 31, 2020

(\$ in millions)	Notes	RMLP	74A	RMCI	74-AR	74-AJ	74B	Inv. Trust	1A Trust	2A Trust	1B Trust	2B Trust	74-AR IR	74-AJ IR
<b>2008 Beginning Equity as of January 1</b>		\$ 379.7	\$ 391.9	\$ 7.6	\$ -	\$ -	\$ 95.5	\$ 99.2	\$ 68.8	\$ 70.9	\$ 0.2	\$ 0.2	\$ -	\$ -
Partnership Contributions (Cash)		16.4	-	-	-	-	-	-	-	-	-	-	-	-
Other Cash	<b>1</b>	-	-	-	174.1	179.8	-	-	0.0	-	-	-	118.0	38.2
Non-Cash	<b>2</b>	39.0	-	-	1,122.2	1,106.5	-	-	-	-	-	-	1,545.8	1,499.9
Contributions		55.4	-	-	1,296.3	1,286.3	-	-	0.0	-	-	-	1,663.8	1,538.1
Partnership Distributions (Cash)	<b>3</b>	(4,301.2)	-	-	-	-	-	-	-	-	-	-	-	-
Other Cash	<b>1</b>	-	(313.4)	(35.0)	(118.0)	(38.2)	-	-	(13.2)	(2.6)	-	-	(25.0)	(15.5)
Non Cash Taxes Paid Directly by Purdue Pharma, et al.	<b>4</b>	(385.1)	-	-	-	-	-	-	-	-	-	-	-	-
Other Non-Cash	<b>2</b>	-	(2,228.9)	-	(1,553.8)	(1,499.7)	-	-	(15.1)	(1.6)	-	-	(10.8)	(17.7)
(Withdrawals)		(4,686.3)	(2,542.3)	(35.0)	(1,671.8)	(1,537.9)	-	-	(28.3)	(4.2)	-	-	(35.8)	(33.2)
Receipts from Purdue (Cash)	<b>5</b>	4,090.0	0.1	-	-	-	-	-	-	-	3.0	3.0	-	-
Distributions from Partners (Cash)	<b>3</b>	1.2	4,215.2	86.0	-	-	-	-	-	-	-	-	-	-
Other Net Cash	<b>6</b>	192.8	(3,884.7)	(50.8)	(53.9)	(141.1)	3.9	(3.7)	19.1	138.6	(0.4)	(0.4)	(45.5)	54.4
Net Non-Cash	<b>7</b>	596.2	2,729.8	22.2	446.3	407.6	45.9	(570.2)	783.5	811.9	0.0	0.0	5.9	(77.0)
Net Income / (Loss)		4,880.2	3,060.4	57.4	392.4	266.5	49.8	(573.9)	802.7	950.5	2.6	2.6	(39.6)	(22.6)
<b>2020 Ending Equity as of March 31</b>		\$ 622.5	\$ 903.5	\$ 29.9	\$ 17.0	\$ 14.9	\$ 145.3	\$ (474.7)	\$ 843.3	\$ 1,011.0	\$ 2.8	\$ 2.8	\$ 1,586.6	\$ 1,482.0
<b>2020 Ending Equity as of March 31 (Net of Pharma Assets)</b>	<b>8</b>	\$ (0.1)	\$ 899.0	\$ 29.9	\$ 17.0	\$ 14.9	\$ 145.3	\$ (474.7)	\$ 366.3	\$ 533.6	\$ 2.8	\$ 2.8	\$ 1,586.6	\$ 1,482.0

- 1 This is primarily comprised of cash transfers associated with the 74A Division (2015) and 74-AR and 74-AJ Decanting (2019) as well as other cash transfers between Top-Level entities with an equity account impact (See Significant Transaction Section).
- 2 This is primarily comprised of non-cash transfers associated with the 74A Division (2015) and 74-AR and 74-AJ Decanting (2019) as well as other cash transfers between Top-Level entities (See Significant Transaction Section).
- 3 This is primarily comprised of cash partnership distributions by RMLP to 74A (98%) and RMCI (2%).
- 4 Reflects the distribution of benefits associated with taxes paid directly by Purdue Pharma, et al. (See Significant Transactions Section).
- 5 Receipts of cash from Purdue Pharma, LP, et al.
- 6 Net remaining cash receipts and distributions.
- 7 Net remaining non-cash receipts and distributions (See Appendix B).
- 8 Ending Equity less investments in Purdue Pharma, LP et al. and IACs

- A consolidated equity position was not presented.
- Refer to slide 21 for a description of the above categories.

# Significant Transactions

# Summary of Significant Transactions

## **Significant “Intra-Trust” Transfers (may include cash and non-cash components):**

- A. Division of 74A (2015)
- B. Intra-Trust Activity (74A, 74-AR, 1A) (2017)
- C. Intra-Trust Activity (74A, 74-AJ, 1A) (2017)
- D. Decanting of 74-AR (2019)
- E. Decanting of 74-AJ (2019)

## **Significant “Non-Cash” Transfers:**

- F. Taxes paid directly by Purdue (2008 – 2018)
- G. Distribution of Securities of a Publicly Traded Company (2009)

## A. Division of 74A (2015)

- In 2015, 74-AJ and 74-AR were created by a division of 74A.
- The purpose of the division was to allow non-pharma business related assets to be invested and managed separately with respect to the two families (i.e., the Richard Sackler family and the Jonathan Sackler family).
- After that division occurred, 74A continued to hold \$20 million of cash, the limited partner interest in RMLP, and it also holds a 50% limited partner interest in Purdue Associates L.P.
- The balance of 74A assets was divided between 74-AJ and 74-AR in equal amounts.

## B. Intra-Trust Activity (74A, 74-AR, 1A)

- As previously disclosed, over the course of several years, 1A borrowed \$565M in aggregate from 74A.
- In 2013, 74A bought \$131.9M of investments from 1A. 1A used the value of the investments to pay down \$100M of borrowings from 74A.
- In 2015, 74A transferred its 1A note receivables to 74-AR in connection with the 74A division (see page 35). Following the division, 1A made the following payments to 74-AR to retire its outstanding indebtedness:
  - Cash: 1A remitted \$86M of cash to the 74-AR Trust between 2015 and 2018.
  - Non-Cash: 1A transferred \$379M of non-cash assets to 74-AR in late 2015. The non-cash assets consisted of investments in publicly traded securities, hedge funds, private equity funds and real estate funds.
- In addition, 1A paid \$45.3M in total interest charges to 74-AR. Interest on each loan was calculated using the current applicable federal rate (i.e., "AFR rate"), as published by the IRS.



## C. Intra-Trust Activity (74A, 74-AJ, 2A)

- As previously disclosed, over the course of several years, 2A borrowed \$665M from 74A.
- In 2013, 74A bought \$155.8M of investments from 2A. 2A used the value of the investments to repay \$200M to 74A.
- In 2015, 74A transferred its 2A note receivables to 74-AJ in connection with the 74A division (see page 35). Following the division, 2A made the following payments to 74-AJ to retire its outstanding indebtedness:
  - Cash: 2A remitted a total of \$133M cash to 74-AJ between 2015 and 2018.
  - Non-Cash: 2A transferred a total of \$332M of non-cash assets to 74-AJ in late 2015. The non-cash assets consisted of investments in publicly traded securities, hedge funds, private equity funds and real estate funds.
- In addition, 2A paid \$45.5 million in total interest charges to 74-AJ. Interest on each loan was calculated using the current applicable federal rate (i.e., "AFR rate"), as published by the IRS.

## D. Decanting of 74-AR

- As previously disclosed, in 2019 74-AR transferred substantially all its assets to 74-AR IR.
- The purpose of these transactions was to facilitate adoption of modern trust provisions. The assets transferred included: cash totaling \$118M, notes receivable with a principal balance of \$139.5M, and securities with a book value of \$974.6M.
- Beneficial ownership of these assets was transferred by 74-AR to 74-AR IR as of July 23, 2019 (the effective date of the decanting), but due to the nature of the 74-AR investments (e.g., those that require third-party consent to transfer), most assets were not transferred on the books and records to 74-AR IR until a later date.
- 74-AR held the assets as nominee for 74-AR IR pending the recorded transfers. This decanting is subject to a Receipt, Refunding and Guarantee Agreement and provisions in the 74-AR IR instrument which preserve the rights of the trust's creditors.

## E. Decanting of 74-AJ

- As previously disclosed, in 2019 74-AJ transferred substantially all its assets to 74-AJ IR.
- The purpose of these transactions was to facilitate adoption of modern trust provisions. The assets transferred included: cash totaling \$38.2M, notes receivable with a principal balance of \$107.2M, and securities with a book value of \$1.3B.
- Beneficial ownership of these assets was transferred by 74-AJ to 74-AJ IR as of June 8, 2019 (the effective date of the decanting), but due to the nature of the 74-AJ investments (e.g., those that require third-party consent to transfer), most assets were not transferred on the books and records to 74-AJ IR until a later date.
- 74-AJ held the assets as nominee for 74-AJ IR pending the recorded transfers. This decanting is subject to a Receipt, Refunding and Guarantee Agreement and provisions in the 74-AJ IR instrument which preserve the rights of the trust's creditors.

## F. Taxes paid directly by Purdue (2008 – 2018)

- In addition to the \$4.1B in cash Purdue distributed to the Top-Level Entities (which is inclusive of tax distributions), Purdue also remitted payments totaling \$384.0M directly to taxing authorities on behalf of the Top-Level Entities.
- Refer to pages 11 and 15 for the non-cash impact of these transactions as reflected in the equity rollforwards for RMLP, 74A, and RMCI.

# G. Distribution of Securities of a Publicly Traded Company (2009)

Case 1:23-cv-00522-CLM Document 15-1 Filed 05/11/23 Page 21 of 21  
Pg 292 of 725

- In 2009, 1A Trust distributed publicly traded securities with a value of \$10M to two of its beneficiaries. Marianna and Rebecca Sackler each received securities valued (at the time) at approximately \$4.9 million.

# Appendix A: 2008 – 2019 Annual Sources and Uses of Cash

(\$ in millions)	Notes	Total	RMLP	74A	RMCI	74-AR	74-AJ	74B	Inv. Trust	1A Trust	2A Trust	1B Trust	2B Trust	74-AR IR	74-AJ IR
<b>Beginning January 1, 2008 Balance</b>		\$ 19.4	\$ 2.0	\$ 7.5	\$ 0.0	\$ -	\$ -	\$ 2.3	\$ 4.3	\$ 2.1	\$ 1.1	\$ 0.0	\$ 0.0	\$ -	\$ -
<b>Sources of Cash:</b>															
Receipts from Purdue		380.9	380.9	0.0	-	-	-	-	-	-	-	-	-	-	-
74A Division		-	-	-	-	-	-	-	-	-	-	-	-	-	-
74-AR & 74-AJ Decanting		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Partnership Contributions		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Partnership Distributions		377.4	-	369.9	7.5	-	-	-	-	-	-	-	-	-	-
Dividends		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Top-Level Entity Transfers		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Loan Activity between Top-Level Entities		168.0	-	-	-	-	-	-	-	84.0	84.0	-	-	-	-
Interest Income from Top-Level Entity		0.6	-	0.6	-	-	-	-	0.0	-	-	-	-	-	-
Loan Repayment from Sackler Family Members		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Loan Repayment from Family Owned Entities (non-Top-Level Entities)		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest Income from Sackler Family Members		0.2	-	-	-	-	-	-	0.2	-	-	-	-	-	-
Interest Income from Family Owned Entities (non-Top-Level Entities)		0.2	-	-	-	-	-	0.2	-	-	-	-	-	-	-
Independent Associated Companies (IACs)		33.0	-	-	-	-	-	-	-	16.5	16.5	-	-	-	-
Loan Proceeds from Bank		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest and Dividends		1.6	0.1	0.8	0.0	-	-	0.1	0.2	0.2	0.1	0.0	0.0	-	-
Third Party - Other		0.0	0.0	-	-	-	-	-	-	-	-	-	-	-	-
Family Owned Business Investments		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Third Party Investments		2.1	-	-	-	-	-	1.4	0.7	-	-	-	-	-	-
Family Owned Entity Holding Third Party Investments		34.5	-	0.7	-	-	-	8.4	19.4	2.9	3.1	-	-	-	-
Tax Refunds		12.5	0.6	11.0	0.3	-	-	0.0	0.1	0.3	0.2	-	-	-	-
		1,011.0	381.6	383.0	7.9	-	-	10.0	20.6	103.9	104.0	0.0	0.0	-	-
<b>Uses of Cash:</b>															
Payments to Purdue		(0.0)	(0.0)	-	-	-	-	-	-	(0.0)	(0.0)	-	-	-	-
74A Division		-	-	-	-	-	-	-	-	-	-	-	-	-	-
74-AR & 74-AJ Decanting		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Partnership Contributions		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Partnership Distributions		(377.4)	(377.4)	-	-	-	-	-	-	-	-	-	-	-	-
Dividends		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Top-Level Entity Transfers		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Loan Activity between Top-Level Entities		(168.0)	-	(100.0)	-	-	-	-	-	(34.0)	(34.0)	-	-	-	-
Interest Payments to Top-Level Entity		(1.2)	-	-	-	-	-	-	-	(0.6)	(0.6)	-	-	-	-
Loans to Sackler Family Members		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Loan Payments to Family Owned Entities (non-Top-Level Entities)		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest Payments to Family Owned Entities (non-Top-Level Entities)		(0.1)	-	-	-	-	-	-	-	(0.0)	(0.0)	-	-	-	-
Independent Associated Companies (IACs)		(0.0)	-	-	-	-	-	-	-	(0.0)	(0.0)	-	-	-	-
Repayment of Bank Debt		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Directors' Fees - Sackler Family	1	(0.2)	-	-	(0.2)	-	-	-	-	-	-	-	-	-	-
Distributions to Sackler Family Beneficiaries		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Third Party - Other		(0.2)	(0.0)	(0.0)	(0.1)	-	-	(0.0)	(0.0)	(0.0)	(0.0)	-	-	-	-
Family Owned Business Investments		(0.2)	-	-	-	-	-	-	(0.2)	-	-	-	-	-	-
Consulting and Professional Fees		(1.4)	(0.3)	(0.2)	(0.1)	-	-	(0.3)	(0.2)	(0.2)	(0.1)	-	-	-	-
Third Party Investments		(16.9)	-	-	-	-	-	(1.0)	(2.1)	(7.8)	(6.0)	-	-	-	-
Family Owned Entity Holding Third Party Investments		(133.6)	(2.3)	(31.5)	-	-	-	(5.4)	(12.0)	(41.5)	(40.8)	-	-	-	-
Tax Payments		(50.0)	(0.0)	(31.5)	(0.6)	-	-	(1.4)	(0.9)	(7.7)	(7.9)	-	-	-	-
		(749.2)	(380.0)	(163.2)	(1.0)	-	-	(8.2)	(15.4)	(91.8)	(89.5)	-	-	-	-
<b>Total Cash Flow</b>		261.8	1.6	219.7	6.9	-	-	1.8	5.2	12.0	14.5	0.0	0.0	-	-
<b>Ending December 31, 2008 Balance</b>		\$ 281.2	\$ 3.6	\$ 227.2	\$ 7.0	\$ -	\$ -	\$ 4.1	\$ 9.5	\$ 14.1	\$ 15.7	\$ 0.0	\$ 0.0	\$ -	\$ -

1 Payments of \$100,000 to Jonathan Sackler and \$75,000 to Richard Sackler

(\$ in millions)	Notes	Total	RMLP	74A	RMCI	74-AR	74-AJ	74B	Inv. Trust	1A Trust	2A Trust	1B Trust	2B Trust	74-AR IR	74-AJ IR
<b>Beginning January 1, 2009 Balance</b>		\$ 281.2	\$ 3.6	\$ 227.2	\$ 7.0	\$ -	\$ -	\$ 4.1	\$ 9.5	\$ 14.1	\$ 15.7	\$ 0.0	\$ 0.0	\$ -	\$ -
<b>Sources of Cash:</b>															
Receipts from Purdue		785.8	785.8	0.0	-	-	-	-	-	-	-	-	-	-	-
74A Division		-	-	-	-	-	-	-	-	-	-	-	-	-	-
74-AR & 74-AJ Decanting		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Partnership Contributions		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Partnership Distributions		775.1	-	759.6	15.5	-	-	-	-	-	-	-	-	-	-
Dividends		10.0	-	-	-	-	-	-	-	5.0	5.0	-	-	-	-
Top-Level Entity Transfers		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Loan Activity between Top-Level Entities		70.0	-	-	-	-	-	-	-	35.0	35.0	-	-	-	-
Interest Income from Top-Level Entity		4.2	-	4.2	-	-	-	-	-	-	-	-	-	-	-
Loan Repayment from Sackler Family Members		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Loan Repayment from Family Owned Entities (non-Top-Level Entities)		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest Income from Sackler Family Members		0.2	-	-	-	-	-	-	0.2	-	-	-	-	-	-
Interest Income from Family Owned Entities (non-Top-Level Entities)		0.2	-	-	0.0	-	-	0.2	-	-	-	-	-	-	-
Independent Associated Companies (IACs)		20.5	-	-	-	-	-	-	-	10.2	10.2	-	-	-	-
Loan Proceeds from Bank		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest and Dividends		0.4	0.0	0.4	0.0	-	-	0.0	0.0	0.0	0.0	-	0.0	-	-
Third Party - Other		0.1	-	-	0.1	-	-	0.0	-	0.0	0.0	-	-	-	-
Family Owned Business Investments		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Third Party Investments		11.7	-	-	-	-	-	7.6	0.6	3.5	-	-	-	-	-
Family Owned Entity Holding Third Party Investments		20.5	-	3.8	-	-	-	1.3	10.5	1.2	3.7	-	-	-	-
Tax Refunds		21.6	0.9	19.1	0.7	-	-	0.0	0.0	0.0	0.9	-	-	-	-
		1,720.3	786.7	787.1	16.3	-	-	9.2	11.3	54.9	54.8	-	0.0	-	-
<b>Uses of Cash:</b>															
Payments to Purdue		-	-	-	-	-	-	-	-	-	-	-	-	-	-
74A Division		-	-	-	-	-	-	-	-	-	-	-	-	-	-
74-AR & 74-AJ Decanting		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Partnership Contributions		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Partnership Distributions		(775.1)	(775.1)	-	-	-	-	-	-	-	-	-	-	-	-
Dividends		(10.0)	-	-	(10.0)	-	-	-	-	-	-	-	-	-	-
Top-Level Entity Transfers		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Loan Activity between Top-Level Entities		(70.0)	-	(70.0)	-	-	-	-	-	-	-	-	-	-	-
Interest Payments to Top-Level Entity		(3.7)	-	-	-	-	-	-	-	(1.8)	(1.8)	-	-	-	-
Loans to Sackler Family Members		(8.0)	-	-	-	-	-	-	(8.0)	-	-	-	-	-	-
Loan Payments to Family Owned Entities (non-Top-Level Entities)		(0.1)	-	-	(0.1)	-	-	-	-	-	-	-	-	-	-
Interest Payments to Family Owned Entities (non-Top-Level Entities)		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Independent Associated Companies (IACs)		(16.7)	(10.8)	-	-	-	-	-	-	(2.9)	(2.9)	-	-	-	-
Repayment of Bank Debt		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Directors' Fees - Sackler Family	1	(0.2)	-	-	(0.2)	-	-	-	-	-	-	-	-	-	-
Distributions to Sackler Family Beneficiaries		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Third Party - Other		(0.4)	(0.2)	(0.0)	(0.0)	-	-	(0.0)	(0.0)	(0.1)	(0.1)	-	-	-	-
Family Owned Business Investments		(0.2)	-	-	-	-	-	-	(0.2)	-	-	-	-	-	-
Consulting and Professional Fees		(2.9)	(1.0)	(0.4)	(0.1)	-	-	(0.4)	(0.3)	(0.4)	(0.4)	-	-	-	-
Third Party Investments		(5.8)	-	(0.5)	-	-	-	(0.3)	(0.6)	(4.1)	(0.2)	-	-	-	-
Family Owned Entity Holding Third Party Investments		(120.3)	(1.7)	(5.3)	-	-	-	(0.1)	(2.5)	(53.9)	(56.7)	-	-	-	-
Tax Payments		(227.0)	(0.3)	(213.2)	(6.8)	-	-	(1.2)	(0.5)	(2.2)	(2.8)	-	-	-	-
		(1,240.2)	(789.1)	(289.4)	(17.3)	-	-	(2.1)	(12.2)	(65.4)	(64.9)	-	-	-	-
<b>Total Cash Flow</b>		480.0	(2.4)	497.7	(1.0)	-	-	7.1	(0.8)	(10.5)	(10.1)	-	0.0	-	-
<b>Ending December 31, 2009 Balance</b>		\$ 761.3	\$ 1.2	\$ 724.9	\$ 6.0	\$ -	\$ -	\$ 11.3	\$ 8.7	\$ 3.6	\$ 5.6	\$ 0.0	\$ 0.0	\$ -	\$ -

1 Payments of \$100,000 to Jonathan Sackler and \$75,000 to Richard Sackler



# 2010 Annual Sources and Uses of Cash

(\$ in millions)	Notes	Total	RMLP	74A	RMCI	74-AR	74-AJ	74B	Inv. Trust	1A Trust	2A Trust	1B Trust	2B Trust	74-AR IR	74-AJ IR
<b>Beginning January 1, 2010 Balance</b>		\$ 761.3	\$ 1.2	\$ 724.9	\$ 6.0	\$ -	\$ -	\$ 11.3	\$ 8.7	\$ 3.6	\$ 5.6	\$ 0.0	\$ 0.0	\$ -	\$ -
<b>Sources of Cash:</b>															
Receipts from Purdue		734.7	734.7	0.0	-	-	-	-	-	-	-	-	-	-	-
74A Division		-	-	-	-	-	-	-	-	-	-	-	-	-	-
74-AR & 74-AJ Decanting		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Partnership Contributions		1.0	1.0	-	-	-	-	-	-	-	-	-	-	-	-
Partnership Distributions		741.7	-	726.8	14.8	-	-	-	-	-	-	-	-	-	-
Dividends		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Top-Level Entity Transfers		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Loan Activity between Top-Level Entities		274.3	-	-	-	-	-	-	10.0	195.7	68.6	-	-	-	-
Interest Income from Top-Level Entity		6.0	-	6.0	-	-	-	-	-	-	-	-	-	-	-
Loan Repayment from Sackler Family Members		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Loan Repayment from Family Owned Entities (non-Top-Level Entities)		0.2	0.0	-	0.2	-	-	-	-	-	-	-	-	-	-
Interest Income from Sackler Family Members		0.5	-	-	-	-	-	-	0.5	-	-	-	-	-	-
Interest Income from Family Owned Entities (non-Top-Level Entities)		0.2	0.0	0.0	0.0	-	-	0.2	0.0	-	-	-	-	-	-
Independent Associated Companies (IACs)		34.3	7.5	-	-	-	-	-	-	13.4	13.4	-	-	-	-
Loan Proceeds from Bank		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest and Dividends		0.9	0.0	0.9	0.0	-	-	0.0	0.0	0.0	0.0	0.0	0.0	-	-
Third Party - Other		0.2	0.1	-	-	-	-	-	-	-	0.1	-	-	-	-
Family Owned Business Investments		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Third Party Investments		7.4	-	0.2	-	-	-	1.8	5.4	-	-	-	-	-	-
Family Owned Entity Holding Third Party Investments		49.9	15.0	10.7	-	-	-	6.5	10.2	2.3	5.2	-	-	-	-
Tax Refunds		5.6	0.1	3.3	0.2	-	-	0.0	0.3	0.7	0.9	-	-	-	-
		1,856.7	758.4	748.0	15.2	-	-	8.5	26.4	212.0	88.2	0.0	0.0	-	-
<b>Uses of Cash:</b>															
Payments to Purdue		-	-	-	-	-	-	-	-	-	-	-	-	-	-
74A Division		-	-	-	-	-	-	-	-	-	-	-	-	-	-
74-AR & 74-AJ Decanting		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Partnership Contributions		(1.0)	-	(1.0)	(0.0)	-	-	-	-	-	-	-	-	-	-
Partnership Distributions		(741.7)	(741.7)	-	-	-	-	-	-	-	-	-	-	-	-
Dividends		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Top-Level Entity Transfers		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Loan Activity between Top-Level Entities		(274.3)	-	(274.3)	-	-	-	-	-	-	-	-	-	-	-
Interest Payments to Top-Level Entity		(6.0)	-	-	-	-	-	-	(0.0)	(3.2)	(2.8)	-	-	-	-
Loans to Sackler Family Members		(4.0)	-	-	-	-	-	-	(4.0)	-	-	-	-	-	-
Loan Payments to Family Owned Entities (non-Top-Level Entities)		(7.0)	-	-	-	-	-	-	(7.0)	-	-	-	-	-	-
Interest Payments to Family Owned Entities (non-Top-Level Entities)		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Independent Associated Companies (IACs)		(9.2)	(9.2)	-	-	-	-	-	-	(0.0)	(0.0)	-	-	-	-
Repayment of Bank Debt		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Directors' Fees - Sackler Family	1	(0.4)	-	-	(0.4)	-	-	-	-	-	-	-	-	-	-
Distributions to Sackler Family Beneficiaries	2	(8.7)	-	-	-	-	-	-	-	(8.7)	-	-	-	-	-
Third Party - Other		(0.1)	(0.0)	(0.0)	(0.0)	-	-	(0.0)	(0.0)	(0.0)	(0.0)	-	-	-	-
Family Owned Business Investments		(13.2)	-	-	-	-	-	-	(13.2)	-	-	-	-	-	-
Consulting and Professional Fees		(4.3)	(1.4)	(0.6)	(0.1)	-	-	(0.3)	(0.2)	(0.6)	(1.1)	-	-	-	-
Third Party Investments		(32.2)	-	(9.7)	-	-	-	(0.0)	(0.0)	(5.2)	(17.3)	-	-	-	-
Family Owned Entity Holding Third Party Investments		(356.9)	(1.5)	(88.1)	-	-	-	(10.2)	(2.6)	(191.2)	(63.3)	-	-	-	-
Tax Payments		(423.1)	-	(405.4)	(5.6)	-	-	(0.5)	(0.3)	(5.2)	(6.1)	-	-	-	-
		(1,882.0)	(753.7)	(779.0)	(6.1)	-	-	(11.1)	(27.3)	(214.1)	(90.7)	-	-	-	-
<b>Total Cash Flow</b>		(25.3)	4.7	(31.0)	9.1	-	-	(2.6)	(1.0)	(2.1)	(2.5)	0.0	0.0	-	-
<b>Ending December 31, 2010 Balance</b>		\$ 736.0	\$ 5.9	\$ 693.9	\$ 15.1	\$ -	\$ -	\$ 8.7	\$ 7.7	\$ 1.5	\$ 3.1	\$ 0.0	\$ 0.0	\$ -	\$ -

1 Payments of \$290,000 to Jonathan Sackler and \$75,000 to Richard Sackler

2 Payments of \$4,367,000 to both Marianna Sackler and Rebecca Sackler on March 5, 2010. Related to distribution of securities of a publicly traded company (See Significant Transactions Section)

NAS2618

PROFESSIONALS' EYES ONLY/HIGHLY CONFIDENTIAL—SUBJECT TO PROPOSED PROTECTIVE ORDER AND FRE 408

This presentation may only be viewed by the professionals identified on page 2, and it may not be shared.

(\$ in millions)	Notes	Total	RMLP	74A	RMCI	74-AR	74-AJ	74B	Inv. Trust	1A Trust	2A Trust	1B Trust	2B Trust	74-AR IR	74-AJ IR
<b>Beginning January 1, 2011 Balance</b>		\$ 736.0	\$ 5.9	\$ 693.9	\$ 15.1	\$ -	\$ -	\$ 8.7	\$ 7.7	\$ 1.5	\$ 3.1	\$ 0.0	\$ 0.0	\$ -	\$ -
<b>Sources of Cash:</b>															
Receipts from Purdue		533.1	533.1	0.0	-	-	-	-	-	-	-	-	-	-	-
74A Division		-	-	-	-	-	-	-	-	-	-	-	-	-	-
74-AR & 74-AJ Decanting		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Partnership Contributions		1.4	1.4	-	-	-	-	-	-	-	-	-	-	-	-
Partnership Distributions		531.4	-	520.8	10.6	-	-	-	-	-	-	-	-	-	-
Dividends		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Top-Level Entity Transfers		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Loan Activity between Top-Level Entities		686.5	-	-	-	-	-	-	58.0	269.4	359.2	-	-	-	-
Interest Income from Top-Level Entity		17.6	-	17.6	-	-	-	-	-	-	-	-	-	-	-
Loan Repayment from Sackler Family Members		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Loan Repayment from Family Owned Entities (non-Top-Level Entities)		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest Income from Sackler Family Members		0.5	-	-	-	-	-	-	0.5	-	-	-	-	-	-
Interest Income from Family Owned Entities (non-Top-Level Entities)		0.3	-	-	-	-	-	0.2	0.1	-	-	-	-	-	-
Independent Associated Companies (IACs)		40.3	16.1	-	-	-	-	-	-	12.1	12.1	-	-	-	-
Loan Proceeds from Bank		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest and Dividends		0.4	0.0	0.4	0.0	-	-	0.0	0.0	0.0	0.0	0.0	0.0	-	-
Third Party - Other		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Family Owned Business Investments		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Third Party Investments		20.5	1.1	-	-	-	-	17.6	1.7	-	0.1	-	-	-	-
Family Owned Entity Holding Third Party Investments		109.7	0.0	41.8	-	-	-	20.0	20.6	7.3	20.0	-	-	-	-
Tax Refunds		10.0	0.0	1.8	0.1	-	-	-	0.1	4.9	3.1	-	-	-	-
		1,951.7	551.7	582.5	10.7	-	-	37.8	81.0	293.7	394.4	0.0	0.0	-	-
<b>Uses of Cash:</b>															
Payments to Purdue		-	-	-	-	-	-	-	-	-	-	-	-	-	-
74A Division		-	-	-	-	-	-	-	-	-	-	-	-	-	-
74-AR & 74-AJ Decanting		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Partnership Contributions		(1.4)	-	(1.4)	(0.0)	-	-	-	-	-	-	-	-	-	-
Partnership Distributions		(531.4)	(531.4)	-	-	-	-	-	-	-	-	-	-	-	-
Dividends		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Top-Level Entity Transfers		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Loan Activity between Top-Level Entities		(686.5)	-	(681.5)	-	-	-	-	-	-	(5.0)	-	-	-	-
Interest Payments to Top-Level Entity		(17.6)	-	-	-	-	-	-	(0.6)	(8.5)	(8.6)	-	-	-	-
Loans to Sackler Family Members		(13.0)	-	-	-	-	-	-	(10.0)	(3.0)	-	-	-	-	-
Loan Payments to Family Owned Entities (non-Top-Level Entities)		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest Payments to Family Owned Entities (non-Top-Level Entities)		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Independent Associated Companies (IACs)		(10.2)	(10.2)	-	-	-	-	-	-	(0.0)	(0.0)	-	-	-	-
Repayment of Bank Debt		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Directors' Fees - Sackler Family	1	(0.2)	-	-	(0.2)	-	-	-	-	-	-	-	-	-	-
Distributions to Sackler Family Beneficiaries		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Third Party - Other		(0.1)	-	(0.0)	-	-	-	(0.0)	-	(0.0)	(0.0)	(0.0)	(0.0)	-	-
Family Owned Business Investments		(71.1)	-	-	-	-	-	-	(71.1)	-	-	-	-	-	-
Consulting and Professional Fees		(8.1)	(1.8)	(1.1)	(0.1)	-	-	(0.3)	(0.3)	(2.2)	(2.3)	-	-	-	-
Third Party Investments		(150.2)	-	(24.3)	-	-	-	(4.8)	(0.7)	(38.2)	(82.2)	-	-	-	-
Family Owned Entity Holding Third Party Investments		(671.0)	(1.0)	(128.6)	-	-	-	(7.3)	(1.7)	(238.8)	(293.7)	-	-	-	-
Tax Payments		(175.1)	-	(163.1)	(3.0)	-	-	(0.7)	(2.0)	(4.3)	(1.9)	-	-	-	-
		(2,335.9)	(544.3)	(1,000.1)	(3.4)	-	-	(13.1)	(86.3)	(295.0)	(393.7)	(0.0)	(0.0)	-	-
<b>Total Cash Flow</b>		(384.2)	7.4	(417.6)	7.3	-	-	24.6	(5.3)	(1.3)	0.7	(0.0)	(0.0)	-	-
<b>Ending December 31, 2011 Balance</b>		\$ 351.8	\$ 13.3	\$ 276.3	\$ 22.4	\$ -	\$ -	\$ 33.3	\$ 2.4	\$ 0.3	\$ 3.8	\$ 0.0	\$ 0.0	\$ -	\$ -

1 Payments of \$140,000 to Jonathan Sackler and \$75,000 to Richard Sackler

# 2012 Annual Sources and Uses of Cash

(\$ in millions)	Notes	Total	RMLP	74A	RMCI	74-AR	74-AJ	74B	Inv. Trust	1A Trust	2A Trust	1B Trust	2B Trust	74-AR IR	74-AJ IR
<b>Beginning January 1, 2012 Balance</b>		\$ 351.8	\$ 13.3	\$ 276.3	\$ 22.4	\$ -	\$ -	\$ 33.3	\$ 2.4	\$ 0.3	\$ 3.8	\$ 0.0	\$ 0.0	\$ -	\$ -
<b>Sources of Cash:</b>															
Receipts from Purdue		461.3	455.2	0.0	-	-	-	-	-	-	-	3.0	3.0	-	-
74A Division		-	-	-	-	-	-	-	-	-	-	-	-	-	-
74-AR & 74-AJ Decanting		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Partnership Contributions		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Partnership Distributions		428.2	-	419.6	8.6	-	-	-	-	-	-	-	-	-	-
Dividends		25.0	-	-	-	-	-	-	-	12.5	12.5	-	-	-	-
Top-Level Entity Transfers		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Loan Activity between Top-Level Entities		409.7	-	-	-	-	-	-	246.0	40.0	123.7	-	-	-	-
Interest Income from Top-Level Entity		25.1	-	25.1	-	-	-	-	-	-	-	-	-	-	-
Loan Repayment from Sackler Family Members		9.9	-	-	-	-	-	-	9.9	-	-	-	-	-	-
Loan Repayment from Family Owned Entities (non-Top-Level Entities)		2.0	-	-	-	-	-	-	-	1.0	1.0	-	-	-	-
Interest Income from Sackler Family Members		0.8	-	-	-	-	-	-	0.7	0.1	-	-	-	-	-
Interest Income from Family Owned Entities (non-Top-Level Entities)		0.2	-	-	-	-	-	0.1	0.1	-	0.0	-	-	-	-
Independent Associated Companies (IACs)		37.2	13.1	-	-	-	-	-	-	12.0	12.0	-	-	-	-
Loan Proceeds from Bank		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest and Dividends		0.0	0.0	0.0	0.0	-	-	0.0	0.0	0.0	0.0	0.0	0.0	-	-
Third Party - Other		0.0	-	-	-	-	-	0.0	-	-	0.0	-	-	-	-
Family Owned Business Investments		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Third Party Investments		115.1	-	77.2	-	-	-	1.2	1.2	20.4	15.2	-	-	-	-
Family Owned Entity Holding Third Party Investments		322.6	0.0	92.5	-	-	-	1.6	3.1	137.4	88.0	-	-	-	-
Tax Refunds		1.2	-	1.2	0.0	-	-	-	-	-	-	-	-	-	-
		1,838.3	468.4	615.6	8.6	-	-	2.9	261.0	223.5	252.4	3.0	3.0	-	-
<b>Uses of Cash:</b>															
Payments to Purdue		-	-	-	-	-	-	-	-	-	-	-	-	-	-
74A Division		-	-	-	-	-	-	-	-	-	-	-	-	-	-
74-AR & 74-AJ Decanting		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Partnership Contributions		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Partnership Distributions		(428.2)	(428.2)	-	-	-	-	-	-	-	-	-	-	-	-
Dividends		(25.0)	-	-	(25.0)	-	-	-	-	-	-	-	-	-	-
Top-Level Entity Transfers		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Loan Activity between Top-Level Entities		(409.7)	-	(409.7)	-	-	-	-	-	-	-	-	-	-	-
Interest Payments to Top-Level Entity		(25.1)	-	-	-	-	(25.1)	-	(1.5)	(11.3)	(12.3)	-	-	-	-
Loans to Sackler Family Members		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Loan Payments to Family Owned Entities (non-Top-Level Entities)		(2.0)	-	-	-	-	-	-	-	(1.0)	(1.0)	-	-	-	-
Interest Payments to Family Owned Entities (non-Top-Level Entities)		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Independent Associated Companies (IACs)		(19.6)	(19.6)	-	-	-	-	-	-	(0.0)	(0.0)	-	-	-	-
Repayment of Bank Debt		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Directors' Fees - Sackler Family	1	(0.2)	-	-	(0.2)	-	-	-	-	-	-	-	-	-	-
Distributions to Sackler Family Beneficiaries		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Third Party - Other		(0.0)	(0.0)	(0.0)	0.0	-	-	(0.0)	-	(0.0)	(0.0)	-	-	-	-
Family Owned Business Investments		(256.1)	-	-	-	-	-	-	(256.1)	-	-	-	-	-	-
Consulting and Professional Fees		(11.2)	(2.6)	(0.9)	(0.2)	-	-	(0.3)	(0.3)	(2.3)	(4.6)	-	-	-	-
Third Party Investments		(95.7)	-	(19.6)	-	-	-	(0.0)	(0.0)	(56.8)	(19.2)	-	-	-	-
Family Owned Entity Holding Third Party Investments		(509.0)	(0.5)	(181.3)	-	-	-	(3.8)	(1.2)	(130.4)	(191.8)	-	-	-	-
Tax Payments		(182.1)	(0.0)	(170.7)	(3.6)	-	-	(1.1)	(0.5)	(2.8)	(3.5)	-	-	-	-
		(1,964.0)	(451.0)	(782.2)	(28.9)	-	-	(5.2)	(259.6)	(204.7)	(232.4)	-	-	-	-
<b>Total Cash Flow</b>		(125.7)	17.4	(166.6)	(20.4)	-	-	(2.3)	1.4	18.8	20.0	3.0	3.0	-	-
<b>Ending December 31, 2012 Balance</b>		\$ 226.1	\$ 30.7	\$ 109.7	\$ 2.0	\$ -	\$ -	\$ 31.1	\$ 3.7	\$ 19.0	\$ 23.8	\$ 3.0	\$ 3.0	\$ -	\$ -

1 Payments of \$140,000 to Jonathan Sackler and \$75,000 to Richard Sackler

NAS2620

PROFESSIONALS' EYES ONLY/HIGHLY CONFIDENTIAL—SUBJECT TO PROPOSED PROTECTIVE ORDER AND FRE 408

This presentation may only be viewed by the professionals identified on page 2, and it may not be shared.

# 2013 Annual Sources and Uses of Cash

(\$ in millions)	Notes	Total	RMLP	74A	RMCI	74-AR	74-AJ	74B	Inv. Trust	1A Trust	2A Trust	1B Trust	2B Trust	74-AR IR	74-AJ IR
<b>Beginning January 1, 2013 Balance</b>		\$ 226.1	\$ 30.7	\$ 109.7	\$ 2.0	\$ -	\$ -	\$ 31.1	\$ 3.7	\$ 19.0	\$ 23.8	\$ 3.0	\$ 3.0	\$ -	\$ -
<b>Sources of Cash:</b>															
Receipts from Purdue		348.2	348.2	0.0	-	-	-	-	-	-	-	-	-	-	-
74A Division		-	-	-	-	-	-	-	-	-	-	-	-	-	-
74-AR & 74-AJ Decanting		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Partnership Contributions		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Partnership Distributions		594.1	-	582.2	11.9	-	-	-	-	-	-	-	-	-	-
Dividends		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Top-Level Entity Transfers		287.7	-	-	-	-	-	-	-	131.9	155.8	-	-	-	-
Loan Activity between Top-Level Entities		410.0	-	350.0	-	-	-	-	60.0	-	-	-	-	-	-
Interest Income from Top-Level Entity		26.8	-	26.8	-	-	-	-	-	-	-	-	-	-	-
Loan Repayment from Sackler Family Members		3.0	-	-	-	-	-	-	-	3.0	-	-	-	-	-
Loan Repayment from Family Owned Entities (non-Top-Level Entities)		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest Income from Sackler Family Members		0.6	-	-	-	-	-	-	0.6	0.0	-	-	-	-	-
Interest Income from Family Owned Entities (non-Top-Level Entities)		0.1	-	-	0.0	-	-	0.1	-	-	-	-	-	-	-
Independent Associated Companies (IACs)		16.0	10.7	-	-	-	-	-	-	2.6	2.6	-	-	-	-
Loan Proceeds from Bank		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest and Dividends		0.4	0.0	0.3	-	-	-	0.0	0.0	0.1	0.0	0.0	0.0	-	-
Third Party - Other		0.0	-	-	-	-	-	0.0	-	-	-	-	-	-	-
Family Owned Business Investments		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Third Party Investments	1	305.8	220.9	5.0	-	-	-	0.7	0.4	75.6	3.2	-	-	-	-
Family Owned Entity Holding Third Party Investments		563.8	0.6	95.1	-	-	-	15.6	5.9	238.7	207.9	-	-	-	-
Tax Refunds		6.7	0.0	5.4	0.1	-	-	0.0	0.0	0.8	0.4	-	-	-	-
		2,563.1	580.4	1,064.8	11.9	-	-	16.4	66.9	452.7	369.8	0.0	0.0	-	-
<b>Uses of Cash:</b>															
Payments to Purdue		-	-	-	-	-	-	-	-	-	-	-	-	-	-
74A Division		-	-	-	-	-	-	-	-	-	-	-	-	-	-
74-AR & 74-AJ Decanting		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Partnership Contributions		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Partnership Distributions		(594.1)	(594.1)	-	-	-	-	-	-	-	-	-	-	-	-
Dividends		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Top-Level Entity Transfers		(287.7)	-	(287.7)	-	-	-	-	-	-	-	-	-	-	-
Loan Activity between Top-Level Entities		(410.0)	-	(60.0)	-	-	-	-	-	(125.0)	(225.0)	-	-	-	-
Interest Payments to Top-Level Entity		(26.8)	-	-	-	-	-	-	(3.9)	(10.9)	(12.0)	-	-	-	-
Loans to Sackler Family Members		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Loan Payments to Family Owned Entities (non-Top-Level Entities)		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest Payments to Family Owned Entities (non-Top-Level Entities)		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Independent Associated Companies (IACs)		(12.0)	(11.9)	-	-	-	-	-	-	(0.0)	(0.0)	-	-	-	-
Repayment of Bank Debt		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Directors' Fees – Sackler Family	2	(0.2)	-	-	(0.2)	-	-	-	-	-	-	-	-	-	-
Distributions to Sackler Family Beneficiaries	3	(7.0)	-	-	-	-	-	-	-	(4.4)	(2.6)	-	-	-	-
Third Party - Other		(0.0)	(0.0)	(0.0)	(0.0)	-	-	(0.0)	(0.0)	(0.0)	(0.0)	-	-	-	-
Family Owned Business Investments		(60.1)	-	-	-	-	-	-	(60.1)	-	-	-	-	-	-
Consulting and Professional Fees		(14.3)	(2.2)	(0.6)	(0.1)	-	-	(0.2)	(0.2)	(5.8)	(5.1)	-	-	-	-
Third Party Investments		(225.6)	-	(18.2)	-	-	-	(0.1)	(0.3)	(190.3)	(16.7)	-	-	-	-
Family Owned Entity Holding Third Party Investments		(376.4)	(0.2)	(190.8)	-	-	-	(28.6)	(0.4)	(85.4)	(71.0)	-	-	-	-
Tax Payments		(260.9)	(0.6)	(212.5)	(3.4)	-	-	(0.6)	(0.0)	(18.5)	(24.3)	(0.4)	(0.4)	-	-
		(2,275.1)	(609.1)	(769.7)	(3.8)	-	-	(29.6)	(64.9)	(440.2)	(356.8)	(0.4)	(0.4)	-	-
<b>Total Cash Flow</b>		288.0	(28.7)	295.1	8.2	-	-	(13.2)	2.0	12.5	13.0	(0.4)	(0.4)	-	-
<b>Ending December 31, 2013 Balance</b>		\$ 514.1	\$ 2.0	\$ 404.8	\$ 10.2	\$ -	\$ -	\$ 17.8	\$ 5.7	\$ 31.5	\$ 36.8	\$ 2.6	\$ 2.6	\$ -	\$ -

1 In 2013, RMLP received approximately \$219.0 million in connection with the sale of its holdings of Infinity Pharmaceuticals Inc. ("Infinity") publicly-traded stock. Purdue Pharma acquired Infinity shares at various times and distributed such shares to the A-Side and B-Side families in equal proportions in 2008, 2009, and 2013.

2 Payments of \$140,000 to Jonathan Sackler and \$75,000 to Richard Sackler

3 Payments of \$4,422,000 to D. Sackler on April 12, 2013 and \$2,088,821 to Clare Sackler and \$502,453 to M. Sackler on December 24, 2013.

NAS2621

PROFESSIONALS' EYES ONLY/HIGHLY CONFIDENTIAL—SUBJECT TO PROPOSED PROTECTIVE ORDER AND FRE 408

This presentation may only be viewed by the professionals identified on page 2, and it may not be shared.

# 2014 Annual Sources and Uses of Cash

(\$ in millions)	Notes	Total	RMLP	74A	RMCI	74-AR	74-AJ	74B	Inv. Trust	1A Trust	2A Trust	1B Trust	2B Trust	74-AR IR	74-AJ IR
<b>Beginning January 1, 2014 Balance</b>		\$ 514.1	\$ 2.0	\$ 404.8	\$ 10.2	\$ -	\$ -	\$ 17.8	\$ 5.7	\$ 31.5	\$ 36.8	\$ 2.6	\$ 2.6	\$ -	\$ -
<b>Sources of Cash:</b>															
Receipts from Purdue		295.3	295.3	0.0	-	-	-	-	-	-	-	-	-	-	-
74A Division		-	-	-	-	-	-	-	-	-	-	-	-	-	-
74-AR & 74-AJ Decanting		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Partnership Contributions		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Partnership Distributions		302.3	-	296.3	6.0	-	-	-	-	-	-	-	-	-	-
Dividends		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Top-Level Entity Transfers		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Loan Activity between Top-Level Entities		9.9	-	-	-	-	-	-	9.9	-	-	-	-	-	-
Interest Income from Top-Level Entity		19.7	-	19.7	-	-	-	-	-	-	-	-	-	-	-
Loan Repayment from Sackler Family Members		5.0	-	-	-	-	-	-	-	5.0	-	-	-	-	-
Loan Repayment from Family Owned Entities (non-Top-Level Entities)		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest Income from Sackler Family Members		0.5	-	-	-	-	-	-	0.5	0.0	-	-	-	-	-
Interest Income from Family Owned Entities (non-Top-Level Entities)		0.2	-	-	-	-	-	0.1	0.1	-	-	-	-	-	-
Independent Associated Companies (IACs)		49.3	25.3	-	-	-	-	-	-	12.0	12.0	-	-	-	-
Loan Proceeds from Bank		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest and Dividends		0.4	-	0.3	-	-	-	0.0	-	0.1	0.0	0.0	0.0	-	-
Third Party - Other		0.0	-	0.0	-	-	-	-	-	0.0	0.0	-	-	-	-
Family Owned Business Investments		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Third Party Investments		78.7	-	6.8	-	-	-	1.2	0.3	11.7	58.7	-	-	-	-
Family Owned Entity Holding Third Party Investments		450.6	0.0	143.3	-	-	-	18.8	2.6	123.1	162.9	-	-	-	-
Tax Refunds		1.1	0.0	0.9	0.2	-	-	-	-	0.0	0.0	-	-	-	-
		1,213.0	320.6	467.4	6.2	-	-	20.0	13.4	151.8	233.6	0.0	0.0	-	-
<b>Uses of Cash:</b>															
Payments to Purdue		-	-	-	-	-	-	-	-	-	-	-	-	-	-
74A Division		-	-	-	-	-	-	-	-	-	-	-	-	-	-
74-AR & 74-AJ Decanting		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Partnership Contributions		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Partnership Distributions		(302.3)	(302.3)	-	-	-	-	-	-	-	-	-	-	-	-
Dividends		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Top-Level Entity Transfers		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Loan Activity between Top-Level Entities		(9.9)	-	(9.9)	-	-	-	-	-	-	-	-	-	-	-
Interest Payments to Top-Level Entity		(19.7)	-	-	-	-	-	-	(4.1)	(8.2)	(7.4)	-	-	-	-
Loans to Sackler Family Members		(14.9)	-	-	-	-	-	-	(9.9)	(5.0)	-	-	-	-	-
Loan Payments to Family Owned Entities (non-Top-Level Entities)		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest Payments to Family Owned Entities (non-Top-Level Entities)		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Independent Associated Companies (IACs)		(14.9)	(14.7)	-	-	-	-	-	-	(0.1)	(0.1)	-	-	-	-
Repayment of Bank Debt		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Directors' Fees - Sackler Family	1	(0.2)	-	-	(0.2)	-	-	-	-	-	-	-	-	-	-
Distributions to Sackler Family Beneficiaries		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Third Party - Other		(0.1)	0.0	(0.1)	-	-	-	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	-	-
Family Owned Business Investments		(0.1)	-	-	-	-	-	-	(0.1)	-	-	-	-	-	-
Consulting and Professional Fees		(19.4)	(2.1)	(2.1)	(0.1)	-	-	(0.3)	(0.3)	(6.2)	(8.2)	-	-	-	-
Third Party Investments		(157.7)	-	(34.9)	-	-	-	(0.0)	(0.1)	(10.1)	(112.5)	-	-	-	-
Family Owned Entity Holding Third Party Investments		(377.6)	(0.4)	(152.4)	-	-	-	(0.3)	(0.3)	(126.1)	(98.0)	-	-	-	-
Tax Payments		(192.8)	(0.4)	(146.2)	(3.4)	-	-	(4.5)	(0.0)	(12.8)	(25.3)	-	-	-	-
		(1,109.5)	(320.0)	(345.7)	(3.8)	-	-	(5.2)	(14.8)	(168.6)	(251.5)	(0.0)	(0.0)	-	-
<b>Total Cash Flow</b>		103.5	0.7	121.7	2.4	-	-	14.8	(1.4)	(16.8)	(18.0)	0.0	0.0	-	-
<b>Ending December 31, 2014 Balance</b>		\$ 617.6	\$ 2.7	\$ 526.5	\$ 12.7	\$ -	\$ -	\$ 32.6	\$ 4.3	\$ 14.8	\$ 18.8	\$ 2.6	\$ 2.6	\$ -	\$ -

1 Payments of \$140,000 to Jonathan Sackler and \$75,000 to Richard Sackler

NAS2622

PROFESSIONALS' EYES ONLY/HIGHLY CONFIDENTIAL—SUBJECT TO PROPOSED PROTECTIVE ORDER AND FRE 408

This presentation may only be viewed by the professionals identified on page 2, and it may not be shared.

# 2015 Annual Sources and Uses of Cash

(\$ in millions)	Notes	Total	RMLP	74A	RMCI	74-AR	74-AJ	74B	Inv. Trust	1A Trust	2A Trust	1B Trust	2B Trust	74-AR IR	74-AJ IR
<b>Beginning January 1, 2015 Balance</b>		\$ 617.6	\$ 2.7	\$ 526.5	\$ 12.7	\$ -	\$ -	\$ 32.6	\$ 4.3	\$ 14.8	\$ 18.8	\$ 2.6	\$ 2.6	\$ -	\$ -
<b>Sources of Cash:</b>															
Receipts from Purdue		273.5	273.5	0.0	-	-	-	-	-	-	-	-	-	-	-
74A Division	1	293.4	-	-	-	139.1	154.3	-	-	-	-	-	-	-	-
74-AR & 74-AJ Decanting		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Partnership Contributions		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Partnership Distributions		273.3	-	267.8	5.5	-	-	-	-	-	-	-	-	-	-
Dividends		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Top-Level Entity Transfers		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Loan Activity between Top-Level Entities		143.6	-	-	-	20.0	20.0	-	45.0	-	58.6	-	-	-	-
Interest Income from Top-Level Entity		7.3	-	0.0	-	3.1	3.9	0.2	-	-	-	-	-	-	-
Loan Repayment from Sackler Family Members		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Loan Repayment from Family Owned Entities (non-Top-Level Entities)		0.0	-	-	0.0	-	-	-	-	-	-	-	-	-	-
Interest Income from Sackler Family Members		0.7	-	-	-	-	-	-	0.7	0.0	-	-	-	-	-
Interest Income from Family Owned Entities (non-Top-Level Entities)		0.2	-	-	0.0	-	-	0.1	0.1	0.0	-	-	-	-	-
Independent Associated Companies (IACs)		33.1	5.7	-	-	-	-	-	-	13.7	13.7	-	-	-	-
Loan Proceeds from Bank		75.0	-	-	-	75.0	-	-	-	-	-	-	-	-	-
Interest and Dividends		0.4	-	0.2	-	0.1	0.1	0.0	-	0.0	0.0	0.0	0.0	-	-
Third Party - Other		0.0	-	-	-	-	-	-	-	0.0	0.0	-	-	-	-
Family Owned Business Investments		20.0	-	-	-	20.0	-	-	-	-	-	-	-	-	-
Third Party Investments		51.5	-	1.1	-	23.7	2.3	1.5	0.5	3.3	19.1	-	-	-	-
Family Owned Entity Holding Third Party Investments		308.8	0.0	28.0	-	121.2	52.3	2.6	10.6	49.9	44.2	-	-	-	-
Tax Refunds		0.8	0.1	0.6	0.1	-	-	0.0	-	-	0.0	-	-	-	-
		1,481.5	279.3	297.8	5.6	402.1	232.8	4.4	56.9	67.0	135.7	0.0	0.0	-	-
<b>Uses of Cash:</b>															
Payments to Purdue		-	-	-	-	-	-	-	-	-	-	-	-	-	-
74A Division	1	(293.4)	-	(293.4)	-	-	-	-	-	-	-	-	-	-	-
74-AR & 74-AJ Decanting		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Partnership Contributions		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Partnership Distributions		(273.3)	(273.3)	-	-	-	-	-	-	-	-	-	-	-	-
Dividends		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Top-Level Entity Transfers		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Loan Activity between Top-Level Entities		(143.6)	-	(113.6)	-	-	-	(30.0)	-	-	-	-	-	-	-
Interest Payments to Top-Level Entity		(7.3)	-	-	-	(0.0)	(0.0)	-	(4.5)	(1.0)	(1.7)	-	-	-	-
Loans to Sackler Family Members		(2.0)	-	-	-	-	-	-	-	(2.0)	-	-	-	-	-
Loan Payments to Family Owned Entities (non-Top-Level Entities)		(6.0)	-	-	-	-	-	-	-	(6.0)	-	-	-	-	-
Interest Payments to Family Owned Entities (non-Top-Level Entities)		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Independent Associated Companies (IACs)		(3.3)	(3.3)	-	-	-	-	-	-	(0.0)	(0.0)	-	-	-	-
Repayment of Bank Debt		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest		(0.1)	-	-	-	(0.1)	-	-	-	-	-	-	-	-	-
Directors' Fees - Sackler Family	2	(1.2)	-	-	(1.2)	-	-	-	-	-	-	-	-	-	-
Distributions to Sackler Family Beneficiaries		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Third Party - Other		(0.1)	(0.0)	(0.0)	-	-	-	(0.0)	(0.0)	(0.0)	(0.0)	-	-	-	-
Family Owned Business Investments		(55.1)	-	-	-	(5.0)	-	-	(50.1)	-	-	-	-	-	-
Consulting and Professional Fees		(24.2)	(1.9)	(3.2)	(0.1)	(3.4)	(1.7)	(0.4)	(0.3)	(6.9)	(6.3)	-	-	-	-
Third Party Investments		(262.3)	-	(29.0)	-	(179.2)	(12.8)	(1.5)	(0.0)	(0.1)	(39.7)	-	-	-	-
Family Owned Entity Holding Third Party Investments		(375.7)	-	(16.5)	-	(105.0)	(147.2)	(0.0)	(0.1)	(35.1)	(71.8)	-	-	-	-
Tax Payments		(266.6)	(0.3)	(238.3)	(2.5)	-	-	(2.5)	(0.2)	(7.8)	(15.0)	(0.0)	(0.0)	-	-
		(1,714.2)	(278.9)	(694.0)	(3.9)	(292.7)	(161.7)	(34.4)	(55.3)	(58.8)	(134.5)	(0.0)	(0.0)	-	-
<b>Total Cash Flow</b>		(232.7)	0.4	(396.2)	1.7	109.4	71.0	(30.0)	1.6	8.2	1.1	0.0	0.0	-	-
<b>Ending December 31, 2015 Balance</b>		\$ 384.9	\$ 3.2	\$ 130.3	\$ 14.4	\$ 109.4	\$ 71.0	\$ 2.7	\$ 5.9	\$ 23.0	\$ 19.9	\$ 2.6	\$ 2.6	\$ -	\$ -

- 1 In 2015, 74-AR and 74-AJ were created by the division of 74-A (See Significant Transactions Section).  
2 Payments of \$640,000 to Jonathan Sackler, \$75,000 to Richard Sackler, and \$500,000 to David Sackler

# 2016 Annual Sources and Uses of Cash

(\$ in millions)	Notes	Total	RMLP	74A	RMCI	74-AR	74-AJ	74B	Inv. Trust	1A Trust	2A Trust	1B Trust	2B Trust	74-AR IR	74-AJ IR
<b>Beginning January 1, 2016 Balance</b>		\$ 384.9	\$ 3.2	\$ 130.3	\$ 14.4	\$ 109.4	\$ 71.0	\$ 2.7	\$ 5.9	\$ 23.0	\$ 19.9	\$ 2.6	\$ 2.6	\$ -	\$ -
<b>Sources of Cash:</b>															
Receipts from Purdue		209.0	209.0	0.0	-	-	-	-	-	-	-	-	-	-	-
74A Division		15.0	-	-	-	7.5	7.5	-	-	-	-	-	-	-	-
74-AR & 74-AJ Decanting		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Partnership Contributions		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Partnership Distributions		198.9	-	195.0	4.0	-	-	-	-	-	-	-	-	-	-
Dividends		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Top-Level Entity Transfers		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Loan Activity between Top-Level Entities		133.8	-	-	-	59.0	49.8	-	25.0	-	-	-	-	-	-
Interest Income from Top-Level Entity		9.4	-	2.0	-	3.0	3.9	0.5	-	-	-	-	-	-	-
Loan Repayment from Sackler Family Members		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Loan Repayment from Family Owned Entities (non-Top-Level Entities)		0.1	0.1	-	-	-	-	-	-	-	-	-	-	-	-
Interest Income from Sackler Family Members		0.7	-	-	-	-	-	-	0.7	0.0	-	-	-	-	-
Interest Income from Family Owned Entities (non-Top-Level Entities)		0.4	0.0	-	-	-	-	0.1	0.3	0.0	-	-	-	-	-
Independent Associated Companies (IACs)		15.4	3.3	-	-	-	-	-	-	6.0	6.0	-	-	-	-
Loan Proceeds from Bank		33.0	-	-	-	33.0	-	-	-	-	-	-	-	-	-
Interest and Dividends		1.9	-	0.1	-	0.8	1.0	0.0	-	0.1	0.0	0.0	0.0	-	-
Third Party - Other		0.0	0.0	-	-	-	-	0.0	-	0.0	0.0	-	-	-	-
Family Owned Business Investments		5.0	-	-	-	5.0	-	-	-	-	-	-	-	-	-
Third Party Investments		74.0	-	-	-	15.2	9.7	1.6	0.4	44.0	3.2	-	-	-	-
Family Owned Entity Holding Third Party Investments		310.0	0.0	-	-	116.8	118.9	12.2	8.8	10.2	43.0	-	-	-	-
Tax Refunds		1.8	0.0	1.5	0.2	0.0	0.0	0.0	0.0	0.0	0.0	-	-	-	-
		1,008.3	212.5	198.5	4.2	240.3	190.7	14.3	35.2	60.3	52.3	0.0	0.0	-	-
<b>Uses of Cash:</b>															
Payments to Purdue		-	-	-	-	-	-	-	-	-	-	-	-	-	-
74A Division		(15.0)	-	(15.0)	-	-	-	-	-	-	-	-	-	-	-
74-AR & 74-AJ Decanting		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Partnership Contributions		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Partnership Distributions		(198.9)	(198.9)	-	-	-	-	-	-	-	-	-	-	-	-
Dividends		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Top-Level Entity Transfers		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Loan Activity between Top-Level Entities		(133.8)	-	(104.8)	-	-	-	-	-	(29.0)	-	-	-	-	-
Interest Payments to Top-Level Entity		(9.4)	-	-	-	(0.6)	(0.9)	-	(5.1)	(0.9)	(1.8)	-	-	-	-
Loans to Sackler Family Members		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Loan Payments to Family Owned Entities (non-Top-Level Entities)		(1.0)	-	-	-	-	-	-	-	(1.0)	-	-	-	-	-
Interest Payments to Family Owned Entities (non-Top-Level Entities)		(0.0)	-	-	-	-	-	-	-	(0.0)	(0.0)	-	-	-	-
Independent Associated Companies (IACs)		(4.2)	(3.9)	-	-	-	-	-	-	(0.1)	(0.1)	(0.0)	(0.0)	-	-
Repayment of Bank Debt		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest		(2.0)	-	-	-	(2.0)	-	-	-	-	-	-	-	-	-
Directors' Fees - Sackler Family	1	(0.6)	-	-	(0.6)	-	-	-	-	-	-	-	-	-	-
Distributions to Sackler Family Beneficiaries	2	(0.1)	-	-	-	-	-	-	-	(0.1)	-	-	-	-	-
Third Party - Other		(0.0)	(0.0)	-	-	-	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	-	-	-	-
Family Owned Business Investments		(35.2)	-	-	-	(10.1)	-	-	(25.1)	-	-	-	-	-	-
Consulting and Professional Fees		(25.5)	(1.9)	(0.5)	(0.1)	(10.9)	(6.3)	(0.4)	(0.3)	(2.4)	(2.8)	-	-	-	-
Third Party Investments		(107.3)	-	-	-	(61.5)	(12.8)	(0.0)	(0.0)	(23.2)	(9.8)	-	-	-	-
Family Owned Entity Holding Third Party Investments		(319.1)	-	(1.1)	-	(208.3)	(77.5)	(0.0)	(0.4)	(19.6)	(12.2)	-	-	-	-
Tax Payments		(164.2)	(0.6)	(119.3)	(0.9)	(14.4)	(16.3)	(0.0)	(1.5)	(4.9)	(6.2)	(0.0)	(0.0)	-	-
		(1,016.3)	(205.3)	(240.7)	(1.7)	(307.7)	(114.0)	(0.4)	(32.5)	(81.1)	(33.1)	(0.0)	(0.0)	-	-
<b>Total Cash Flow</b>		(8.0)	7.2	(42.1)	2.5	(67.3)	76.7	13.9	2.7	(20.8)	19.2	(0.0)	(0.0)	-	-
<b>Ending December 31, 2016 Balance</b>		\$ 376.9	\$ 10.3	\$ 88.2	\$ 16.9	\$ 42.1	\$ 147.8	\$ 16.6	\$ 8.6	\$ 2.1	\$ 39.1	\$ 2.6	\$ 2.6	\$ -	\$ -

- 1 Payments of \$320,000 to Jonathan Sackler, \$37,500 to Richard Sackler, and \$250,000 to David Sackler  
2 Payment of \$50,000 to Marianna Sackler on December 14, 2016

NAS2624

PROFESSIONALS' EYES ONLY/HIGHLY CONFIDENTIAL—SUBJECT TO PROPOSED PROTECTIVE ORDER AND FRE 408

This presentation may only be viewed by the professionals identified on page 2, and it may not be shared.

# 2017 Annual Sources and Uses of Cash

(\$ in millions)	Notes	Total	RMLP	74A	RMCI	74-AR	74-AJ	74B	Inv. Trust	1A Trust	2A Trust	1B Trust	2B Trust	74-AR IR	74-AJ IR
<b>Beginning January 1, 2017 Balance</b>		\$ 376.9	\$ 10.3	\$ 88.2	\$ 16.9	\$ 42.1	\$ 147.8	\$ 16.6	\$ 8.6	\$ 2.1	\$ 39.1	\$ 2.6	\$ 2.6	\$ -	\$ -
<b>Sources of Cash:</b>															
Receipts from Purdue		73.6	73.6	0.0	-	-	-	-	-	-	-	-	-	-	-
74A Division		5.0	-	-	-	2.5	2.5	-	-	-	-	-	-	-	-
74-AR & 74-AJ Decanting		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Partnership Contributions		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Partnership Distributions		78.7	-	77.1	1.6	-	-	-	-	-	-	-	-	-	-
Dividends		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Top-Level Entity Transfers		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Loan Activity between Top-Level Entities		139.9	-	-	-	25.0	56.2	-	35.0	11.9	11.9	-	-	-	-
Interest Income from Top-Level Entity		8.6	-	3.0	-	2.3	2.9	0.5	-	-	-	-	-	-	-
Loan Repayment from Sackler Family Members		10.0	-	-	-	-	-	-	10.0	-	-	-	-	-	-
Loan Repayment from Family Owned Entities (non-Top-Level Entities)		6.0	-	-	-	-	-	-	-	6.0	-	-	-	-	-
Interest Income from Sackler Family Members		0.6	-	-	-	-	-	-	0.6	0.0	-	-	-	-	-
Interest Income from Family Owned Entities (non-Top-Level Entities)		1.1	-	-	-	-	-	0.1	0.9	0.1	0.0	-	-	-	-
Independent Associated Companies (IACs)		35.8	1.1	-	-	-	-	-	-	17.4	17.4	-	-	-	-
Loan Proceeds from Bank		102.4	-	-	-	100.0	-	-	-	2.4	-	-	-	-	-
Interest and Dividends		3.0	0.0	0.4	0.2	0.6	1.1	0.1	0.1	0.1	0.3	0.0	0.0	-	-
Third Party - Other		0.2	0.0	(0.0)	(0.0)	0.1	(0.0)	(0.0)	(0.0)	0.1	0.0	(0.0)	(0.0)	-	-
Family Owned Business Investments		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Third Party Investments		66.6	-	-	-	28.3	10.0	1.1	0.5	13.5	13.1	-	-	-	-
Family Owned Entity Holding Third Party Investments		285.3	0.0	-	-	127.5	94.7	2.5	2.9	13.0	44.8	-	-	-	-
Tax Refunds		3.0	0.3	1.6	0.1	0.0	0.1	0.0	0.9	-	0.0	-	-	-	-
		819.8	75.0	82.1	1.8	286.3	167.5	4.2	50.9	64.5	87.5	0.0	0.0	-	-
<b>Uses of Cash:</b>															
Payments to Purdue		-	-	-	-	-	-	-	-	-	-	-	-	-	-
74A Division		(5.0)	-	(5.0)	-	-	-	-	-	-	-	-	-	-	-
74-AR & 74-AJ Decanting		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Partnership Contributions		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Partnership Distributions		(78.7)	(78.7)	-	-	-	-	-	-	-	-	-	-	-	-
Dividends		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Top-Level Entity Transfers		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Loan Activity between Top-Level Entities		(139.9)	-	(65.0)	-	(11.9)	(11.9)	-	-	(10.0)	(41.2)	-	-	-	-
Interest Payments to Top-Level Entity		(8.6)	-	-	-	-	-	-	(6.0)	(0.9)	(1.7)	-	-	-	-
Loans to Sackler Family Members		(7.8)	-	-	-	-	(0.8)	-	-	(7.0)	-	-	-	-	-
Loan Payments to Family Owned Entities (non-Top-Level Entities)		(11.2)	-	-	-	-	-	-	-	(5.6)	(5.6)	-	-	-	-
Interest Payments to Family Owned Entities (non-Top-Level Entities)		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Independent Associated Companies (IACs)		(3.5)	(1.5)	-	-	-	-	-	-	(1.0)	(1.0)	-	-	-	-
Repayment of Bank Debt		(8.0)	-	-	-	(8.0)	-	-	-	-	-	-	-	-	-
Interest		(3.2)	-	-	-	(3.2)	-	-	-	-	-	-	-	-	-
Directors' Fees - Sackler Family		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Distributions to Sackler Family Beneficiaries		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Third Party - Other		(0.1)	(0.0)	-	-	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	-	-	-	-
Family Owned Business Investments		(48.8)	-	-	-	(3.7)	-	-	(45.1)	-	-	-	-	-	-
Consulting and Professional Fees		(27.2)	(2.1)	(0.8)	(0.1)	(11.3)	(5.9)	(0.3)	(0.1)	(2.3)	(4.2)	-	-	-	-
Third Party Investments		(161.5)	-	-	-	(91.6)	(57.0)	(3.0)	(0.0)	(3.9)	(6.0)	-	-	-	-
Family Owned Entity Holding Third Party Investments		(304.2)	-	(1.2)	-	(90.1)	(168.0)	-	(0.9)	(16.0)	(27.9)	-	-	-	-
Tax Payments		(90.4)	(0.2)	(47.8)	(0.4)	(10.0)	(13.5)	(0.6)	(0.0)	(10.8)	(7.1)	(0.0)	(0.0)	-	-
		(897.9)	(82.4)	(119.9)	(0.5)	(229.8)	(256.9)	(3.9)	(52.2)	(57.6)	(94.7)	(0.0)	(0.0)	-	-
<b>Total Cash Flow</b>		(78.1)	(7.5)	(37.8)	1.2	56.5	(89.4)	0.3	(1.3)	6.9	(7.2)	0.0	0.0	-	-
<b>Ending December 31, 2017 Balance</b>		\$ 298.8	\$ 2.9	\$ 50.4	\$ 18.2	\$ 98.6	\$ 58.4	\$ 16.9	\$ 7.4	\$ 9.0	\$ 31.9	\$ 2.6	\$ 2.6	\$ -	\$ -

NAS2625

PROFESSIONALS' EYES ONLY/HIGHLY CONFIDENTIAL—SUBJECT TO PROPOSED PROTECTIVE ORDER AND FRE 408

This presentation may only be viewed by the professionals identified on page 2, and it may not be shared.



(\$ in millions)	Notes	Total	RMLP	74A	RMCI	74-AR	74-AJ	74B	Inv. Trust	1A Trust	2A Trust	1B Trust	2B Trust	74-AR IR	74-AJ IR
<b>Beginning January 1, 2018 Balance</b>		\$ 298.8	\$ 2.9	\$ 50.4	\$ 18.2	\$ 98.6	\$ 58.4	\$ 16.9	\$ 7.4	\$ 9.0	\$ 31.9	\$ 2.6	\$ 2.6	\$ -	\$ -
<b>Sources of Cash:</b>															
Receipts from Purdue		0.7	0.7	0.0	-	-	-	-	-	-	-	-	-	-	-
74A Division		-	-	-	-	-	-	-	-	-	-	-	-	-	-
74-AR & 74-AJ Decanting		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Partnership Contributions		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Partnership Distributions		0.2	-	0.2	0.0	-	-	-	-	-	-	-	-	-	-
Dividends		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Top-Level Entity Transfers		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Loan Activity between Top-Level Entities		191.9	-	-	-	73.4	103.5	-	-	15.0	-	-	-	-	-
Interest Income from Top-Level Entity		10.9	-	4.0	-	3.5	2.9	0.5	-	-	-	-	-	-	-
Loan Repayment from Sackler Family Members		7.8	-	-	-	-	0.8	-	7.0	-	-	-	-	-	-
Loan Repayment from Family Owned Entities (non-Top-Level Entities)		1.3	0.3	-	-	-	-	-	-	1.0	-	-	-	-	-
Interest Income from Sackler Family Members		0.5	-	-	-	-	0.0	-	0.4	0.2	-	-	-	-	-
Interest Income from Family Owned Entities (non-Top-Level Entities)		1.7	0.0	-	-	-	-	0.1	1.4	0.1	0.1	-	-	-	-
Independent Associated Companies (IACs)		257.4	0.1	-	-	-	-	-	-	128.6	128.6	-	-	-	-
Loan Proceeds from Bank		40.0	-	-	-	40.0	-	-	-	-	-	-	-	-	-
Interest and Dividends		4.5	0.0	0.6	0.3	0.9	1.8	0.3	0.1	0.1	0.3	0.0	0.0	-	-
Third Party - Other		0.4	0.0	0.0	0.0	0.2	0.1	0.0	0.0	0.0	0.0	0.0	0.0	-	-
Family Owned Business Investments		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Third Party Investments		125.4	-	-	-	44.9	28.1	1.0	0.0	9.2	42.2	-	-	-	-
Family Owned Entity Holding Third Party Investments		381.1	0.0	0.8	-	153.8	204.6	1.6	1.6	4.4	14.3	-	-	-	-
Tax Refunds		1.8	0.5	0.4	0.1	0.7	0.0	-	0.0	-	0.0	-	-	-	-
		1,025.6	1.8	6.1	0.4	317.6	341.7	3.3	10.6	158.5	185.5	0.0	0.0	-	-
<b>Uses of Cash:</b>															
Payments to Purdue		-	-	-	-	-	-	-	-	-	-	-	-	-	-
74A Division		-	-	-	-	-	-	-	-	-	-	-	-	-	-
74-AR & 74-AJ Decanting		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Partnership Contributions		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Partnership Distributions		(0.2)	(0.2)	-	-	-	-	-	-	-	-	-	-	-	-
Dividends		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Top-Level Entity Transfers		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Loan Activity between Top-Level Entities		(191.9)	-	-	-	(15.0)	-	-	-	(73.4)	(103.5)	-	-	-	-
Interest Payments to Top-Level Entity		(10.9)	-	-	-	-	-	-	(9.2)	(1.0)	(0.8)	-	-	-	-
Loans to Sackler Family Members		(10.0)	-	-	-	-	-	-	(7.0)	(3.0)	-	-	-	-	-
Loan Payments to Family Owned Entities (non-Top-Level Entities)		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest Payments to Family Owned Entities (non-Top-Level Entities)		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Independent Associated Companies (IACs)		(0.0)	-	-	-	-	-	-	-	(0.0)	(0.0)	-	-	-	-
Repayment of Bank Debt		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest		(8.9)	-	-	-	(8.9)	-	-	-	-	-	-	-	-	-
Directors' Fees - Sackler Family		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Distributions to Sackler Family Beneficiaries		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Third Party - Other		(0.3)	(0.0)	-	-	(0.0)	(0.0)	(0.0)	-	(0.3)	0.0	-	-	-	-
Family Owned Business Investments		(4.4)	-	-	-	(3.3)	-	-	(0.1)	(0.9)	-	-	-	-	-
Consulting and Professional Fees		(30.0)	(1.5)	(2.3)	(0.1)	(13.0)	(7.1)	(0.5)	(0.2)	(2.5)	(2.8)	(0.0)	(0.0)	-	-
Third Party Investments		(171.3)	-	(6.8)	-	(92.7)	(44.5)	(6.7)	(0.0)	(11.9)	(8.7)	-	-	-	-
Family Owned Entity Holding Third Party Investments		(458.9)	-	(4.6)	-	(225.6)	(215.5)	-	(0.0)	(4.9)	(8.3)	-	-	-	-
Tax Payments		(86.9)	(0.0)	(10.7)	(0.1)	(19.8)	(18.1)	(1.4)	(0.0)	(16.4)	(20.3)	(0.1)	(0.1)	-	-
		(973.6)	(1.7)	(24.4)	(0.2)	(378.2)	(285.3)	(8.5)	(16.5)	(114.4)	(144.2)	(0.1)	(0.1)	-	-
<b>Total Cash Flow</b>		52.0	0.1	(18.4)	0.2	(60.6)	56.4	(5.2)	(5.9)	44.2	41.3	(0.0)	(0.0)	-	-
<b>Ending December 31, 2018 Balance</b>		\$ 350.8	\$ 2.9	\$ 32.0	\$ 18.3	\$ 38.0	\$ 114.8	\$ 11.8	\$ 1.4	\$ 53.2	\$ 73.2	\$ 2.5	\$ 2.5	\$ -	\$ -

# 2019 Annual Sources and Uses of Cash

(\$ in millions)	Notes	Total	RMLP	74A	RMCI	74-AR	74-AJ	74B	Inv. Trust	1A Trust	2A Trust	1B Trust	2B Trust	74-AR IR	74-AJ IR
<b>Beginning January 1, 2019 Balance</b>		\$ 350.8	\$ 2.9	\$ 32.0	\$ 18.3	\$ 38.0	\$ 114.8	\$ 11.8	\$ 1.4	\$ 53.2	\$ 73.2	\$ 2.5	\$ 2.5	\$ -	\$ -
<b>Sources of Cash:</b>															
Receipts from Purdue		0.0	0.0	0.0	-	-	-	-	-	-	-	-	-	-	-
74A Division		-	-	-	-	-	-	-	-	-	-	-	-	-	-
74-AR & 74-AJ Decanting	1	156.2	-	-	-	-	-	-	-	-	-	-	-	118.0	38.2
Partnership Contributions		2.0	2.0	-	-	-	-	-	-	-	-	-	-	-	-
Partnership Distributions		1.2	1.2	-	-	-	-	-	-	-	-	-	-	-	-
Dividends		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Top-Level Entity Transfers		82.0	-	-	-	-	-	-	-	-	-	-	-	39.5	42.4
Loan Activity between Top-Level Entities		39.0	39.0	-	-	-	-	-	-	-	-	-	-	-	-
Interest Income from Top-Level Entity		8.4	-	2.8	0.3	-	-	0.5	-	-	-	-	-	2.6	2.2
Loan Repayment from Sackler Family Members		4.0	-	-	-	-	-	-	4.0	-	-	-	-	-	-
Loan Repayment from Family Owned Entities (non-Top-Level Entities)		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest Income from Sackler Family Members		0.7	-	-	-	-	-	-	0.4	0.3	-	-	-	-	-
Interest Income from Family Owned Entities (non-Top-Level Entities)		1.7	-	-	-	-	-	0.1	1.4	0.1	0.1	-	-	0.0	-
Independent Associated Companies (IACs)		55.5	2.4	-	-	-	-	-	-	26.6	26.6	-	-	-	-
Loan Proceeds from Bank		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest and Dividends		7.2	0.1	0.3	0.1	0.7	1.7	0.2	0.1	0.8	2.0	0.1	0.1	0.4	0.8
Third Party - Other		1.0	0.0	0.0	0.0	0.0	0.0	(0.0)	(0.0)	0.0	(0.0)	(0.0)	(0.0)	(0.0)	1.0
Family Owned Business Investments		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Third Party Investments		7.1	-	6.9	-	-	0.2	-	-	-	0.0	-	-	(0.0)	(0.0)
Family Owned Entity Holding Third Party Investments		680.1	0.0	0.3	-	271.1	81.4	2.8	1.1	41.9	78.3	-	-	122.5	80.8
Tax Refunds		26.3	0.1	25.3	-	0.1	0.6	0.0	0.1	-	-	0.0	0.0	-	-
		1,072.4	44.8	35.6	0.5	271.8	84.0	3.6	7.0	69.6	107.0	0.1	0.1	283.0	165.2
<b>Uses of Cash:</b>															
Payments to Purdue		-	-	-	-	-	-	-	-	-	-	-	-	-	-
74A Division		-	-	-	-	-	-	-	-	-	-	-	-	-	-
74-AR & 74-AJ Decanting	1	(156.2)	-	-	-	(118.0)	(38.2)	-	-	-	-	-	-	-	-
Partnership Contributions		(2.0)	-	(2.0)	(0.0)	-	-	-	-	-	-	-	-	-	-
Partnership Distributions		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Dividends		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Top-Level Entity Transfers		(82.0)	-	-	-	(39.5)	(42.4)	-	-	-	-	-	-	-	-
Loan Activity between Top-Level Entities		(39.0)	-	(21.0)	(18.0)	-	-	-	-	-	-	-	-	-	-
Interest Payments to Top-Level Entity		(8.4)	(0.7)	-	-	-	-	-	(7.7)	-	-	-	-	-	-
Loans to Sackler Family Members		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Loan Payments to Family Owned Entities (non-Top-Level Entities)		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest Payments to Family Owned Entities (non-Top-Level Entities)		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Independent Associated Companies (IACs)		(0.0)	(0.0)	-	-	-	-	-	-	(0.0)	(0.0)	-	-	-	-
Repayment of Bank Debt		(100.0)	-	-	-	-	-	-	-	-	-	-	-	(100.0)	-
Interest		(8.8)	-	-	-	(5.3)	-	-	-	-	-	-	-	(3.5)	-
Directors' Fees - Sackler Family		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Distributions to Sackler Family Beneficiaries		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Third Party - Other	2	(38.0)	(37.8)	-	(0.0)	-	-	(0.0)	-	(0.2)	(0.0)	-	-	-	-
Family Owned Business Investments		(3.9)	-	-	-	(2.5)	-	-	(0.1)	-	-	-	-	(1.3)	-
Consulting and Professional Fees		(85.8)	(7.9)	(3.7)	(0.2)	(26.0)	(6.1)	(0.7)	(0.1)	(3.8)	(2.9)	(0.0)	(0.0)	(15.1)	(19.2)
Third Party Investments		(7.2)	-	(1.5)	-	(0.5)	0.2	(1.5)	-	(4.0)	(0.0)	-	-	-	-
Family Owned Entity Holding Third Party Investments		(539.1)	-	(3.8)	-	(87.5)	(102.5)	(3.5)	(0.0)	(84.1)	(45.6)	-	-	(137.2)	(74.9)
Tax Payments		(51.1)	(0.1)	(0.1)	(0.0)	(28.3)	(9.2)	(2.1)	(0.0)	(8.8)	(2.5)	-	-	-	-
		(1,121.6)	(46.6)	(32.0)	(18.3)	(307.6)	(198.2)	(7.8)	(7.9)	(101.0)	(51.1)	(0.0)	(0.0)	(257.1)	(94.0)
<b>Total Cash Flow</b>		(49.2)	(1.7)	3.7	(17.8)	(35.7)	(114.2)	(4.2)	(0.9)	(31.4)	55.8	0.1	0.1	25.9	71.2
<b>Ending December 31, 2019 Balance</b>		\$ 301.6	\$ 1.2	\$ 35.7	\$ 0.5	\$ 2.2	\$ 0.6	\$ 7.5	\$ 0.6	\$ 21.8	\$ 129.1	\$ 2.6	\$ 2.6	\$ 25.9	\$ 71.2

1 In 2019, 74-AR and 74-AJ decanted substantially all assets to 74-AR IR and 74-AJ IR trusts, respectively (See Significant Transactions Section).

2 Payment of \$37.5 million legal settlement with the State of Oklahoma

NAS2627

PROFESSIONALS' EYES ONLY/HIGHLY CONFIDENTIAL—SUBJECT TO PROPOSED PROTECTIVE ORDER AND FRE 408

This presentation may only be viewed by the professionals identified on page 2, and it may not be shared.

## Appendix B: 2008 – 2020 Equity Rollforward

(\$ in millions)		Notes	RMLP	74A	RMCI	74-AR	74-AJ	74B	Inv. Trust	1A Trust	2A Trust	1B Trust	2B Trust	74-AR IR	74-AJ IR
2008	Beginning Equity		\$ 379.7	\$ 391.9	\$ 7.6	\$ -	\$ -	\$ 95.5	\$ 99.2	\$ 68.8	\$ 70.9	\$ 0.2	\$ 0.2	\$ -	\$ -
2008	Partnership Contributions (Cash)		-	-	-	-	-	-	-	-	-	-	-	-	-
2008	Other Cash														
2008	Non-Cash														
2008	Contributions		-	-	-	-	-	-	-	-	-	-	-	-	-
2008	Partnership Distributions (Cash)		(377.4)	-	-	-	-	-	-	-	-	-	-	-	-
2008	Other Cash														
2008	Non Cash Taxes Paid Directly by Purdue Pharma, et al.		(268.3)	-	-	-	-	-	-	-	-	-	-	-	-
2008	Other Non-Cash														
2008	(Withdrawals)		(645.8)	-	-	-	-	-	-	-	-	-	-	-	-
2008	Receipts from Purdue (Cash)		380.9	0.0	-	-	-	-	-	-	-	-	-	-	-
2008	Distributions from Partners (Cash)		-	369.9	7.5	-	-	-	-	-	-	-	-	-	-
2008	Other Net Cash		(1.9)	(150.2)	(0.6)	-	-	1.8	5.2	12.0	14.5	0.0	0.0	-	-
2008	Net Non-Cash	1	321.3	176.3	1.2	-	-	(18.7)	(19.5)	(53.3)	(65.5)	0.0	0.0	-	-
2008	Net Income / (Loss)		700.3	396.0	8.1	-	-	(16.9)	(14.3)	(41.3)	(50.9)	0.0	0.0	-	-
2008	Ending Equity		\$ 434.3	\$ 788.0	\$ 15.8	\$ -	\$ -	\$ 78.6	\$ 84.9	\$ 27.6	\$ 20.0	\$ 0.2	\$ 0.2	\$ -	\$ -

- A consolidated equity position was not presented.

1 RMLP: Includes entries for taxes of \$268.3M paid directly by Purdue Pharma, et al.

74A: Includes entries of \$263.0M (offsetting debits and credits) to reflect tax obligations of 74A paid directly by Purdue Pharma, et al.

RMCI: Includes entries of \$5.4M (offsetting debits and credits) to reflect tax obligations of 74A paid directly by Purdue Pharma, et al.

(\$ in millions)		Notes	RMLP	74A	RMCI	74-AR	74-AJ	74B	Inv. Trust	1A Trust	2A Trust	1B Trust	2B Trust	74-AR IR	74-AJ IR
2008	Ending Equity		\$ 434.3	\$ 788.0	\$ 15.8	\$ -	\$ -	\$ 78.6	\$ 84.9	\$ 27.6	\$ 20.0	\$ 0.2	\$ 0.2	\$ -	\$ -
2009	Partnership Contributions (Cash)		-	-	-	-	-	-	-	-	-	-	-	-	-
2009	Other Cash														
2009	Non-Cash														
2009	Contributions		-	-	-	-	-	-	-	-	-	-	-	-	-
2009	Partnership Distributions (Cash)		(775.1)	-	-	-	-	-	-	-	-	-	-	-	-
2009	Other Cash	1			(10.0)					(8.7)					
2009	Non Cash Taxes Paid Directly by Purdue Pharma, et al.		(11.9)	-	-	-	-	-	-	-	-	-	-	-	-
2009	Other Non-Cash	1								(12.6)					
2009	(Withdrawals)		(787.0)	-	(10.0)	-	-	-	-	(21.3)	-	-	-	-	-
2009	Receipts from Purdue (Cash)		785.8	0.0	-	-	-	-	-	-	-	-	-	-	-
2009	Distributions from Partners (Cash)		-	759.6	15.5	-	-	-	-	-	-	-	-	-	-
2009	Other Net Cash		(13.1)	(261.8)	(6.5)	-	-	7.1	(0.8)	(1.8)	(10.1)	-	0.0	-	-
2009	Net Non-Cash	2	29.7	88.5	0.4	-	-	7.9	2.6	47.6	56.7	0.0	0.0	-	-
2009	Net Income / (Loss)		802.4	586.2	9.4	-	-	15.1	1.8	45.8	46.6	0.0	0.0	-	-
2009	Ending Equity		\$ 449.8	\$ 1,374.2	\$ 15.1	\$ -	\$ -	\$ 93.6	\$ 86.7	\$ 52.1	\$ 66.6	\$ 0.2	\$ 0.2	\$ -	\$ -

- A consolidated equity position was not presented.

- 1A: Distribution of securities of a publicly traded company to certain Sackler family members (See Significant Transactions Section)
- 2 RMLP: Includes entries for taxes of \$11.9M paid directly by Purdue Pharma, et al.  
74A: Includes entries of \$11.7M (offsetting debits and credits) to reflect tax obligations of 74A paid directly by Purdue Pharma, et al.  
RMCI: Includes entries of \$0.2M (offsetting debits and credits) to reflect tax obligations of 74A paid directly by Purdue Pharma, et al.

(\$ in millions)		Notes	RMLP	74A	RMCI	74-AR	74-AJ	74B	Inv. Trust	1A Trust	2A Trust	1B Trust	2B Trust	74-AR IR	74-AJ IR
2009	Ending Equity		\$ 449.8	\$ 1,374.2	\$ 15.1	\$ -	\$ -	\$ 93.6	\$ 86.7	\$ 52.1	\$ 66.6	\$ 0.2	\$ 0.2	\$ -	\$ -
2010	Partnership Contributions (Cash)		1.0	-	-	-	-	-	-	-	-	-	-	-	-
2010	Other Cash														
2010	Non-Cash														
2010	Contributions		1.0	-	-	-	-	-	-	-	-	-	-	-	-
2010	Partnership Distributions (Cash)		(741.7)	-	-	-	-	-	-	-	-	-	-	-	-
2010	Other Cash														
2010	Non Cash Taxes Paid Directly by Purdue Pharma, et al.		(22.1)	-	-	-	-	-	-	-	-	-	-	-	-
2010	Other Non-Cash														
2010	(Withdrawals)		(763.7)	-	-	-	-	-	-	-	-	-	-	-	-
2010	Receipts from Purdue (Cash)		734.7	0.0	-	-	-	-	-	-	-	-	-	-	-
2010	Distributions from Partners (Cash)		-	726.8	14.8	-	-	-	-	-	-	-	-	-	-
2010	Other Net Cash		10.8	(757.8)	(5.7)	-	-	(2.6)	(1.0)	(2.1)	(2.5)	0.0	0.0	-	-
2010	Net Non-Cash	1	16.9	364.6	(0.2)	-	-	8.0	(6.2)	35.9	31.4	0.0	0.0	-	-
2010	Net Income / (Loss)		762.3	333.6	8.9	-	-	5.5	(7.2)	33.8	28.9	0.0	0.0	-	-
2010	Ending Equity		\$ 449.3	\$ 1,707.8	\$ 24.1	\$ -	\$ -	\$ 99.1	\$ 79.5	\$ 85.9	\$ 95.5	\$ 0.2	\$ 0.2	\$ -	\$ -

- A consolidated equity position was not presented.

1 RMLP: Includes entries for taxes of \$22.1M paid directly by Purdue Pharma, et al.  
74A: Includes entries of \$21.6M (offsetting debits and credits) to reflect tax obligations of 74A paid directly by Purdue Pharma, et al.  
RMCI: Includes entries of \$0.4M (offsetting debits and credits) to reflect tax obligations of 74A paid directly by Purdue Pharma, et al.

# 2011 Equity Rollforward

(\$ in millions)		Notes	RMLP	74A	RMCI	74-AR	74-AJ	74B	Inv. Trust	1A Trust	2A Trust	1B Trust	2B Trust	74-AR IR	74-AJ IR
<b>2010</b>	<b>Ending Equity</b>		\$ 449.3	\$ 1,707.8	\$ 24.1	\$ -	\$ -	\$ 99.1	\$ 79.5	\$ 85.9	\$ 95.5	\$ 0.2	\$ 0.2	\$ -	\$ -
2011	Partnership Contributions (Cash)		1.4	-	-	-	-	-	-	-	-	-	-	-	-
2011	Other Cash														
2011	Non-Cash														
2011	Contributions		1.4	-	-	-	-	-	-	-	-	-	-	-	-
2011	Partnership Distributions (Cash)		(531.4)	-	-	-	-	-	-	-	-	-	-	-	-
2011	Other Cash														
2011	Non Cash Taxes Paid Directly by Purdue Pharma, et al.		(22.7)	-	-	-	-	-	-	-	-	-	-	-	-
2011	Other Non-Cash														
2011	(Withdrawals)		(554.1)	-	-	-	-	-	-	-	-	-	-	-	-
2011	Receipts from Purdue (Cash)		533.1	0.0	-	-	-	-	-	-	-	-	-	-	-
2011	Distributions from Partners (Cash)		-	520.8	10.6	-	-	-	-	-	-	-	-	-	-
2011	Other Net Cash		4.3	(938.4)	(3.3)	-	-	24.6	(5.3)	(1.3)	0.7	(0.0)	(0.0)	-	-
2011	Net Non-Cash	<b>1</b>	24.0	792.8	0.2	-	-	(29.1)	(48.1)	(25.5)	(10.6)	(0.0)	(0.0)	-	-
2011	Net Income / (Loss)		561.4	375.1	7.5	-	-	(4.4)	(53.4)	(26.8)	(9.9)	(0.0)	(0.0)	-	-
<b>2011</b>	<b>Ending Equity</b>		\$ 458.0	\$ 2,082.9	\$ 31.6	\$ -	\$ -	\$ 94.7	\$ 26.1	\$ 59.1	\$ 85.6	\$ 0.2	\$ 0.2	\$ -	\$ -

- A consolidated equity position was not presented.

1 RMLP: Includes entries for taxes of \$22.7M paid directly by Purdue Pharma, et al.

74A: Includes entries of \$22.3M (offsetting debits and credits) to reflect tax obligations of 74A paid directly by Purdue Pharma, et al.

RMCI: Includes entries of \$0.5M (offsetting debits and credits) to reflect tax obligations of 74A paid directly by Purdue Pharma, et al.

(\$ in millions)		Notes	RMLP	74A	RMCI	74-AR	74-AJ	74B	Inv. Trust	1A Trust	2A Trust	1B Trust	2B Trust	74-AR IR	74-AJ IR
2011	Ending Equity		\$ 458.0	\$ 2,082.9	\$ 31.6	\$ -	\$ -	\$ 94.7	\$ 26.1	\$ 59.1	\$ 85.6	\$ 0.2	\$ 0.2	\$ -	\$ -
2012	Partnership Contributions (Cash)		-	-	-	-	-	-	-	-	-	-	-	-	-
2012	Other Cash														
2012	Non-Cash														
2012	Contributions		-	-	-	-	-	-	-	-	-	-	-	-	-
2012	Partnership Distributions (Cash)		(428.2)	-	-	-	-	-	-	-	-	-	-	-	-
2012	Other Cash				(25.0)										
2012	Non Cash Taxes Paid Directly by Purdue Pharma, et al.		(13.6)	-	-	-	-	-	-	-	-	-	-	-	-
2012	Other Non-Cash														
2012	(Withdrawals)		(441.8)	-	(25.0)	-	-	-	-	-	-	-	-	-	-
2012	Receipts from Purdue (Cash)		455.2	0.0	-	-	-	-	-	-	-	3.0	3.0	-	-
2012	Distributions from Partners (Cash)		-	419.6	8.6	-	-	-	-	-	-	-	-	-	-
2012	Other Net Cash		(9.7)	(586.2)	(3.9)	-	-	(2.3)	1.4	18.8	20.0	0.0	0.0	-	-
2012	Net Non-Cash	1	155.0	672.1	3.2	-	-	6.8	(138.1)	48.9	66.8	(0.0)	(0.0)	-	-
2012	Net Income / (Loss)		600.6	505.5	7.8	-	-	4.6	(136.8)	67.7	86.8	3.0	3.0	-	-
2012	Ending Equity		\$ 616.9	\$ 2,588.5	\$ 14.4	\$ -	\$ -	\$ 99.2	\$ (110.7)	\$ 126.9	\$ 172.4	\$ 3.2	\$ 3.2	\$ -	\$ -

- A consolidated equity position was not presented.

1 RMLP: Includes entries for taxes of \$13.6M paid directly by Purdue Pharma, et al.  
 74A: Includes entries of \$13.3M (offsetting debits and credits) to reflect tax obligations of 74A paid directly by Purdue Pharma, et al.  
 RMCI: Includes entries of \$0.3M (offsetting debits and credits) to reflect tax obligations of 74A paid directly by Purdue Pharma, et al.



(\$ in millions)		Notes	RMLP	74A	RMCI	74-AR	74-AJ	74B	Inv. Trust	1A Trust	2A Trust	1B Trust	2B Trust	74-AR IR	74-AJ IR
2012	Ending Equity		\$ 616.9	\$ 2,588.5	\$ 14.4	\$ -	\$ -	\$ 99.2	\$ (110.7)	\$ 126.9	\$ 172.4	\$ 3.2	\$ 3.2	\$ -	\$ -
2013	Partnership Contributions (Cash)		-	-	-	-	-	-	-	-	-	-	-	-	-
2013	Other Cash														
2013	Non-Cash														
2013	Contributions		-	-	-	-	-	-	-	-	-	-	-	-	-
2013	Partnership Distributions (Cash)		(594.1)	-	-	-	-	-	-	-	-	-	-	-	-
2013	Other Cash									(4.4)	(2.6)				
2013	Non Cash Taxes Paid Directly by Purdue Pharma, et al.		(11.4)	-	-	-	-	-	-	-	-	-	-	-	-
2013	Other Non-Cash									(2.8)	(1.6)				
2013	(Withdrawals)		(605.4)	-	-	-	-	-	-	(7.2)	(4.2)			-	-
2013	Receipts from Purdue (Cash)		348.2	0.0	-	-	-	-	-	-	-	-	-	-	-
2013	Distributions from Partners (Cash)		-	582.2	11.9	-	-	-	-	-	-	-	-	-	-
2013	Other Net Cash		217.2	(287.2)	(3.7)	-	-	(13.2)	2.0	16.9	15.6	(0.4)	(0.4)	-	-
2013	Net Non-Cash	1	(209.6)	(79.4)	(5.0)	-	-	33.5	(122.2)	19.6	60.2	0.0	0.0	-	-
2013	Net Income / (Loss)		355.8	215.6	3.2	-	-	20.3	(120.2)	36.5	75.8	(0.4)	(0.4)	-	-
2013	Ending Equity		\$ 367.3	\$ 2,804.1	\$ 17.6	\$ -	\$ -	\$ 119.5	\$ (230.9)	\$ 156.2	\$ 244.0	\$ 2.7	\$ 2.7	\$ -	\$ -

- A consolidated equity position was not presented.

1 RMLP: Includes entries for taxes of \$11.4M paid directly by Purdue Pharma, et al.  
 74A: Includes entries of \$11.1M (offsetting debits and credits) to reflect tax obligations of 74A paid directly by Purdue Pharma, et al.  
 RMCI: Includes entries of \$0.2M (offsetting debits and credits) to reflect tax obligations of 74A paid directly by Purdue Pharma, et al.

(\$ in millions)		Notes	RMLP	74A	RMCI	74-AR	74-AJ	74B	Inv. Trust	1A Trust	2A Trust	1B Trust	2B Trust	74-AR IR	74-AJ IR
2013	Ending Equity		\$ 367.3	\$ 2,804.1	\$ 17.6	\$ -	\$ -	\$ 119.5	\$ (230.9)	\$ 156.2	\$ 244.0	\$ 2.7	\$ 2.7	\$ -	\$ -
2014	Partnership Contributions (Cash)		-	-	-	-	-	-	-	-	-	-	-	-	-
2014	Other Cash														
2014	Non-Cash														
2014	Contributions		-	-	-	-	-	-	-	-	-	-	-	-	-
2014	Partnership Distributions (Cash)		(302.3)	-	-	-	-	-	-	-	-	-	-	-	-
2014	Other Cash														
2014	Non Cash Taxes Paid Directly by Purdue Pharma, et al.		(12.6)	-	-	-	-	-	-	-	-	-	-	-	-
2014	Other Non-Cash														
2014	(Withdrawals)		(314.9)	-	-	-	-	-	-	-	-	-	-	-	-
2014	Receipts from Purdue (Cash)		295.3	0.0	-	-	-	-	-	-	-	-	-	-	-
2014	Distributions from Partners (Cash)		-	296.3	6.0	-	-	-	-	-	-	-	-	-	-
2014	Other Net Cash		7.7	(174.5)	(3.6)	-	-	14.8	(1.4)	(16.8)	(18.0)	0.0	0.0	-	-
2014	Net Non-Cash	1	62.2	147.3	1.0	-	-	(11.4)	(142.2)	15.1	0.3	(0.0)	(0.0)	-	-
2014	Net Income / (Loss)		365.2	269.1	3.4	-	-	3.3	(143.6)	(1.7)	(17.7)	0.0	0.0	-	-
2014	Ending Equity		\$ 417.6	\$ 3,073.2	\$ 21.0	\$ -	\$ -	\$ 122.9	\$ (374.5)	\$ 154.5	\$ 226.3	\$ 2.7	\$ 2.7	\$ -	\$ -

- A consolidated equity position was not presented.

1 RMLP: Includes entries for taxes of \$12.6M paid directly by Purdue Pharma, et al.  
 74A: Includes entries of \$12.3M (offsetting debits and credits) to reflect tax obligations of 74A paid directly by Purdue Pharma, et al.  
 RMCI: Includes entries of \$0.2M (offsetting debits and credits) to reflect tax obligations of 74A paid directly by Purdue Pharma, et al.

# 2015 Equity Rollforward

19-236249-0001 Doc 07-22 Filed 08/05/21 Entered 08/05/21 15:28:38 Page 10 of 142  
Pg 314 of 725

(\$ in millions)		Notes	RMLP	74A	RMCI	74-AR	74-AJ	74B	Inv. Trust	1A Trust	2A Trust	1B Trust	2B Trust	74-AR IR	74-AJ IR
<b>2014</b>	<b>Ending Equity</b>		\$ 417.6	\$ 3,073.2	\$ 21.0	\$ -	\$ -	\$ 122.9	\$ (374.5)	\$ 154.5	\$ 226.3	\$ 2.7	\$ 2.7	\$ -	\$ -
2015	Partnership Contributions (Cash)		-	-	-	-	-	-	-	-	-	-	-	-	-
2015	Other Cash	<b>1</b>				139.1	154.3			0.0					
2015	Non-Cash	<b>1</b>				1,122.2	1,103.6								
2015	Contributions		-	-	-	1,261.3	1,257.9	-	-	0.0	-	-	-	-	-
2015	Partnership Distributions (Cash)		(273.3)	-	-	-	-	-	-	-	-	-	-	-	-
2015	Other Cash	<b>1</b>		(293.4)											
2015	Non Cash Taxes Paid Directly by Purdue Pharma, et al.		(10.4)	-	-	-	-	-	-	-	-	-	-	-	-
2015	Other Non-Cash	<b>1, 2</b>		(2,226.0)						0.4	(0.0)				
2015	(Withdrawals)		(283.7)	(2,519.4)	-	-	-	-	-	0.4	(0.0)	-	-	-	-
2015	Receipts from Purdue (Cash)		273.5	0.0	-	-	-	-	-	-	-	-	-	-	-
2015	Distributions from Partners (Cash)		-	267.8	5.5	-	-	-	-	-	-	-	-	-	-
2015	Other Net Cash		0.2	(370.7)	(3.7)	(29.7)	(83.2)	(30.0)	1.6	8.2	1.1	0.0	0.0	-	-
2015	Net Non-Cash	<b>2, 3</b>	60.8	201.0	1.0	109.5	137.5	26.4	31.6	(18.9)	(3.2)	-	-	-	-
2015	Net Income / (Loss)		334.6	98.2	2.7	79.8	54.3	(3.6)	33.3	(10.8)	(2.1)	0.0	0.0	-	-
<b>2015</b>	<b>Ending Equity</b>		\$ 468.5	\$ 651.9	\$ 23.7	\$ 1,341.2	\$ 1,312.2	\$ 119.2	\$ (341.2)	\$ 144.2	\$ 224.2	\$ 2.7	\$ 2.7	\$ -	\$ -

- A consolidated equity position was not presented.

1 Division of 74A (See Significant Transactions Section)

2 Intra-Trust Activity (See Significant Transactions Section)

3 RMLP: Includes entries for taxes of \$10.4M paid directly by Purdue Pharma, et al.

74A: Includes entries of \$10.2M (offsetting debits and credits) to reflect tax obligations of 74A paid directly by Purdue Pharma, et al.

RMCI: Includes entries of \$0.2M (offsetting debits and credits) to reflect tax obligations of 74A paid directly by Purdue Pharma, et al.

NAS2636

PROFESSIONALS' EYES ONLY/HIGHLY CONFIDENTIAL—SUBJECT TO PROPOSED PROTECTIVE ORDER AND FRE 408

This presentation may only be viewed by the professionals identified on page 2, and it may not be shared.

# 2016 Equity Rollforward

19-236249-0001 Doc 07-21 Doc 07-22 Filed 08/05/21 Entered 08/05/21 15:55:51 Page 104 of 142  
Pg 315 of 725

(\$ in millions)		Notes	RMLP	74A	RMCI	74-AR	74-AJ	74B	Inv. Trust	1A Trust	2A Trust	1B Trust	2B Trust	74-AR IR	74-AJ IR
<b>2015</b>	<b>Ending Equity</b>		\$ 468.5	\$ 651.9	\$ 23.7	\$ 1,341.2	\$ 1,312.2	\$ 119.2	\$ (341.2)	\$ 144.2	\$ 224.2	\$ 2.7	\$ 2.7	\$ -	\$ -
2016	Partnership Contributions (Cash)		-	-	-	-	-	-	-	-	-	-	-	-	-
2016	Other Cash	<b>1</b>				7.5	7.5								
2016	Non-Cash	<b>1</b>				-	2.9								
2016	Contributions		-	-	-	7.5	10.4	-	-	-	-	-	-	-	-
2016	Partnership Distributions (Cash)		(198.9)	-	-	-	-	-	-	-	-	-	-	-	-
2016	Other Cash	<b>1</b>		(15.0)						(0.1)					
2016	Non Cash Taxes Paid Directly by Purdue Pharma, et al.		(7.1)	-	-	-	-	-	-	-	-	-	-	-	-
2016	Other Non-Cash	<b>1</b>		(2.9)											
2016	(Withdrawals)		(206.0)	(17.9)	-	-	-	-	-	(0.1)	-	-	-	-	-
2016	Receipts from Purdue (Cash)		209.0	0.0	-	-	-	-	-	-	-	-	-	-	-
2016	Distributions from Partners (Cash)		-	195.0	4.0	-	-	-	-	-	-	-	-	-	-
2016	Other Net Cash		(2.9)	(222.1)	(1.4)	(74.8)	69.2	13.9	2.7	(20.8)	19.2	(0.0)	(0.0)	-	-
2016	Net Non-Cash	<b>2</b>	92.9	196.9	1.9	150.5	(9.7)	(5.4)	(3.2)	85.1	0.4	0.0	0.0	-	-
2016	Net Income / (Loss)		299.0	169.8	4.4	75.7	59.5	8.6	(0.5)	64.3	19.6	0.0	0.0	-	-
<b>2016</b>	<b>Ending Equity</b>		\$ 561.6	\$ 803.8	\$ 28.1	\$ 1,424.4	\$ 1,382.1	\$ 127.8	\$ (341.8)	\$ 208.4	\$ 243.8	\$ 2.7	\$ 2.7	\$ -	\$ -

- A consolidated equity position was not presented.

1 Division of 74A (See Significant Transactions Section)

2 RMLP: Includes entries for taxes of \$7.1M paid directly by Purdue Pharma, et al.

74A: Includes entries of \$6.9M (offsetting debits and credits) to reflect tax obligations of 74A paid directly by Purdue Pharma, et al.

RMCI: Includes entries of \$0.1M (offsetting debits and credits) to reflect tax obligations of 74A paid directly by Purdue Pharma, et al.

NAS2637

PROFESSIONALS' EYES ONLY/HIGHLY CONFIDENTIAL—SUBJECT TO PROPOSED PROTECTIVE ORDER AND FRE 408

This presentation may only be viewed by the professionals identified on page 2, and it may not be shared.

# 2017 Equity Rollforward

19-236249-00007-21 Doc 37422-0 Filed 08/05/21 Entered 08/05/21 15:55:51 Page 10 of 142  
Pg 316 of 725

(\$ in millions)		Notes	RMLP	74A	RMCI	74-AR	74-AJ	74B	Inv. Trust	1A Trust	2A Trust	1B Trust	2B Trust	74-AR IR	74-AJ IR
<b>2016</b>	<b>Ending Equity</b>		\$ 561.6	\$ 803.8	\$ 28.1	\$ 1,424.4	\$ 1,382.1	\$ 127.8	\$ (341.8)	\$ 208.4	\$ 243.8	\$ 2.7	\$ 2.7	\$ -	\$ -
2017	Partnership Contributions (Cash)		-	-	-	-	-	-	-	-	-	-	-	-	-
2017	Other Cash	<b>1</b>				2.5	2.5								
2017	Non-Cash														
2017	Contributions		-	-	-	2.5	2.5	-	-	-	-	-	-	-	-
2017	Partnership Distributions (Cash)		(78.7)	-	-	-	-	-	-	-	-	-	-	-	-
2017	Other Cash	<b>1</b>		(5.0)											
2017	Non Cash Taxes Paid Directly by Purdue Pharma, et al.		(3.7)	-	-	-	-	-	-	-	-	-	-	-	-
2017	Other Non-Cash														
2017	(Withdrawals)		(82.3)	(5.0)	-	-	-	-	-	-	-	-	-	-	-
2017	Receipts from Purdue (Cash)		73.6	0.0	-	-	-	-	-	-	-	-	-	-	-
2017	Distributions from Partners (Cash)		-	77.1	1.6	-	-	-	-	-	-	-	-	-	-
2017	Other Net Cash		(2.4)	(109.9)	(0.3)	54.0	(91.9)	0.3	(1.3)	6.9	(7.2)	0.0	0.0	-	-
2017	Net Non-Cash	<b>2</b>	18.6	73.9	0.1	62.9	184.0	7.0	(53.7)	617.2	704.5	0.0	0.0	-	-
2017	Net Income / (Loss)		89.8	41.1	1.4	117.0	92.2	7.3	(55.0)	624.0	697.2	0.0	0.0	-	-
<b>2017</b>	<b>Ending Equity</b>		\$ 569.1	\$ 839.9	\$ 29.5	\$ 1,543.8	\$ 1,476.8	\$ 135.2	\$ (396.8)	\$ 832.5	\$ 941.1	\$ 2.7	\$ 2.7	\$ -	\$ -

- A consolidated equity position was not presented.

1 Division of 74A (See Significant Transactions Section)

2 RMLP: Includes entries for taxes of \$3.7M paid directly by Purdue Pharma, et al.

74A: Includes entries of \$3.6M (offsetting debits and credits) to reflect tax obligations of 74A paid directly by Purdue Pharma, et al.

RMCI: Includes entries of \$0.1M (offsetting debits and credits) to reflect tax obligations of 74A paid directly by Purdue Pharma, et al.

NAS2638

PROFESSIONALS' EYES ONLY/HIGHLY CONFIDENTIAL—SUBJECT TO PROPOSED PROTECTIVE ORDER AND FRE 408

This presentation may only be viewed by the professionals identified on page 2, and it may not be shared.

(\$ in millions)		Notes	RMLP	74A	RMCi	74-AR	74-AJ	74B	Inv. Trust	1A Trust	2A Trust	1B Trust	2B Trust	74-AR IR	74-AJ IR
2017	Ending Equity		\$ 569.1	\$ 839.9	\$ 29.5	\$ 1,543.8	\$ 1,476.8	\$ 135.2	\$ (396.8)	\$ 832.5	\$ 941.1	\$ 2.7	\$ 2.7	\$ -	\$ -
2018	Partnership Contributions (Cash)		-	-	-	-	-	-	-	-	-	-	-	-	-
2018	Other Cash														
2018	Non-Cash														
2018	Contributions		-	-	-	-	-	-	-	-	-	-	-	-	-
2018	Partnership Distributions (Cash)		(0.2)	-	-	-	-	-	-	-	-	-	-	-	-
2018	Other Cash														
2018	Non Cash Taxes Paid Directly by Purdue Pharma, et al.		(1.4)	-	-	-	-	-	-	-	-	-	-	-	-
2018	Other Non-Cash														
2018	(Withdrawals)		(1.6)	-	-	-	-	-	-	-	-	-	-	-	-
2018	Receipts from Purdue (Cash)		0.7	0.0	-	-	-	-	-	-	-	-	-	-	-
2018	Distributions from Partners (Cash)		-	0.2	0.0	-	-	-	-	-	-	-	-	-	-
2018	Other Net Cash		(0.5)	(18.6)	0.2	(60.6)	56.4	(5.2)	(5.9)	44.2	41.3	(0.0)	(0.0)	-	-
2018	Net Non-Cash	1	3.3	19.9	0.0	53.5	(63.8)	7.4	(15.8)	(29.8)	(36.9)	0.0	0.0	-	-
2018	Net Income / (Loss)		3.6	1.6	0.2	(7.1)	(7.4)	2.2	(21.7)	14.3	4.4	(0.0)	(0.0)	-	-
2018	Ending Equity		\$ 571.0	\$ 841.4	\$ 29.7	\$ 1,536.7	\$ 1,469.4	\$ 137.4	\$ (418.5)	\$ 846.8	\$ 945.5	\$ 2.7	\$ 2.7	\$ -	\$ -

- A consolidated equity position was not presented.

1 RMLP: Includes entries for taxes of \$1.4M paid directly by Purdue Pharma, et al.

74A: Includes entries of \$1.4M (offsetting debits and credits) to reflect tax obligations of 74A paid directly by Purdue Pharma, et al.

RMCI: Includes entries of \$0.0M (offsetting debits and credits) to reflect tax obligations of 74A paid directly by Purdue Pharma, et al.

(\$ in millions)		Notes	RMLP	74A	RMCI	74-AR	74-AJ	74B	Inv. Trust	1A Trust	2A Trust	1B Trust	2B Trust	74-AR IR	74-AJ IR
2018	Ending Equity		\$ 571.0	\$ 841.4	\$ 29.7	\$ 1,536.7	\$ 1,469.4	\$ 137.4	\$ (418.5)	\$ 846.8	\$ 945.5	\$ 2.7	\$ 2.7	\$ -	\$ -
2019	Partnership Contributions (Cash)		2.0	-	-	-	-	-	-	-	-	-	-	-	-
2019	Other Cash	1					5.3							118.0	38.2
2019	Non-Cash	1												1,401.6	1,495.9
2019	Contributions		41.0	-	-	-	5.3	-	-	-	-	-	-	1,519.6	1,534.0
2019	Partnership Distributions (Cash)		-	-	-	-	-	-	-	-	-	-	-	-	-
2019	Other Cash	1				(118.0)	(38.2)								(5.3)
2019	Non Cash Taxes Paid Directly by Purdue Pharma, et al.	1													
2019	Other Non-Cash					(1,409.6)	(1,495.7)							(10.8)	(17.7)
2019	(Withdrawals)		-	-	-	(1,527.6)	(1,533.8)	-	-	-	-	-	-	(10.8)	(23.0)
2019	Receipts from Purdue (Cash)		0.0	0.0	-	-	-	-	-	-	-	-	-	-	-
2019	Distributions from Partners (Cash)		1.2	-	-	-	-	-	-	-	-	-	-	-	-
2019	Other Net Cash		(4.9)	3.6	(17.8)	82.3	(81.3)	(4.2)	(0.9)	(31.4)	55.8	0.1	0.1	(92.1)	38.3
2019	Net Non-Cash		21.4	77.3	18.4	74.5	159.3	12.5	(32.2)	64.5	54.2	(0.0)	(0.0)	111.5	16.7
2019	Net Income / (Loss)		17.7	81.0	0.6	156.8	77.9	8.3	(33.1)	33.1	110.1	0.1	0.1	19.4	55.0
2019	Ending Equity	2	\$ 629.7	\$ 922.4	\$ 30.3	\$ 165.9	\$ 18.8	\$ 145.7	\$ (451.6)	\$ 879.9	\$ 1,055.5	\$ 2.8	\$ 2.8	\$ 1,528.2	\$ 1,566.0

- A consolidated equity position was not presented.

1 RMLP: Includes \$35.4 million in legal fees paid by other entities on behalf of RMLP Decanting of 74-AR & 74-AJ (See Significant Transactions Section)

2 The 2019 accounting for the Top-Level entities is not complete and remains subject to change. For this reason the balance sheet for the 2020 Equity Roll has a different Beginning Equity Balance than the Ending Equity Balance for the 2019 Equity Roll.

(\$ in millions)		Notes	RMLP	74A	RMCI	74-AR	74-AJ	74B	Inv. Trust	1A Trust	2A Trust	1B Trust	2B Trust	74-AR IR	74-AJ IR
2019	Ending Equity	1	\$ 629.7	\$ 922.4	\$ 30.3	\$ 165.9	\$ 18.8	\$ 145.7	\$ (451.6)	\$ 879.9	\$ 1,055.5	\$ 2.8	\$ 2.8	\$ 1,528.2	\$ 1,566.0
2020	Partnership Contributions (Cash)		12.0	-	-	-	-	-	-	-	-	-	-	-	-
2020	Other Cash					25.0	10.2								
2020	Non-Cash	2												144.1	4.0
2020	Contributions		12.0	-	-	25.0	10.2	-	-	-	-	-	-	144.1	4.0
2020	Partnership Distributions (Cash)		-	-	-	-	-	-	-	-	-	-	-	-	-
2020	Other Cash													(25.0)	(10.2)
2020	Non Cash Taxes Paid Directly by Purdue Pharma, et al.		-	-	-	-	-	-	-	-	-	-	-	-	-
2020	Other Non-Cash	2				(144.1)	(4.0)								
2020	(Withdrawals)		-	-	-	(144.1)	(4.0)	-	-	-	-	-	-	(25.0)	(10.2)
2020	Receipts from Purdue (Cash)		-	-	-	-	-	-	-	-	-	-	-	-	-
2020	Distributions from Partners (Cash)		-	-	-	-	-	-	-	-	-	-	-	-	-
2020	Other Net Cash		(12.1)	(11.0)	(0.2)	(25.0)	(10.4)	(1.3)	0.1	(13.7)	8.1	(0.0)	(0.0)	46.6	16.1
2020	Net Non-Cash		(0.6)	(1.5)	(0.0)	(4.7)	0.3	0.9	(23.2)	(22.8)	(46.4)	(0.0)	(0.0)	(105.6)	(93.7)
2020	Net Income / (Loss)		(12.6)	(12.5)	(0.3)	(29.7)	(10.1)	(0.4)	(23.1)	(36.5)	(38.3)	(0.0)	(0.0)	(59.0)	(77.6)
2020	Ending Equity as of March 31	3	\$ 622.5	\$ 903.5	\$ 29.9	\$ 17.0	\$ 14.9	\$ 145.3	\$ (474.7)	\$ 843.3	\$ 1,011.0	\$ 2.8	\$ 2.8	\$ 1,586.6	\$ 1,482.0

- A consolidated equity position was not presented.

- 1 The 2019 accounting for the Top-Level entities is not complete and remains subject to change. For this reason the balance sheet for the 2020 Equity Roll has a different Beginning Equity Balance than the Ending Equity Balance for the 2019 Equity Roll.
- 2 Decanting of 74-AR & 74-AJ (See Significant Transactions Section)
- 3 The 2020 accounting for the Top-Level entities is not complete and remains subject to change. For this reason the balance sheet for the 2020 Equity Roll has a different Beginning Equity Balance than the Ending Equity Balance for the 2019 Equity Roll.



# Appendix C: 2008 – 2020 Statement of Operations

(\$ in millions)	RMLP	74A	RMCI	74-AR	74-AJ	74B	Inv. Trust	1A Trust	2A Trust	1B Trust	2B Trust	74-AR IR	74-AJ IR
Year Ended:	12/31/08	12/31/08	12/31/08	12/31/08	12/31/08	12/31/08	12/31/08	12/31/08	12/31/08	12/31/08	12/31/08	12/31/08	12/31/08
<b>Revenues:</b>													
Ordinary Income (Loss)	\$ 730.0	\$ 712.9	\$ 14.5	\$ -	\$ -	\$ (0.5)	\$ 2.6	\$ 4.6	\$ 4.3	\$ -	\$ -	\$ -	\$ -
Interest Income	5.9	7.4	0.1	-	-	1.4	1.2	0.4	0.4	-	-	-	-
Dividend Income	3.3	4.3	0.1	-	-	0.6	0.6	8.2	8.3	-	-	-	-
Royalty Income	11.1	10.9	0.2	-	-	0.0	0.0	0.0	0.0	-	-	-	-
Rental Income	2.1	2.1	0.0	-	-	(0.2)	(0.9)	(0.0)	(0.0)	-	-	-	-
Net Capital Gains (Losses)	-	-	-	-	-	-	-	-	-	-	-	-	-
Section 1231	-	-	-	-	-	(3.9)	1.2	0.0	0.0	-	-	-	-
Section 1256	-	0.0	-	-	-	(0.0)	0.2	0.5	0.4	-	-	-	-
Short-Term	-	(2.0)	-	-	-	(0.5)	(0.9)	(5.2)	(8.1)	-	-	-	-
Long-Term	-	(1.0)	-	-	-	1.8	0.2	(5.3)	(4.0)	-	-	-	-
Other Portfolio Income	-	0.0	-	-	-	0.5	0.2	0.2	0.1	-	-	-	-
Tax Refunds	-	-	-	-	-	-	-	-	-	-	-	-	-
Federal	-	11.7	0.4	-	-	0.3	0.3	2.2	2.0	-	-	-	-
State	0.9	4.1	0.1	-	-	0.2	0.3	0.5	0.5	-	-	-	-
Subpart F Income	0.0	0.0	0.0	-	-	-	-	7.2	6.5	-	-	-	-
Other Income (Loss)	-	-	-	-	-	0.1	0.0	1.6	1.8	0.0	0.0	-	-
Federal Tax Exempt Income	-	-	-	-	-	0.0	0.0	0.0	0.0	-	-	-	-
Tax Exempt Income	-	-	-	-	-	-	-	-	-	-	-	-	-
Nontaxable Income	(47.5)	(51.6)	(0.9)	-	-	(12.6)	(8.4)	(38.1)	(44.5)	-	-	-	-
<b>Total revenues</b>	<b>705.9</b>	<b>698.9</b>	<b>14.6</b>	<b>-</b>	<b>-</b>	<b>(12.7)</b>	<b>(3.3)</b>	<b>(23.3)</b>	<b>(32.5)</b>	<b>0.0</b>	<b>0.0</b>	<b>-</b>	<b>-</b>
<b>Costs and expenses:</b>													
Interest Expense	-	0.5	-	-	-	0.6	1.3	5.0	5.1	-	-	-	-
Charitable Contributions	-	-	-	-	-	-	0.0	-	-	-	-	-	-
Intangible Drilling and Development Costs	-	-	-	-	-	-	5.7	-	-	-	-	-	-
Production Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-
Taxes - Domestic	-	-	-	-	-	-	-	-	-	-	-	-	-
Federal	-	258.0	5.3	-	-	1.5	1.1	8.1	8.0	-	-	-	-
State	0.3	40.9	0.9	-	-	0.4	0.3	1.9	2.0	-	-	-	-
Local	-	-	-	-	-	-	-	-	-	-	-	-	-
Other Payroll Taxes	0.0	-	-	-	-	-	-	-	-	-	-	-	-
Other	-	-	-	-	-	-	-	-	-	-	-	-	-
Taxes - Foreign	2.5	2.4	0.1	-	-	0.0	0.0	2.0	2.1	-	-	-	-
Portfolio Deductions	0.1	0.3	-	-	-	0.9	1.0	0.7	1.2	-	-	-	-
Depreciation, Depletion & Amortization	0.0	-	-	-	-	-	1.4	-	-	-	-	-	-
Salaries & Wages	0.8	-	-	-	-	-	-	-	-	-	-	-	-
Legal Fees	0.3	0.0	0.0	-	-	0.0	-	0.1	0.1	-	-	-	-
Travel	0.1	-	-	-	-	-	-	-	-	-	-	-	-
General & Administrative Expenses	1.3	0.1	0.2	-	-	0.1	0.1	0.1	0.1	0.0	0.0	-	-
Nondeductible	0.1	0.7	0.0	-	-	0.6	0.0	0.0	0.0	-	-	-	-
Personal Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-
<b>Total costs and expenses</b>	<b>5.6</b>	<b>302.8</b>	<b>6.4</b>	<b>-</b>	<b>-</b>	<b>4.1</b>	<b>11.0</b>	<b>17.9</b>	<b>18.5</b>	<b>0.0</b>	<b>0.0</b>	<b>-</b>	<b>-</b>
<b>Net income (loss)</b>	<b>\$ 700.3</b>	<b>\$ 396.0</b>	<b>\$ 8.1</b>	<b>\$ -</b>	<b>\$ -</b>	<b>\$ (16.9)</b>	<b>\$ (14.3)</b>	<b>\$ (41.3)</b>	<b>\$ (50.9)</b>	<b>\$ -</b>	<b>\$ -</b>	<b>\$ -</b>	<b>\$ -</b>

The above amounts have not been consolidated.

NAS2643

(\$ in millions)	RMLP	74A	RMCI	74-AR	74-AJ	74B	Inv. Trust	1A Trust	2A Trust	1B Trust	2B Trust	74-AR IR	74-AJ IR
Year Ended:	12/31/09	12/31/09	12/31/09	12/31/09	12/31/09	12/31/09	12/31/09	12/31/09	12/31/09	12/31/09	12/31/09	12/31/09	12/31/09
<b>Revenues:</b>													
Ordinary Income (Loss)	\$ 873.6	\$ 851.5	\$ 17.4	\$ -	\$ -	\$ (0.3)	\$ (0.1)	\$ 9.3	\$ 8.0	\$ -	\$ -	\$ -	\$ -
Interest Income	0.6	6.7	0.1	-	-	1.2	0.7	1.5	1.5	-	-	-	-
Dividend Income	0.5	0.8	0.0	-	-	0.5	0.2	9.7	10.7	-	-	-	-
Royalty Income	18.3	18.0	0.4	-	-	0.0	0.0	0.0	0.0	-	-	-	-
Rental Income	(0.3)	(0.3)	(0.0)	-	-	(0.3)	(0.7)	0.0	(0.0)	-	-	-	-
Net Capital Gains (Losses)	-	-	-	-	-	-	-	-	-	-	-	-	-
Section 1231	(1.7)	(1.7)	(0.0)	-	-	0.0	0.4	0.0	0.0	-	-	-	-
Section 1256	-	(0.2)	-	-	-	(0.1)	(0.1)	(0.4)	(2.3)	-	-	-	-
Short-Term	-	0.3	-	-	-	1.7	0.1	4.3	3.0	-	-	-	-
Long-Term	-	(1.0)	-	-	-	6.2	(1.4)	(10.3)	(7.1)	-	-	-	-
Other Portfolio Income	-	(0.0)	-	-	-	0.0	0.0	(0.0)	(0.0)	-	-	-	-
Tax Refunds	-	-	-	-	-	-	-	-	-	-	-	-	-
Federal	-	41.2	2.7	-	-	1.5	0.6	3.3	4.0	-	-	-	-
State	0.0	13.9	0.2	-	-	0.5	0.1	0.8	1.1	-	-	-	-
Subpart F Income	0.0	0.0	0.0	-	-	-	-	-	7.9	-	-	-	-
Other Income (Loss)	-	0.0	-	-	-	0.1	0.0	10.0	1.4	-	-	-	-
Federal Tax Exempt Income	-	-	-	-	-	0.0	0.0	1.4	0.0	-	-	-	-
Tax Exempt Income	-	-	-	-	-	-	-	0.0	-	-	-	-	-
Nontaxable Income	(80.6)	(73.8)	(1.6)	-	-	9.1	7.7	30.6	35.9	-	-	-	-
<b>Total revenues</b>	<b>810.5</b>	<b>855.4</b>	<b>19.1</b>	<b>-</b>	<b>-</b>	<b>20.2</b>	<b>7.7</b>	<b>60.2</b>	<b>64.1</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>Costs and expenses:</b>													
Interest Expense	-	0.6	-	-	-	0.3	0.5	7.7	6.9	-	-	-	-
Charitable Contributions	-	-	-	-	-	-	0.0	-	-	-	-	-	-
Intangible Drilling and Development Costs	-	-	-	-	-	-	2.7	0.0	-	-	-	-	-
Production Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-
Taxes - Domestic	-	-	-	-	-	-	-	-	-	-	-	-	-
Federal	-	208.5	8.4	-	-	2.5	1.0	1.9	5.7	-	-	-	-
State	-	53.7	1.0	-	-	0.7	0.2	1.2	1.0	-	-	-	-
Local	-	-	-	-	-	-	-	-	-	-	-	-	-
Other Payroll Taxes	0.0	-	-	-	-	-	-	-	-	-	-	-	-
Other	-	-	-	-	-	-	-	-	-	-	-	-	-
Taxes - Foreign	2.3	2.2	0.0	-	-	0.0	0.0	2.1	2.1	-	-	-	-
Portfolio Deductions	0.1	1.2	-	-	-	0.8	0.7	1.2	1.6	-	-	-	-
Depreciation, Depletion & Amortization	0.0	-	-	-	-	-	0.6	-	-	-	-	-	-
Salaries & Wages	0.8	-	-	-	-	-	-	-	-	-	-	-	-
Legal Fees	0.3	0.0	0.0	-	-	0.0	0.0	0.1	0.1	-	-	-	-
Travel	0.1	-	-	-	-	-	-	-	-	-	-	-	-
General & Administrative Expenses	1.6	0.1	0.2	-	-	0.2	0.2	0.1	0.1	-	-	-	-
Nondeductible	2.9	2.9	0.1	-	-	0.7	0.0	0.0	0.0	-	-	-	-
Personal Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-
<b>Total costs and expenses</b>	<b>8.1</b>	<b>269.2</b>	<b>9.8</b>	<b>-</b>	<b>-</b>	<b>5.1</b>	<b>5.9</b>	<b>14.4</b>	<b>17.5</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>Net income (loss)</b>	<b>\$ 802.4</b>	<b>\$ 586.2</b>	<b>\$ 9.4</b>	<b>\$ -</b>	<b>\$ -</b>	<b>\$ 15.1</b>	<b>\$ 1.8</b>	<b>\$ 45.8</b>	<b>\$ 46.6</b>	<b>\$ -</b>	<b>\$ -</b>	<b>\$ -</b>	<b>\$ -</b>

The above amounts have not been consolidated.

NAS2644

(\$ in millions)	RMLP	74A	RMCI	74-AR	74-AJ	74B	Inv. Trust	1A Trust	2A Trust	1B Trust	2B Trust	74-AR IR	74-AJ IR
Year Ended:	12/31/10	12/31/10	12/31/10	12/31/10	12/31/10	12/31/10	12/31/10	12/31/10	12/31/10	12/31/10	12/31/10	12/31/10	12/31/10
<b>Revenues:</b>													
Ordinary Income (Loss)	\$ 806.2	\$ 786.7	\$ 16.1	\$ -	\$ -	\$ (0.1)	\$ (3.3)	\$ 8.6	\$ 7.0	\$ -	\$ -	\$ -	\$ -
Interest Income	0.6	8.1	0.0	-	-	0.5	1.0	1.0	2.9	-	-	-	-
Dividend Income	0.0	1.3	-	-	-	0.5	0.3	7.7	7.8	-	-	-	-
Royalty Income	13.4	13.1	0.3	-	-	0.0	0.0	0.0	0.0	-	-	-	-
Rental Income	1.3	1.2	0.0	-	-	(0.5)	(1.4)	0.0	0.0	-	-	-	-
Net Capital Gains (Losses)	-	-	-	-	-	-	-	-	-	-	-	-	-
Section 1231	-	-	-	-	-	0.0	(0.1)	0.0	(0.0)	-	-	-	-
Section 1256	-	1.7	-	-	-	(0.1)	(0.1)	0.7	(0.6)	-	-	-	-
Short-Term	-	0.7	-	-	-	0.6	1.4	2.6	4.9	-	-	-	-
Long-Term	-	0.5	-	-	-	2.6	5.9	8.9	1.2	-	-	-	-
Other Portfolio Income	-	(0.0)	-	-	-	0.0	0.2	(0.1)	0.1	-	-	-	-
Tax Refunds	-	-	-	-	-	-	-	-	-	-	-	-	-
Federal	-	87.0	2.7	-	-	0.5	0.3	2.2	-	-	-	-	-
State	0.0	19.8	0.3	-	-	0.2	0.4	1.0	0.8	-	-	-	-
Subpart F Income	0.0	0.0	0.0	-	-	-	-	7.9	6.5	-	-	-	-
Other Income (Loss)	0.8	1.5	0.0	-	-	0.0	0.0	1.7	1.9	-	-	-	-
Federal Tax Exempt Income	-	-	-	-	-	-	-	0.0	0.0	-	-	-	-
Tax Exempt Income	-	-	-	-	-	-	-	-	-	-	-	-	-
Nontaxable Income	(54.7)	(51.7)	(1.1)	-	-	4.3	(5.6)	12.8	16.9	-	-	-	-
<b>Total revenues</b>	<b>767.5</b>	<b>869.8</b>	<b>18.3</b>	<b>-</b>	<b>-</b>	<b>8.6</b>	<b>(0.9)</b>	<b>55.0</b>	<b>49.3</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>Costs and expenses:</b>													
Interest Expense	-	0.7	-	-	-	0.2	0.3	9.1	8.5	-	-	-	-
Charitable Contributions	-	0.0	-	-	-	-	0.0	-	-	-	-	-	-
Intangible Drilling and Development Costs	-	0.0	-	-	-	-	3.0	-	-	-	-	-	-
Production Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-
Taxes - Domestic	-	-	-	-	-	-	-	-	-	-	-	-	-
Federal	-	454.9	7.8	-	-	1.0	0.6	6.3	5.7	-	-	-	-
State	-	74.4	1.0	-	-	0.3	0.1	1.1	-	-	-	-	-
Local	-	1.2	0.0	-	-	-	-	-	-	-	-	-	-
Other Payroll Taxes	0.0	-	-	-	-	-	-	-	-	-	-	-	-
Other	-	-	-	-	-	-	-	-	-	-	-	-	-
Taxes - Foreign	2.2	2.2	0.0	-	-	0.0	0.0	2.7	2.8	-	-	-	-
Portfolio Deductions	0.1	2.2	-	-	-	0.6	0.5	1.3	2.9	-	-	-	-
Depreciation, Depletion & Amortization	0.0	-	-	-	-	-	1.4	-	-	-	-	-	-
Salaries & Wages	0.8	-	-	-	-	-	-	-	-	-	-	-	-
Legal Fees	0.6	0.1	0.1	-	-	0.1	0.1	0.3	0.4	-	-	-	-
Travel	0.1	-	-	-	-	-	-	-	-	-	-	-	-
General & Administrative Expenses	1.3	0.3	0.4	-	-	0.2	0.2	0.2	0.2	-	-	-	-
Nondeductible	0.0	0.1	0.0	-	-	0.8	0.0	0.0	0.0	-	-	-	-
Personal Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-
<b>Total costs and expenses</b>	<b>5.2</b>	<b>536.2</b>	<b>9.3</b>	<b>-</b>	<b>-</b>	<b>3.2</b>	<b>6.3</b>	<b>21.2</b>	<b>20.4</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>Net income (loss)</b>	<b>\$ 762.3</b>	<b>\$ 333.6</b>	<b>\$ 8.9</b>	<b>\$ -</b>	<b>\$ -</b>	<b>\$ 5.5</b>	<b>\$ (7.2)</b>	<b>\$ 33.8</b>	<b>\$ 28.9</b>	<b>\$ -</b>	<b>\$ -</b>	<b>\$ -</b>	<b>\$ -</b>

The above amounts have not been consolidated.

NAS2645

The above amounts have not been consolidated.

PROFESSIONALS' EYES ONLY/HIGHLY CONFIDENTIAL—SUBJECT TO PROPOSED PROTECTIVE ORDER AND FRE 408

This presentation may only be viewed by the professionals identified on page 2, and it may not be shared.

(\$ in millions)	Year Ended:	RMLP 12/31/12	74A 12/31/12	RMCI 12/31/12	74-AR 12/31/12	74-AJ 12/31/12	74B 12/31/12	Inv. Trust 12/31/12	1A Trust 12/31/12	2A Trust 12/31/12	1B Trust 12/31/12	2B Trust 12/31/12	74-AR IR 12/31/12	74-AJ IR 12/31/12
<b>Revenues:</b>														
Ordinary Income (Loss)	\$	591.9	\$	576.3	\$	11.8	\$	-	\$	-	\$	-	\$	-
Interest Income		1.2		34.8		0.0		-		0.3		1.0		13.2
Dividend Income		-		0.6		-		-		0.3		0.1		27.6
Royalty Income		8.9		8.7		0.2		-		1.1		0.4		0.0
Rental Income		0.4		(0.4)		0.0		-		0.0		(0.6)		0.1
Net Capital Gains (Losses)		-		-		-		-		-		-		-
Section 1231		-		2.4		-		-		0.1		0.8		0.4
Section 1256		-		(1.4)		-		-		(0.0)		-		(1.3)
Short-Term		-		7.0		-		-		0.3		0.0		1.4
Long-Term		-		48.4		-		-		2.0		1.4		8.3
Other Portfolio Income		-		1.3		-		-		0.1		0.0		0.9
Tax Refunds		-		-		-		-		-		-		-
Federal		0.4		75.0		0.9		-		0.1		0.8		1.7
State		0.2		15.0		0.1		-		0.1		0.1		0.5
Subpart F Income		0.0		0.0		0.0		-		-		10.1		6.8
Other Income (Loss)		1.1		0.6		0.0		-		0.0		0.3		8.6
Federal Tax Exempt Income		-		-		-		-		0.0		0.1		0.1
Tax Exempt Income		-		0.0		-		-		-		-		-
Nontaxable Income		5.6		24.1		0.1		-		3.6		2.9		43.6
<b>Total revenues</b>		<b>609.8</b>		<b>792.3</b>		<b>13.1</b>		<b>-</b>		<b>-</b>		<b>(5.6)</b>		<b>104.5</b>
<b>Costs and expenses:</b>														
Interest Expense		-		1.1		-		-		0.4		1.5		21.1
Charitable Contributions		-		0.0		-		-		-		0.0		-
Intangible Drilling and Development Costs		-		0.2		-		-		0.1		124.2		0.0
Production Expenses		-		-		-		-		0.0		0.0		0.0
Taxes - Domestic		-		-		-		-		-		-		-
Federal		-		229.5		4.0		-		1.0		1.3		4.0
State		0.0		41.9		0.8		-		0.2		0.1		0.6
Local		-		0.1		0.0		-		-		-		-
Other Payroll Taxes		0.0		-		-		-		-		-		-
Other		-		-		-		-		-		-		-
Taxes - Foreign		2.5		2.5		0.0		-		0.0		0.0		2.4
Portfolio Deductions		-		5.9		-		-		0.4		0.3		7.9
Depreciation, Depletion & Amortization		-		-		-		-		3.4		-		0.0
Salaries & Wages		0.4		-		-		-		-		-		-
Legal Fees		0.5		0.2		0.1		-		0.1		0.1		0.4
Travel		0.1		-		-		-		-		-		-
General & Administrative Expenses		1.8		0.4		0.3		-		0.2		0.2		0.2
Nondeductible		3.9		5.0		0.1		-		0.9		0.0		0.0
Personal Expenses		-		-		-		-		-		-		-
<b>Total costs and expenses</b>		<b>9.3</b>		<b>286.8</b>		<b>5.3</b>		<b>-</b>		<b>-</b>		<b>3.2</b>		<b>131.1</b>
<b>Net income (loss)</b>	\$	<b>600.6</b>	\$	<b>505.5</b>	\$	<b>7.8</b>	\$	<b>-</b>	\$	<b>-</b>	\$	<b>4.6</b>	\$	<b>(136.8)</b>

The above amounts have not been consolidated.

NAS2647

(\$ in millions)		RMLP	74A	RMCI	74-AR	74-AJ	74B	Inv. Trust	1A Trust	2A Trust	1B Trust	2B Trust	74-AR IR	74-AJ IR												
	Year Ended:	12/31/13	12/31/13	12/31/13	12/31/13	12/31/13	12/31/13	12/31/13	12/31/13	12/31/13	12/31/13	12/31/13	12/31/13	12/31/13												
<b>Revenues:</b>																										
Ordinary Income (Loss)	\$	409.4	\$	398.3	\$	8.1	\$	-	\$	(0.8)	\$	47.3	\$	(13.9)	\$	(4.7)	\$	-	\$	-	\$	-	\$	-	\$	-
Interest Income		0.7		37.5		0.0		-		0.2		0.8		11.7		24.0		-		-		-		-		-
Dividend Income		-		3.6		-		-		0.1		0.7		13.6		17.1		-		-		-		-		-
Royalty Income		8.6		8.4		0.2		-		1.2		0.4		0.0		0.0		-		-		-		-		-
Rental Income		0.2		0.8		0.0		-		0.0		(0.6)		0.3		0.1		-		-		-		-		-
Net Capital Gains (Losses)		-		-		-		-		-		-		-		-		-		-		-		-		-
Section 1231		-		5.4		-		-		0.3		2.3		1.0		0.0		-		-		-		-		-
Section 1256		-		0.3		-		-		(0.0)		-		0.9		(0.3)		-		-		-		-		-
Short-Term		64.7		71.5		1.3		-		0.5		0.1		10.6		16.1		-		-		-		-		-
Long-Term		77.4		92.8		1.5		-		10.2		0.6		38.2		53.1		-		-		-		-		-
Other Portfolio Income		-		1.2		-		-		0.1		0.0		0.1		0.9		-		-		-		-		-
Tax Refunds		-		-		-		-		-		-		-		-		-		-		-		-		-
Federal		-		61.3		0.7		-		0.6		0.3		14.8		13.3		-		-		-		-		-
State		0.6		18.2		0.1		-		0.1		0.1		0.5		0.2		-		-		-		-		-
Subpart F Income		(0.0)		(0.0)		-		-		0.0		-		8.4		6.7		-		-		-		-		-
Other Income (Loss)		0.7		0.9		0.0		-		0.0		0.1		6.6		(8.5)		-		-		-		-		-
Federal Tax Exempt Income		-		-		-		-		-		0.2		0.1		-		-		-		-		-		-
Tax Exempt Income		-		0.1		-		-		-		-		-		-		-		-		-		-		-
Nontaxable Income		(192.9)		(166.3)		(3.9)		-		11.3		(8.4)		8.7		32.7		-		-		-		-		-
<b>Total revenues</b>		<b>369.3</b>		<b>534.2</b>		<b>8.1</b>		<b>-</b>		<b>23.8</b>		<b>43.7</b>		<b>101.6</b>		<b>150.8</b>		<b>-</b>		<b>-</b>		<b>-</b>		<b>-</b>		<b>-</b>
<b>Costs and expenses:</b>																										
Interest Expense		-		3.2		-		-		0.3		3.9		19.1		23.2		-		-		-		-		-
Charitable Contributions		-		0.0		-		-		-		0.0		0.0		0.0		-		-		-		-		-
Intangible Drilling and Development Costs		-		0.3		-		-		0.0		144.6		0.0		0.3		-		-		-		-		-
Production Expenses		-		-		-		-		-		0.0		-		0.0		-		-		-		-		-
Taxes - Domestic		-		-		-		-		-		-		-		-		-		-		-		-		-
Federal		0.4		254.3		3.9		-		1.1		0.3		30.4		35.7		0.5		0.5		-		-		-
State		0.6		42.7		0.5		-		0.2		0.1		-		0.6		-		-		-		-		-
Local		-		-		0.0		-		-		-		-		-		-		-		-		-		-
Other Payroll Taxes		0.0		-		-		-		-		-		-		-		-		-		-		-		-
Other		-		-		-		-		-		-		-		-		-		-		-		-		-
Taxes - Foreign		2.6		2.7		0.1		-		0.0		0.0		1.1		0.8		-		-		-		-		-
Portfolio Deductions		-		6.4		-		-		0.4		0.3		13.7		13.5		-		-		-		-		-
Depreciation, Depletion & Amortization		-		-		-		-		-		14.4		-		0.0		-		-		-		-		-
Salaries & Wages		0.2		-		-		-		-		-		-		-		-		-		-		-		-
Legal Fees		0.5		0.1		0.0		-		0.1		0.1		0.5		0.5		-		-		-		-		-
Travel		0.1		-		-		-		-		-		-		-		-		-		-		-		-
General & Administrative Expenses		1.9		0.4		0.3		-		0.2		0.2		0.2		0.2		-		-		-		-		-
Nondeductible		7.1		8.4		0.2		-		1.3		0.0		0.1		0.1		-		-		-		-		-
Personal Expenses		-		-		-		-		-		-		-		-		-		-		-		-		-
<b>Total costs and expenses</b>		<b>13.5</b>		<b>318.6</b>		<b>5.0</b>		<b>-</b>		<b>3.5</b>		<b>163.9</b>		<b>65.1</b>		<b>75.0</b>		<b>0.5</b>		<b>0.5</b>		<b>-</b>		<b>-</b>		<b>-</b>
<b>Net income (loss)</b>	\$	<b>355.8</b>	\$	<b>215.6</b>	\$	<b>3.2</b>	\$	<b>-</b>	\$	<b>-</b>	\$	<b>20.3</b>	\$	<b>(120.2)</b>	\$	<b>36.5</b>	\$	<b>75.8</b>	\$	<b>(0.5)</b>	\$	<b>(0.5)</b>	\$	<b>-</b>	\$	<b>-</b>

The above amounts have not been consolidated.

NAS2648

(\$ in millions)	Year Ended:	RMLP 12/31/14	74A 12/31/14	RMCI 12/31/14	74-AR 12/31/14	74-AJ 12/31/14	74B 12/31/14	Inv. Trust 12/31/14	1A Trust 12/31/14	2A Trust 12/31/14	1B Trust 12/31/14	2B Trust 12/31/14	74-AR IR 12/31/14	74-AJ IR 12/31/14												
<b>Revenues:</b>																										
Ordinary Income (Loss)	\$	494.4	\$	485.2	\$	9.8	\$	-	\$	-	\$	(0.2)	\$	53.2	\$	(15.6)	\$	(14.5)	\$	-	\$	-	\$	-	\$	-
Interest Income		0.9		36.5		0.0		-		-		0.1		0.7		6.0		5.7		-		-		-		-
Dividend Income		-		5.2		-		-		-		0.2		0.2		10.9		22.0		-		-		-		-
Royalty Income		7.2		7.2		0.1		-		-		0.6		0.3		0.0		0.0		-		-		-		-
Rental Income		0.2		(3.2)		0.0		-		-		(0.1)		(0.8)		(0.5)		(0.1)		-		-		-		-
Net Capital Gains (Losses)		-		-		-		-		-		-		-		-		-		-		-		-		-
Section 1231		-		8.5		-		-		-		0.0		1.6		0.1		0.5		-		-		-		-
Section 1256		-		3.5		-		-		-		(0.0)		-		(0.3)		0.1		-		-		-		-
Short-Term		-		14.5		-		-		-		0.0		(0.1)		8.3		9.1		-		-		-		-
Long-Term		-		30.4		-		-		-		12.3		1.2		10.0		39.8		-		-		-		-
Other Portfolio Income		0.0		2.9		-		-		-		0.1		0.1		0.7		2.1		-		-		-		-
Tax Refunds		-		-		-		-		-		-		-		-		-		-		-		-		-
Federal		-		41.5		1.5		-		-		0.7		0.3		2.3		0.3		-		-		-		-
State		0.3		16.4		0.2		-		-		0.1		0.1		-		0.1		-		-		-		-
Subpart F Income		(0.0)		(0.0)		-		-		-		-		-		13.0		5.4		-		-		-		-
Other Income (Loss)		0.1		(2.8)		0.0		-		-		0.0		-		1.9		2.8		-		-		-		-
Federal Tax Exempt Income		-		-		-		-		-		0.0		0.0		0.1		0.0		-		-		-		-
Tax Exempt Income		-		0.2		-		-		-		-		-		-		-		-		-		-		-
Nontaxable Income		(94.8)		(104.3)		(1.9)		-		-		(3.3)		(15.9)		9.2		(28.2)		-		-		-		-
<b>Total revenues</b>		<b>408.5</b>		<b>541.6</b>		<b>9.8</b>		<b>-</b>		<b>-</b>		<b>10.7</b>		<b>40.9</b>		<b>45.9</b>		<b>45.2</b>		<b>-</b>		<b>-</b>		<b>-</b>		<b>-</b>
<b>Costs and expenses:</b>																										
Interest Expense		-		5.9		-		-		-		0.2		4.2		0.0		14.4		-		-		-		-
Charitable Contributions		-		0.0		-		-		-		-		0.0		-		0.0		-		-		-		-
Intangible Drilling and Development Costs		-		1.3		-		-		-		-		160.3		16.7		0.7		-		-		-		-
Production Expenses		-		-		-		-		-		0.0		-		0.0		-		-		-		-		-
Taxes - Domestic		-		-		-		-		-		-		-		-		-		-		-		-		-
Federal		-		174.5		4.6		-		-		5.0		0.3		14.8		25.3		-		-		-		-
State		0.3		41.0		0.6		-		-		0.5		0.1		0.0		0.2		-		-		-		-
Local		-		-		0.0		-		-		-		-		-		-		-		-		-		-
Other Payroll Taxes		0.0		-		-		-		-		-		-		-		-		-		-		-		-
Other		-		-		-		-		-		-		-		-		-		-		-		-		-
Taxes - Foreign		2.1		2.3		0.0		-		-		0.0		0.0		1.8		1.6		-		-		-		-
Portfolio Deductions		-		8.8		-		-		-		0.3		0.3		13.0		19.4		-		-		-		-
Depreciation, Depletion & Amortization		-		-		-		-		-		19.1		-		-		-		-		-		-		-
Salaries & Wages		0.3		-		-		-		-		-		-		-		-		-		-		-		-
Legal Fees		0.4		0.4		0.1		-		-		0.1		0.1		0.9		0.8		-		-		-		-
Travel		0.1		-		-		-		-		-		-		-		-		-		-		-		-
General & Administrative Expenses		1.6		0.4		0.3		-		-		0.2		0.2		0.3		0.3		-		-		-		-
Nondeductible		38.4		37.9		0.8		-		-		1.0		0.0		0.1		0.4		-		-		-		-
Personal Expenses		-		-		-		-		-		-		-		-		-		-		-		-		-
<b>Total costs and expenses</b>		<b>43.2</b>		<b>272.5</b>		<b>6.3</b>		<b>-</b>		<b>-</b>		<b>7.3</b>		<b>184.6</b>		<b>47.5</b>		<b>62.9</b>		<b>-</b>		<b>-</b>		<b>-</b>		<b>-</b>
<b>Net income (loss)</b>	\$	<b>365.2</b>	\$	<b>269.1</b>	\$	<b>3.4</b>	\$	<b>-</b>	\$	<b>-</b>	\$	<b>3.3</b>	\$	<b>(143.6)</b>	\$	<b>(1.7)</b>	\$	<b>(17.7)</b>	\$	<b>-</b>	\$	<b>-</b>	\$	<b>-</b>	\$	<b>-</b>

The above amounts have not been consolidated.

NAS2649



# 2015 Statement of Operations

19-23648-0001 Doc 07-22 Filed 08/05/21 Entered 08/05/21 14:28:38 Page 11 of 142  
 28 of 725

(\$ in millions)	RMLP	74A	RMCI	74-AR	74-AJ	74B	Inv. Trust	1A Trust	2A Trust	1B Trust	2B Trust	74-AR IR	74-AJ IR
Year Ended:	12/31/15	12/31/15	12/31/15	12/31/15	12/31/15	12/31/15	12/31/15	12/31/15	12/31/15	12/31/15	12/31/15	12/31/15	12/31/15
<b>Revenues:</b>													
Ordinary Income (Loss)	\$ 417.5	\$ 407.4	\$ 8.3	\$ (3.1)	\$ 0.5	\$ (0.0)	\$ 65.5	\$ (18.7)	\$ (17.4)	\$ -	\$ -	\$ -	\$ -
Interest Income	1.0	4.4	0.0	13.1	14.6	0.4	0.9	5.4	4.4	-	-	-	-
Dividend Income	-	2.1	-	6.2	3.4	0.2	0.1	6.8	13.9	-	-	-	-
Royalty Income	13.0	12.7	0.3	0.0	0.0	1.0	0.0	0.0	0.0	-	-	-	-
Rental Income	(0.1)	(0.1)	(0.0)	(4.7)	(3.7)	(0.1)	(0.6)	(0.3)	(0.7)	-	-	-	-
Net Capital Gains (Losses)	-	-	-	-	-	-	-	-	-	-	-	-	-
Section 1231	0.9	0.9	0.0	10.8	10.6	0.1	2.0	2.1	1.3	-	-	-	-
Section 1256	-	1.6	-	2.6	(0.2)	0.0	-	0.8	0.2	-	-	-	-
Short-Term	-	2.7	-	(0.8)	(2.0)	(0.5)	(0.3)	(9.8)	3.8	-	-	-	-
Long-Term	-	4.6	-	4.3	10.1	1.5	6.0	53.6	30.7	-	-	-	-
Other Portfolio Income	(0.0)	0.8	-	0.3	2.2	0.1	0.1	0.2	0.7	-	-	-	-
Tax Refunds	-	-	-	-	-	-	-	-	-	-	-	-	-
Federal	-	25.2	1.1	-	-	0.8	-	6.6	6.9	-	-	-	-
State	0.3	13.5	0.1	-	-	0.0	0.1	-	0.1	-	-	-	-
Subpart F Income	(0.0)	(0.0)	-	-	-	-	-	6.9	4.4	-	-	-	-
Other Income (Loss)	(0.2)	1.4	(0.0)	3.8	(0.2)	0.0	0.0	1.1	1.4	-	-	-	-
Federal Tax Exempt Income	-	-	-	0.1	0.3	0.0	0.0	0.1	0.0	-	-	-	-
Tax Exempt Income	-	0.0	-	-	-	-	-	-	-	-	-	-	-
Nontaxable Income	(84.9)	(74.4)	(1.7)	59.1	29.3	(1.7)	32.2	(16.0)	0.3	-	-	-	-
<b>Total revenues</b>	<b>347.5</b>	<b>402.9</b>	<b>8.1</b>	<b>91.7</b>	<b>65.0</b>	<b>1.8</b>	<b>105.8</b>	<b>38.9</b>	<b>49.9</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>Costs and expenses:</b>													
Interest Expense	-	1.9	-	3.9	4.2	0.3	4.6	0.2	12.8	-	-	-	-
Charitable Contributions	-	0.0	-	0.0	0.0	-	0.0	-	0.0	-	-	-	-
Intangible Drilling and Development Costs	-	0.1	-	0.5	0.5	-	51.7	15.9	0.4	-	-	-	-
Production Expenses	-	0.0	-	0.0	0.0	-	-	0.0	0.0	-	-	-	-
Taxes - Domestic	-	-	-	-	-	-	-	-	-	-	-	-	-
Federal	-	249.8	3.3	-	-	3.2	0.2	14.8	21.8	-	-	-	-
State	0.5	36.1	0.6	0.0	0.0	0.1	0.1	-	0.2	-	-	-	-
Local	-	-	0.0	-	-	-	-	-	-	-	-	-	-
Other Payroll Taxes	-	-	-	-	-	-	-	-	-	-	-	-	-
Other	-	-	-	-	-	-	-	-	-	-	-	-	-
Taxes - Foreign	1.3	1.4	0.0	0.1	0.1	0.0	0.0	1.1	0.9	-	-	-	-
Portfolio Deductions	-	4.7	-	7.0	5.6	0.3	0.2	16.4	14.4	-	-	-	-
Depreciation, Depletion & Amortization	-	-	-	-	-	-	15.4	-	-	-	-	-	-
Salaries & Wages	-	-	-	-	-	-	-	-	-	-	-	-	-
Legal Fees	0.2	0.3	0.0	0.1	0.1	0.1	0.1	0.5	0.7	-	-	-	-
Travel	0.1	-	-	-	-	-	-	-	-	-	-	-	-
General & Administrative Expenses	1.7	0.5	1.3	0.0	0.0	0.3	0.3	0.3	0.3	-	-	-	-
Nondeductible	9.2	10.0	0.2	0.1	0.1	1.1	0.0	0.4	0.4	-	-	-	-
Personal Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-
<b>Total costs and expenses</b>	<b>12.9</b>	<b>304.7</b>	<b>5.4</b>	<b>11.9</b>	<b>10.7</b>	<b>5.5</b>	<b>72.6</b>	<b>49.7</b>	<b>52.0</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>Net income (loss)</b>	<b>\$ 334.6</b>	<b>\$ 98.2</b>	<b>\$ 2.7</b>	<b>\$ 79.8</b>	<b>\$ 54.3</b>	<b>\$ (3.6)</b>	<b>\$ 33.3</b>	<b>\$ (10.8)</b>	<b>\$ (2.1)</b>	<b>\$ -</b>	<b>\$ -</b>	<b>\$ -</b>	<b>\$ -</b>

The above amounts have not been consolidated.

NAS2650

PROFESSIONALS' EYES ONLY/HIGHLY CONFIDENTIAL—SUBJECT TO PROPOSED PROTECTIVE ORDER AND FRE 408

This presentation may only be viewed by the professionals identified on page 2, and it may not be shared.

# 2016 Statement of Operations

19-23648-001 Doc 07522-0 Filed 08/05/21 Entered 08/05/21 14:28:38 Page 11 of 142  
 29 of 725

(\$ in millions)	RMLP	74A	RMCI	74-AR	74-AJ	74B	Inv. Trust	1A Trust	2A Trust	1B Trust	2B Trust	74-AR IR	74-AJ IR
Year Ended:	12/31/16	12/31/16	12/31/16	12/31/16	12/31/16	12/31/16	12/31/16	12/31/16	12/31/16	12/31/16	12/31/16	12/31/16	12/31/16
<b>Revenues:</b>													
Ordinary Income (Loss)	\$ 201.6	\$ 195.6	\$ 4.0	\$ (16.2)	\$ (5.0)	\$ (0.0)	\$ 21.3	\$ (5.4)	\$ (6.4)	\$ -	\$ -	\$ -	\$ -
Interest Income	1.5	3.5	0.0	12.9	12.6	0.6	1.0	4.2	2.9	-	-	-	-
Dividend Income	-	0.1	0.0	9.8	7.4	0.1	0.0	8.1	6.4	-	-	-	-
Royalty Income	8.5	8.3	0.2	0.0	0.0	1.2	0.1	-	0.0	-	-	-	-
Rental Income	(0.0)	(0.0)	(0.0)	(5.9)	(3.0)	(0.0)	(0.2)	(0.0)	(1.4)	-	-	-	-
Net Capital Gains (Losses)	-	-	-	-	-	-	-	-	-	-	-	-	-
Section 1231	-	-	-	22.7	23.0	0.1	0.9	0.0	0.5	-	-	-	-
Section 1256	-	-	-	0.9	0.5	0.0	-	-	0.2	-	-	-	-
Short-Term	-	-	-	(6.4)	(1.5)	(0.2)	0.0	(6.0)	(2.4)	-	-	-	-
Long-Term	7.4	7.2	0.1	15.7	17.1	1.3	0.0	26.6	25.2	-	-	-	-
Other Portfolio Income	-	-	-	0.1	1.6	0.0	0.0	0.1	0.4	-	-	-	-
Tax Refunds	-	-	-	-	-	-	-	-	-	-	-	-	-
Federal	-	43.7	1.6	3.7	5.2	0.7	1.6	1.5	8.9	-	-	-	-
State	0.7	14.6	0.3	0.2	0.7	0.1	0.1	-	0.0	-	-	-	-
Subpart F Income	-	-	-	-	-	-	-	14.9	11.4	-	-	-	-
Other Income (Loss)	(0.1)	(0.1)	(0.0)	3.9	1.3	0.0	0.1	0.2	0.1	-	-	-	-
Federal Tax Exempt Income	-	-	-	0.3	0.4	-	-	-	-	-	-	-	-
Tax Exempt Income	-	-	-	-	-	-	-	-	-	-	-	-	-
Nontaxable Income	83.7	82.0	1.7	82.6	47.7	7.7	0.3	46.7	7.9	-	-	-	-
<b>Total revenues</b>	<b>303.2</b>	<b>354.9</b>	<b>7.9</b>	<b>124.2</b>	<b>108.1</b>	<b>11.6</b>	<b>25.2</b>	<b>91.0</b>	<b>53.6</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>Costs and expenses:</b>													
Interest Expense	-	-	-	13.3	9.3	0.3	5.1	8.9	7.2	-	-	-	-
Charitable Contributions	-	-	-	0.0	0.0	0.0	0.0	-	0.0	-	-	-	-
Intangible Drilling and Development Costs	-	-	-	0.4	0.4	-	6.9	-	0.3	-	-	-	-
Production Expenses	-	-	-	-	-	-	-	-	0.0	-	-	-	-
Taxes - Domestic	-	-	-	-	-	-	-	-	-	-	-	-	-
Federal	-	138.6	2.4	17.1	19.6	0.7	3.1	6.4	15.1	-	-	-	-
State	0.7	44.3	0.3	1.4	2.9	0.1	0.1	0.1	0.2	-	-	-	-
Local	-	-	-	-	-	-	-	-	-	-	-	-	-
Other Payroll Taxes	-	-	-	-	-	-	-	-	-	-	-	-	-
Other	-	-	-	-	-	-	-	0.2	-	-	-	-	-
Taxes - Foreign	0.6	0.6	0.0	0.3	0.2	0.0	-	1.4	1.3	-	-	-	-
Portfolio Deductions	-	0.1	-	14.9	15.2	0.2	0.2	9.2	8.8	-	-	-	-
Depreciation, Depletion & Amortization	-	-	-	-	-	-	10.1	-	-	-	-	-	-
Salaries & Wages	-	-	-	-	-	-	-	-	-	-	-	-	-
Legal Fees	0.2	0.1	0.0	0.3	0.1	0.1	0.1	0.3	0.3	-	-	-	-
Travel	0.1	-	-	-	-	-	-	-	-	-	-	-	-
General & Administrative Expenses	1.8	0.3	0.7	0.2	0.2	0.3	0.3	0.4	0.3	-	-	-	-
Nondeductible	0.9	1.0	0.0	0.6	0.6	1.3	0.0	0.0	0.4	-	-	-	-
Personal Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-
<b>Total costs and expenses</b>	<b>4.2</b>	<b>185.2</b>	<b>3.4</b>	<b>48.5</b>	<b>48.6</b>	<b>3.0</b>	<b>25.8</b>	<b>26.7</b>	<b>34.0</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>Net income (loss)</b>	<b>\$ 299.0</b>	<b>\$ 169.8</b>	<b>\$ 4.4</b>	<b>\$ 75.7</b>	<b>\$ 59.5</b>	<b>\$ 8.6</b>	<b>\$ (0.5)</b>	<b>\$ 64.3</b>	<b>\$ 19.6</b>	<b>\$ -</b>	<b>\$ -</b>	<b>\$ -</b>	<b>\$ -</b>

The above amounts have not been consolidated.

NAS2651

PROFESSIONALS' EYES ONLY/HIGHLY CONFIDENTIAL—SUBJECT TO PROPOSED PROTECTIVE ORDER AND FRE 408

This presentation may only be viewed by the professionals identified on page 2, and it may not be shared.

(\$ in millions)		RMLP	74A	RMCI	74-AR	74-AJ	74B	Inv. Trust	1A Trust	2A Trust	1B Trust	2B Trust	74-AR IR	74-AJ IR												
	Year Ended:	12/31/17	12/31/17	12/31/17	12/31/17	12/31/17	12/31/17	12/31/17	12/31/17	12/31/17	12/31/17	12/31/17	12/31/17	12/31/17												
<b>Revenues:</b>																										
Ordinary Income (Loss)	\$	16.8	\$	15.3	\$	0.3	\$	(9.9)	\$	(6.3)	\$	0.1	\$	19.0	\$	2.0	\$	0.8	\$	-	\$	-	\$	-	\$	-
Interest Income		5.1		8.0		0.1		15.9		14.5		0.6		1.6		3.8		3.4		-		-		-		-
Dividend Income		0.0		0.4		0.2		17.6		10.4		0.2		0.1		13.1		11.8		0.0		0.0		-		-
Royalty Income		11.6		11.4		0.2		0.2		(0.1)		1.1		0.1		0.0		0.0		-		-		-		-
Rental Income		0.0		0.0		-		(11.0)		(3.5)		1.0		(0.3)		(0.2)		(1.8)		-		-		-		-
Net Capital Gains (Losses)		-		-		-		-		-		-		-		-		-		-		-		-		-
Section 1231		(8.8)		(8.6)		(0.2)		11.5		4.1		0.3		0.8		0.1		0.8		-		-		-		-
Section 1256		-		-		-		8.2		(1.0)		(0.0)		-		(0.0)		(0.2)		-		-		-		-
Short-Term		-		(0.0)		(0.0)		0.1		(0.3)		-		(0.0)		2.5		(2.8)		-		-		-		-
Long-Term		0.0		0.0		-		55.2		38.5		1.6		2.2		23.7		28.4		-		-		-		-
Other Portfolio Income		-		-		-		(3.0)		(2.7)		0.1		0.0		(1.4)		1.0		-		-		-		-
Tax Refunds		-		-		-		-		-		-		-		-		-		-		-		-		-
Federal		-		35.8		0.9		3.0		2.6		0.5		1.6		-		4.8		-		-		-		-
State		0.9		19.5		0.1		0.2		0.9		0.0		0.1		-		-		-		-		-		-
Subpart F Income		-		-		-		-		-		-		-		13.3		9.9		-		-		-		-
Other Income (Loss)		3.2		3.1		0.1		3.1		1.0		0.0		0.0		613.6		622.4		-		-		-		-
Federal Tax Exempt Income		-		-		-		0.0		0.2		-		-		-		-		-		-		-		-
Tax Exempt Income		2.2		2.1		0.0		-		0.6		-		-		461.6		467.9		-		-		-		-
Nontaxable Income		68.8		67.8		1.4		73.7		79.0		5.2		(4.9)		(14.4)		51.4		-		-		-		-
<b>Total revenues</b>		<b>99.6</b>		<b>154.8</b>		<b>3.1</b>		<b>164.9</b>		<b>138.0</b>		<b>10.7</b>		<b>20.2</b>		<b>1,117.7</b>		<b>1,197.9</b>		<b>0.0</b>		<b>0.0</b>		<b>-</b>		<b>-</b>
<b>Costs and expenses:</b>																										
Interest Expense		-		-		-		17.1		8.2		0.4		6.0		9.4		7.1		-		-		-		-
Charitable Contributions		-		-		-		0.0		0.0		-		0.0		-		0.0		-		-		-		-
Intangible Drilling and Development Costs		-		-		-		0.6		0.6		-		60.2		0.7		1.5		-		-		-		-
Production Expenses		-		-		-		0.2		0.2		-		-		0.0		0.0		-		-		-		-
Taxes - Domestic		-		-		-		-		-		-		-		-		-		-		-		-		-
Federal		-		83.3		1.2		11.5		13.4		1.1		0.7		10.7		11.8		-		-		-		-
State		0.0		21.8		0.2		1.6		3.3		0.0		0.1		-		0.1		-		-		-		-
Local		-		-		-		-		-		-		-		-		-		-		-		-		-
Other Payroll Taxes		-		-		-		-		-		-		-		-		-		-		-		-		-
Other		-		-		-		-		-		-		0.0		0.3		-		-		-		-		-
Taxes - Foreign		4.7		4.6		0.1		0.3		0.3		0.0		-		1.3		1.4		-		-		-		-
Portfolio Deductions		-		0.1		-		15.5		18.2		0.3		0.1		9.0		9.6		-		-		-		-
Depreciation, Depletion & Amortization		-		-		-		-		-		-		7.9		-		-		-		-		-		-
Salaries & Wages		-		-		-		-		-		-		-		-		-		-		-		-		-
Legal Fees		0.1		0.6		0.0		0.4		0.2		0.0		0.0		0.2		0.1		-		-		-		-
Travel		0.1		-		-		-		-		-		-		-		-		-		-		-		-
General & Administrative Expenses		3.9		2.3		0.1		0.4		1.0		0.3		0.1		462.0		468.3		-		-		-		-
Nondeductible		1.0		0.9		0.0		0.3		0.4		1.4		0.0		0.1		0.7		-		-		-		-
Personal Expenses		-		-		-		-		-		-		-		-		-		-		-		-		-
<b>Total costs and expenses</b>		<b>9.8</b>		<b>113.7</b>		<b>1.7</b>		<b>47.9</b>		<b>45.8</b>		<b>3.4</b>		<b>75.2</b>		<b>493.6</b>		<b>500.6</b>		<b>-</b>		<b>-</b>		<b>-</b>		<b>-</b>
<b>Net income (loss)</b>	\$	<b>89.8</b>	\$	<b>41.1</b>	\$	<b>1.4</b>	\$	<b>117.0</b>	\$	<b>92.2</b>	\$	<b>7.3</b>	\$	<b>(55.0)</b>	\$	<b>624.0</b>	\$	<b>697.2</b>	\$	<b>0.0</b>	\$	<b>0.0</b>	\$	<b>-</b>	\$	<b>-</b>

The above amounts have not been consolidated.

NAS2652

# 2018 Statement of Operations

19-23648-0001 Doc 07-22 Filed 08/05/21 Entered 08/05/21 14:28:38 Page 10 of 142

(\$ in millions)	RMLP	74A	RMCI	74-AR	74-AJ	74B	Inv. Trust	1A Trust	2A Trust	1B Trust	2B Trust	74-AR IR	74-AJ IR
Year Ended:	12/31/18	12/31/18	12/31/18	12/31/18	12/31/18	12/31/18	12/31/18	12/31/18	12/31/18	12/31/18	12/31/18	12/31/18	12/31/18
<b>Revenues:</b>													
Ordinary Income (Loss)	\$ (46.9)	\$ (47.6)	\$ (0.9)	\$ 19.7	\$ (15.1)	\$ -	\$ 28.8	\$ 27.5	\$ 29.9	\$ -	\$ -	\$ -	\$ -
Interest Income	12.3	16.1	0.2	21.3	21.3	0.6	1.9	2.4	3.5	-	-	-	-
Dividend Income	0.4	1.0	0.3	36.0	15.9	0.5	0.1	9.9	8.8	0.0	0.0	-	-
Royalty Income	14.9	14.6	0.3	0.2	0.4	2.5	0.1	0.1	0.1	-	-	-	-
Rental Income	0.0	0.0	-	(12.2)	(1.9)	1.9	(0.1)	(0.4)	(1.8)	-	-	-	-
Net Capital Gains (Losses)	-	-	-	-	-	-	-	-	-	-	-	-	-
Section 1231	-	-	-	5.6	5.8	0.0	0.5	0.0	1.0	-	-	-	-
Section 1256	-	-	-	(13.8)	0.7	0.0	-	0.0	0.1	-	-	-	-
Short-Term	-	0.0	0.0	18.4	(10.7)	0.2	0.0	6.5	(1.5)	0.0	0.0	-	-
Long-Term	0.0	0.0	-	77.7	65.1	0.9	0.7	17.0	33.8	-	-	-	-
Other Portfolio Income	-	-	-	4.1	5.4	0.0	0.0	0.1	0.5	-	-	-	-
Tax Refunds	-	-	-	-	-	-	-	-	-	-	-	-	-
Federal	-	38.6	1.1	0.5	4.7	0.6	0.6	-	-	0.0	0.0	-	-
State	0.9	18.2	0.2	0.7	0.9	0.0	0.1	-	0.0	-	-	-	-
Subpart F Income	0.0	0.0	0.0	0.0	0.0	0.0	0.0	7.2	6.0	-	-	-	-
Other Income (Loss)	0.0	0.0	-	0.0	0.1	0.0	0.0	3.2	3.6	-	-	-	-
Federal Tax Exempt Income	-	-	-	-	-	-	-	0.2	0.0	-	-	-	-
Tax Exempt Income	-	-	-	0.0	0.6	-	-	-	-	-	-	-	-
Nontaxable Income	25.6	33.8	0.5	(96.4)	(38.1)	0.7	3.9	(21.2)	(37.5)	-	-	-	-
<b>Total revenues</b>	<b>7.3</b>	<b>74.7</b>	<b>1.7</b>	<b>61.9</b>	<b>55.0</b>	<b>8.1</b>	<b>36.5</b>	<b>52.4</b>	<b>46.5</b>	<b>0.1</b>	<b>0.1</b>	<b>-</b>	<b>-</b>
<b>Costs and expenses:</b>													
Interest Expense	-	-	-	30.8	13.1	0.4	14.5	7.9	5.4	-	-	-	-
Charitable Contributions	-	-	-	0.0	0.0	-	-	0.0	0.0	-	-	-	-
Intangible Drilling and Development Costs	-	-	-	1.2	1.3	1.3	31.4	0.6	1.8	-	-	-	-
Production Expenses	-	-	-	1.3	1.3	-	0.0	0.0	0.0	-	-	-	-
Taxes - Domestic	-	-	-	-	-	-	-	-	-	-	-	-	-
Federal	-	39.3	1.1	19.1	21.3	1.9	0.6	10.4	20.3	0.1	0.1	-	-
State	0.0	29.2	0.3	1.3	2.5	0.1	0.1	6.0	0.0	-	-	-	-
Local	-	-	-	-	-	-	-	-	-	-	-	-	-
Other Payroll Taxes	-	-	-	-	-	-	-	-	-	-	-	-	-
Other	-	-	-	0.0	-	-	-	0.1	-	-	-	-	-
Taxes - Foreign	2.0	2.0	0.0	0.2	0.6	0.0	-	4.2	4.3	-	-	-	-
Portfolio Deductions	-	0.2	-	13.9	21.0	0.4	0.1	7.6	8.9	-	-	-	-
Depreciation, Depletion & Amortization	-	-	-	-	-	-	11.3	-	-	-	-	-	-
Salaries & Wages	-	-	-	-	-	-	-	-	-	-	-	-	-
Legal Fees	0.1	2.1	0.0	0.4	0.1	0.0	0.0	0.2	0.1	0.0	0.0	-	-
Travel	0.1	-	-	-	-	-	-	-	-	-	-	-	-
General & Administrative Expenses	1.3	0.2	0.1	0.5	0.5	0.3	0.1	0.7	0.4	-	-	-	-
Nondeductible	0.2	0.2	0.0	0.3	0.6	1.4	0.0	0.4	0.8	-	-	-	-
Personal Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-
<b>Total costs and expenses</b>	<b>3.7</b>	<b>73.2</b>	<b>1.5</b>	<b>69.0</b>	<b>62.4</b>	<b>5.8</b>	<b>58.2</b>	<b>38.1</b>	<b>42.1</b>	<b>0.1</b>	<b>0.1</b>	<b>-</b>	<b>-</b>
<b>Net income (loss)</b>	<b>\$ 3.6</b>	<b>\$ 1.6</b>	<b>\$ 0.2</b>	<b>\$ (7.1)</b>	<b>\$ (7.4)</b>	<b>\$ 2.2</b>	<b>\$ (21.7)</b>	<b>\$ 14.3</b>	<b>\$ 4.4</b>	<b>\$ (0.0)</b>	<b>\$ (0.0)</b>	<b>\$ -</b>	<b>\$ -</b>

The above amounts have not been consolidated.

NAS2653

PROFESSIONALS' EYES ONLY/HIGHLY CONFIDENTIAL—SUBJECT TO PROPOSED PROTECTIVE ORDER AND FRE 408

This presentation may only be viewed by the professionals identified on page 2, and it may not be shared.

# 2019 Statement of Operations

19-236248-001 Doc 07-22 Filed 08/05/21 Entered 08/05/21 14:28:38 Page 10 of 142

(\$ in millions)		RMLP	74A	RMCI	74-AR	74-AJ	74B	Inv. Trust	1A Trust	2A Trust	1B Trust	2B Trust	74-AR IR	74-AJ IR												
	Year Ended:	12/31/19	12/31/19	12/31/19	12/31/19	12/31/19	12/31/19	12/31/19	12/31/19	12/31/19	12/31/19	12/31/19	12/31/19	12/31/19												
<b>Revenues:</b>																										
Ordinary Income (Loss)	\$	20.4	\$	54.5	\$	0.4	\$	170.8	\$	44.1	\$	11.7	\$	(27.1)	\$	51.3	\$	86.4	\$	-	\$	-	\$	15.4	\$	23.1
Interest Income		0.8		3.6		0.4		5.7		1.9		0.5		1.8		2.0		0.2		0.0		-		3.2		3.3
Dividend Income		0.1		0.3		0.1		6.5		3.2		0.2		0.1		1.0		5.7		0.1		0.1		1.7		2.2
Royalty Income		-		-		-		0.1		0.1		-		-		-		-		-		-		0.0		0.1
Rental Income		-		-		-		(3.3)		(0.0)		-		-		0.0		0.0		-		-		(1.6)		(0.0)
Net Capital Gains (Losses)		-		-		-		-		-		-		-		-		-		-		-		-		-
Section 1231		-		-		-		0.2		0.1		-		-		0.0		-		-		-		0.0		(0.1)
Section 1256		-		-		-		-		0.8		-		-		-		-		-		-		-		0.2
Short-Term		(0.0)		(0.0)		0.0		0.3		5.4		(0.0)		(0.0)		0.8		0.8		(0.0)		(0.0)		0.3		4.0
Long-Term		0.0		5.2		-		9.9		10.6		-		(0.1)		4.9		3.2		-		-		0.1		11.6
Other Portfolio Income		-		-		-		(0.1)		0.1		-		-		0.0		0.0		-		-		(0.1)		0.1
Tax Refunds		-		-		-		-		-		-		-		-		-		-		-		-		-
Federal		-		25.0		-		-		-		0.3		0.4		-		-		0.0		0.0		-		-
State		0.1		0.4		-		0.1		0.7		-		0.1		-		-		-		-		-		-
Subpart F Income		-		-		-		0.0		-		-		-		-		-		-		-		-		-
Other Income (Loss)		(0.7)		(0.7)		(0.0)		0.0		0.1		-		-		0.0		0.0		-		-		0.0		0.0
Federal Tax Exempt Income		-		-		-		-		-		-		-		0.3		-		-		-		-		-
Tax Exempt Income		-		-		-		-		-		-		-		-		-		-		-		-		-
Nontaxable Income		0.0		(4.4)		-		25.4		35.4		0.0		0.1		(2.2)		26.8		-		-		6.9		18.3
<b>Total revenues</b>		20.7		83.9		0.9		215.7		102.4		12.8		(24.9)		58.2		123.1		0.1		0.1		25.9		62.8
<b>Costs and expenses:</b>																										
Interest Expense		0.7		-		-		7.4		3.5		-		7.7		3.9		2.0		-		-		3.5		2.3
Charitable Contributions		-		-		-		0.0		0.0		-		-		0.0		0.0		-		-		-		(0.0)
Intangible Drilling and Development Costs		-		-		-		0.8		0.6		-		-		-		-		-		-		0.2		0.4
Production Expenses		-		-		-		0.0		0.0		-		-		-		-		-		-		0.0		0.0
Taxes - Domestic		-		-		-		-		-		-		-		-		-		-		-		-		-
Federal		-		-		-		27.0		7.8		2.2		0.4		8.8		2.5		0.0		-		-		-
State		0.0		0.0		0.0		1.4		1.4		0.3		0.0		0.0		0.0		-		-		-		-
Local		-		-		-		-		-		-		-		-		-		-		-		-		-
Other Payroll Taxes		-		-		-		-		-		-		-		-		-		-		-		-		-
Other		-		-		-		-		-		-		-		0.0		-		-		-		-		-
Taxes - Foreign		1.3		1.2		0.0		0.0		0.1		-		-		1.6		1.7		-		-		-		0.1
Portfolio Deductions		-		0.5		0.0		21.7		10.3		0.3		0.1		9.6		6.1		-		0.0		0.4		4.9
Depreciation, Depletion & Amortization		-		-		-		-		-		-		-		-		-		-		-		-		-
Salaries & Wages		-		-		-		-		-		-		-		-		-		-		-		-		-
Legal Fees		0.5		0.8		0.0		0.1		0.0		0.1		0.0		0.3		0.2		-		-		0.6		0.2
Travel		0.0		-		-		-		-		-		-		-		-		-		-		-		-
General & Administrative Expenses		0.4		0.3		0.2		0.5		0.5		0.3		0.1		0.5		0.5		-		-		1.9		-
Nondeductible		-		0.1		-		0.1		0.2		1.4		0.0		0.3		0.0		-		-		0.0		(0.1)
Personal Expenses		0.2		-		-		-		-		-		-		-		-		-		-		-		-
<b>Total costs and expenses</b>		3.1		2.9		0.3		58.9		24.5		4.5		8.3		25.1		13.0		0.0		0.0		6.6		7.8
<b>Net income (loss)</b>	\$	17.7	\$	81.0	\$	0.6	\$	156.8	\$	77.9	\$	8.3	\$	(33.1)	\$	33.1	\$	110.1	\$	0.1	\$	0.1	\$	19.4	\$	55.0

The above amounts have not been consolidated.

NAS2654

PROFESSIONALS' EYES ONLY/HIGHLY CONFIDENTIAL—SUBJECT TO PROPOSED PROTECTIVE ORDER AND FRE 408

This presentation may only be viewed by the professionals identified on page 2, and it may not be shared.

# March 31, 2020 Statement of Operations

(\$ in millions)	Quarter ended:	RMLP	74A	RMCI	74-AR	74-AJ	74B	Inv. Trust	1A Trust	2A Trust	1B Trust	2B Trust	74-AR IR	74-AJ IR
		03/31/20	03/31/20	03/31/20	03/31/20	03/31/20	03/31/20	03/31/20	03/31/20	03/31/20	03/31/20	03/31/20	03/31/20	03/31/20
<b>Revenues:</b>														
Ordinary Income (Loss)	\$	-	\$ (5.2)	\$ (0.1)	\$ (1.7)	\$ (0.0)	\$ (0.0)	\$ (23.1)	\$ (31.4)	\$ (25.7)	\$ -	\$ -	\$ (29.1)	\$ (66.1)
Interest Income		0.1	0.1	0.0	-	-	-	-	0.0	0.0	-	-	0.2	0.0
Dividend Income		0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.2	1.1	0.0	0.0	0.3	0.5
Royalty Income		-	-	-	-	-	-	-	-	-	-	-	-	-
Rental Income		-	-	-	-	-	-	-	0.0	0.0	-	-	-	-
Net Capital Gains (Losses)		-	-	-	-	-	-	-	-	-	-	-	-	-
Section 1231		-	-	-	-	-	-	-	-	-	-	-	-	-
Section 1256		-	-	-	-	-	-	-	-	-	-	-	-	-
Short-Term		(0.0)	(0.0)	-	(0.0)	-	(0.0)	-	(0.0)	(1.0)	(0.0)	(0.0)	(1.7)	(0.2)
Long-Term		-	1.5	-	-	-	-	-	(0.0)	(0.1)	-	-	(4.5)	(0.0)
Other Portfolio Income		-	-	-	-	-	-	-	-	0.0	-	-	-	-
Tax Refunds		-	-	-	-	-	-	-	-	-	-	-	-	-
Federal		-	-	-	0.0	-	-	-	-	-	-	-	-	-
State		-	-	-	0.0	-	-	-	-	0.0	-	-	-	-
Subpart F Income		-	-	-	-	-	-	-	-	-	-	-	-	-
Other Income (Loss)		-	-	-	-	0.0	-	-	-	0.0	-	-	-	-
Federal Tax Exempt Income		-	-	-	-	-	-	-	-	-	-	-	-	-
Tax Exempt Income		-	-	-	-	-	-	-	-	-	-	-	-	-
Nontaxable Income		0.0	(1.6)	-	(3.0)	(0.1)	(0.0)	-	(0.1)	(9.6)	-	-	(7.9)	(6.7)
<b>Total revenues</b>		0.1	(5.0)	(0.1)	(4.7)	(0.0)	(0.0)	(23.1)	(31.4)	(35.2)	0.0	0.0	(42.8)	(72.5)
<b>Costs and expenses:</b>														
Interest Expense		-	-	-	-	-	-	-	0.2	-	-	-	1.0	-
Charitable Contributions		-	-	-	-	-	-	-	-	-	-	-	-	-
Intangible Drilling and Development Costs		-	-	-	-	-	-	-	-	-	-	-	-	-
Production Expenses		-	-	-	-	-	-	-	-	-	-	-	-	-
Taxes - Domestic		-	-	-	-	-	-	-	-	-	-	-	-	-
Federal		-	-	-	25.0	10.0	0.2	-	-	0.9	-	-	-	-
State		0.0	0.0	-	0.0	0.0	0.0	-	-	0.0	-	-	-	0.0
Local		-	-	-	-	-	-	-	-	-	-	-	-	-
Other Payroll Taxes		-	-	-	-	-	-	-	-	-	-	-	-	-
Other		0.0	0.0	-	-	-	-	-	-	-	-	-	-	-
Taxes - Foreign		0.0	0.0	-	-	-	-	-	-	0.0	-	-	-	0.0
Portfolio Deductions		-	-	-	0.1	0.1	0.0	0.0	4.8	2.1	0.0	0.0	14.9	5.1
Depreciation, Depletion & Amortization		-	-	-	-	-	-	-	-	-	-	-	-	-
Salaries & Wages		-	-	-	-	-	-	-	-	-	-	-	-	-
Legal Fees		5.0	0.1	-	-	-	0.0	-	0.0	0.0	-	-	0.2	0.0
Travel		-	-	-	-	-	-	-	-	-	-	-	-	-
General & Administrative Expenses		0.2	-	-	-	-	-	-	0.0	0.0	-	-	0.1	-
Nondeductible		7.5	7.4	0.2	-	-	0.1	-	0.1	-	-	-	0.0	-
Personal Expenses		-	-	-	-	-	-	-	-	-	-	-	-	-
<b>Total costs and expenses</b>		12.8	7.5	0.2	25.1	10.1	0.4	0.0	5.2	3.1	0.0	0.0	16.2	5.1
<b>Net income (loss)</b>	\$	(12.7)	\$ (12.5)	\$ (0.3)	\$ (29.7)	\$ (10.1)	\$ (0.4)	\$ (23.1)	\$ (36.5)	\$ (38.3)	\$ (0.0)	\$ (0.0)	\$ (59.0)	\$ (77.6)

The above amounts have not been consolidated.

NAS2655

PROFESSIONALS' EYES ONLY/HIGHLY CONFIDENTIAL—SUBJECT TO PROPOSED PROTECTIVE ORDER AND FRE 408

This presentation may only be viewed by the professionals identified on page 2, and it may not be shared.

# Appendix D: 2008 – 2020 Balance Sheets

# 2008 Balance Sheets

19-236248-21 Doc 07422-0 Filed 08/05/21 Entered 08/05/21 15:21:24 Page 104 of 142  
Pg 335 of 725

(\$ in millions)	As of:	RMLP 12/31/08	74A 12/31/08	RMCI 12/31/08	74-AR 12/31/08	74-AJ 12/31/08	74B 12/31/08	Inv. Trust 12/31/08	1A Trust 12/31/08	2A Trust 12/31/08	1B Trust 12/31/08	2B Trust 12/31/08	74-AR IR 12/31/08	74-AJ IR 12/31/08
<b>Assets:</b>														
<b>Current Assets:</b>														
Cash and Cash Equivalents	\$	3.6	\$ 227.2	\$ 7.0	\$ -	\$ -	\$ 4.1	\$ 9.5	\$ 14.1	\$ 15.7	\$ 0.0	\$ 0.0	\$ -	\$ -
Accounts Receivable		1.0	0.6	0.1	-	-	0.2	4.6	0.5	0.8	-	-	-	-
Prepaid Expenses		-	-	-	-	-	-	-	-	-	-	-	-	-
Prepaid Investments		-	-	-	-	-	-	-	-	-	-	-	-	-
Notes Receivable Due Within One Year		-	-	-	-	-	-	-	-	-	-	-	-	-
Total current assets		4.5	227.8	7.1	-	-	4.3	14.1	14.7	16.5	0.0	0.0	-	-
<b>Noncurrent Assets:</b>														
Notes Receivable Due After One Year		-	100.0	-	-	-	12.9	7.8	-	-	-	-	-	-
Investments		428.1	459.1	8.7	-	-	67.8	63.0	61.1	54.7	0.1	0.1	-	-
Other Investments		2.3	1.1	-	-	-	0.0	-	3.0	-	-	-	-	-
Depreciable/Amorizable Property, Net		-	-	-	-	-	-	-	-	-	-	-	-	-
Total Noncurrent Assets		430.4	560.2	8.7	-	-	80.8	70.8	64.1	54.7	0.1	0.1	-	-
<b>Total Assets</b>	<b>\$</b>	<b>434.9</b>	<b>\$ 788.0</b>	<b>\$ 15.8</b>	<b>\$ -</b>	<b>\$ -</b>	<b>\$ 85.1</b>	<b>\$ 84.9</b>	<b>\$ 78.8</b>	<b>\$ 71.2</b>	<b>\$ 0.2</b>	<b>\$ 0.2</b>	<b>\$ -</b>	<b>\$ -</b>
<b>Liabilities and Equity/Capital:</b>														
<b>Current Liabilities:</b>														
Accounts Payable	\$	0.6	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 0.0	\$ 0.0	\$ -	\$ -	\$ -	\$ -
Short Term Debt Due Within One Year		-	-	-	-	-	-	-	0.5	0.5	-	-	-	-
Total Current Liabilities		0.6	-	-	-	-	-	-	0.5	0.5	-	-	-	-
<b>Noncurrent Liabilities:</b>														
Long Term Debt Due After One Year / Deferred Liabilities - Long Term		-	-	-	-	-	6.5	-	50.7	50.7	-	-	-	-
Total Noncurrent Liabilities		-	-	-	-	-	6.5	-	50.7	50.7	-	-	-	-
<b>Total liabilities</b>		0.6	-	-	-	-	6.5	-	51.2	51.2	-	-	-	-
<b>Equity/Capital</b>														
Beginning Equity/Capital/Retained Earnings		379.7	391.9	7.6	-	-	95.5	99.2	68.8	70.9	0.2	0.2	-	-
Common Stock, @ Par Value		-	-	0.0	-	-	-	-	-	-	-	-	-	-
Paid in Capital		-	-	0.1	-	-	-	-	-	-	-	-	-	-
Contributions		-	-	-	-	-	-	-	-	-	-	-	-	-
Withdrawals		(645.8)	-	-	-	-	-	-	-	-	-	-	-	-
Current Year Earnings		700.3	396.0	8.1	-	-	(16.9)	(14.3)	(41.3)	(50.9)	-	-	-	-
<b>Total Equity/Capital</b>		434.3	788.0	15.8	-	-	78.6	84.9	27.6	20.0	0.2	0.2	-	-
<b>Total Liabilities and Equity/Capital</b>	<b>\$</b>	<b>434.9</b>	<b>\$ 788.0</b>	<b>\$ 15.8</b>	<b>\$ -</b>	<b>\$ -</b>	<b>\$ 85.1</b>	<b>\$ 84.9</b>	<b>\$ 78.8</b>	<b>\$ 71.2</b>	<b>\$ 0.2</b>	<b>\$ 0.2</b>	<b>\$ -</b>	<b>\$ -</b>

The above amounts have not been consolidated.

NAS2657

PROFESSIONALS' EYES ONLY/HIGHLY CONFIDENTIAL—SUBJECT TO PROPOSED PROTECTIVE ORDER AND FRE 408

This presentation may only be viewed by the professionals identified on page 2, and it may not be shared.



# 2009 Balance Sheets

19-236248-21 Doc 07422- Filed 08/05/21 Entered 08/05/21 15:55:11 Page 10 of 142  
Pg 336 of 725

(\$ in millions)	As of:	RMLP 12/31/09	74A 12/31/09	RMCI 12/31/09	74-AR 12/31/09	74-AJ 12/31/09	74B 12/31/09	Inv. Trust 12/31/09	1A Trust 12/31/09	2A Trust 12/31/09	1B Trust 12/31/09	2B Trust 12/31/09	74-AR IR 12/31/09	74-AJ IR 12/31/09
<b>Assets:</b>														
<b>Current Assets:</b>														
Cash and Cash Equivalents	\$	1.2	\$ 724.9	\$ 6.0	\$ -	\$ -	\$ 11.3	\$ 8.7	\$ 3.6	\$ 5.6	\$ 0.0	\$ 0.0	\$ -	\$ -
Accounts Receivable		0.1	0.0	0.1	-	-	0.0	0.1	0.3	0.3	-	-	-	-
Prepaid Expenses		-	-	0.1	-	-	0.0	-	-	-	-	-	-	-
Prepaid Investments		-	1.3	-	-	-	-	-	-	-	-	-	-	-
Notes Receivable Due Within One Year		-	-	-	-	-	-	-	-	-	-	-	-	-
Total current assets		1.3	726.2	6.2	-	-	11.3	8.8	3.9	5.9	0.0	0.0	-	-
<b>Noncurrent Assets:</b>														
Notes Receivable Due After One Year		-	170.0	-	-	-	6.4	15.8	-	-	-	-	-	-
Investments		446.5	476.8	9.0	-	-	75.9	62.1	143.1	146.9	0.1	0.1	-	-
Other Investments		2.3	1.1	-	-	-	0.0	-	-	-	-	-	-	-
Depreciable/Amorizable Property, Net		-	-	-	-	-	-	-	-	-	-	-	-	-
Total Noncurrent Assets		448.8	647.9	9.0	-	-	82.4	77.9	143.1	146.9	0.1	0.1	-	-
<b>Total Assets</b>	<b>\$</b>	<b>450.0</b>	<b>\$ 1,374.2</b>	<b>\$ 15.1</b>	<b>\$ -</b>	<b>\$ -</b>	<b>\$ 93.6</b>	<b>\$ 86.7</b>	<b>\$ 147.0</b>	<b>\$ 152.8</b>	<b>\$ 0.2</b>	<b>\$ 0.2</b>	<b>\$ -</b>	<b>\$ -</b>
<b>Liabilities and Equity/Capital:</b>														
<b>Current Liabilities:</b>														
Accounts Payable	\$	0.3	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 8.7	\$ -	\$ -	\$ -	\$ -	\$ -
Short Term Debt Due Within One Year		-	-	-	-	-	-	-	-	-	-	-	-	-
Total Current Liabilities		0.3	-	-	-	-	-	-	8.7	-	-	-	-	-
<b>Noncurrent Liabilities:</b>														
Long Term Debt Due After One Year / Deferred Liabilities - Long Term		-	-	-	-	-	-	-	86.2	86.2	-	-	-	-
Total Noncurrent Liabilities		-	-	-	-	-	-	-	86.2	86.2	-	-	-	-
<b>Total liabilities</b>		0.3	-	-	-	-	-	-	94.9	86.2	-	-	-	-
<b>Equity/Capital</b>														
Beginning Equity/Capital/Retained Earnings		434.3	788.0	5.7	-	-	78.6	84.9	27.6	20.0	0.2	0.2	-	-
Common Stock, @ Par Value		-	-	0.0	-	-	-	-	-	-	-	-	-	-
Paid in Capital		-	-	0.1	-	-	-	-	-	-	-	-	-	-
Contributions		-	-	-	-	-	-	-	-	-	-	-	-	-
Withdrawals		(787.0)	-	-	-	-	-	-	(21.3)	-	-	-	-	-
Current Year Earnings		802.4	586.2	9.4	-	-	15.1	1.8	45.8	46.6	-	-	-	-
<b>Total Equity/Capital</b>		449.8	1,374.2	15.1	-	-	93.6	86.7	52.1	66.6	0.2	0.2	-	-
<b>Total Liabilities and Equity/Capital</b>	<b>\$</b>	<b>450.0</b>	<b>\$ 1,374.2</b>	<b>\$ 15.1</b>	<b>\$ -</b>	<b>\$ -</b>	<b>\$ 93.6</b>	<b>\$ 86.7</b>	<b>\$ 147.0</b>	<b>\$ 152.8</b>	<b>\$ 0.2</b>	<b>\$ 0.2</b>	<b>\$ -</b>	<b>\$ -</b>

The above amounts have not been consolidated.

NAS2658

PROFESSIONALS' EYES ONLY/HIGHLY CONFIDENTIAL—SUBJECT TO PROPOSED PROTECTIVE ORDER AND FRE 408

This presentation may only be viewed by the professionals identified on page 2, and it may not be shared.

# 2010 Balance Sheets

19-23648-001 Doc 07422-0 Filed 08/05/21 Entered 08/05/21 15:55:11 Page 10 of 142  
Pg 337 of 725

(\$ in millions)	As of:	RMLP 12/31/10	74A 12/31/10	RMCI 12/31/10	74-AR 12/31/10	74-AJ 12/31/10	74B 12/31/10	Inv. Trust 12/31/10	1A Trust 12/31/10	2A Trust 12/31/10	1B Trust 12/31/10	2B Trust 12/31/10	74-AR IR 12/31/10	74-AJ IR 12/31/10
<b>Assets:</b>														
<b>Current Assets:</b>														
Cash and Cash Equivalents	\$	5.9	\$ 693.9	\$ 15.1	\$ -	\$ -	\$ 8.7	\$ 7.7	\$ 1.5	\$ 2.3	\$ 0.0	\$ 0.0	\$ -	\$ -
Accounts Receivable		0.1	0.4	0.0	-	-	0.3	0.1	0.3	0.4	-	-	-	-
Prepaid Expenses		-	-	-	-	-	-	-	71.4	25.1	-	-	-	-
Prepaid Investments		-	-	-	-	-	-	-	-	-	-	-	-	-
Notes Receivable Due Within One Year		-	-	-	-	-	-	-	-	-	-	-	-	-
Total current assets		6.0	694.3	15.1	-	-	9.0	7.9	73.2	27.8	0.0	0.0	-	-
<b>Noncurrent Assets:</b>														
Notes Receivable Due After One Year		-	444.3	-	-	-	6.4	26.8	-	-	-	-	-	-
Investments		441.4	567.6	9.0	-	-	83.7	54.8	294.5	216.5	0.1	0.1	-	-
Other Investments		2.3	1.6	-	-	-	0.0	-	-	6.0	-	-	-	-
Depreciable/Amorizable Property, Net		-	-	-	-	-	-	-	-	-	-	-	-	-
Total Noncurrent Assets		443.7	1,013.5	9.0	-	-	90.1	81.6	294.5	222.5	0.1	0.1	-	-
<b>Total Assets</b>	<b>\$</b>	<b>449.7</b>	<b>\$ 1,707.8</b>	<b>\$ 24.1</b>	<b>\$ -</b>	<b>\$ -</b>	<b>\$ 99.1</b>	<b>\$ 89.5</b>	<b>\$ 367.7</b>	<b>\$ 250.3</b>	<b>\$ 0.2</b>	<b>\$ 0.2</b>	<b>\$ -</b>	<b>\$ -</b>
<b>Liabilities and Equity/Capital:</b>														
<b>Current Liabilities:</b>														
Accounts Payable	\$	0.4	\$ -	\$ -	\$ -	\$ -	\$ 0.0	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Short Term Debt Due Within One Year		-	-	-	-	-	-	-	-	-	-	-	-	-
Total Current Liabilities		0.4	-	-	-	-	0.0	-	-	-	-	-	-	-
<b>Noncurrent Liabilities:</b>														
Long Term Debt Due After One Year / Deferred Liabilities - Long Term		-	-	-	-	-	-	10.0	281.8	154.8	-	-	-	-
Total Noncurrent Liabilities		-	-	-	-	-	-	10.0	281.8	154.8	-	-	-	-
<b>Total liabilities</b>		0.4	-	-	-	-	0.0	10.0	281.8	154.8	-	-	-	-
<b>Equity/Capital</b>														
Beginning Equity/Capital/Retained Earnings		449.8	1,374.2	15.1	-	-	93.6	86.7	52.1	66.6	0.2	0.2	-	-
Common Stock, @ Par Value		-	-	0.0	-	-	-	-	-	-	-	-	-	-
Paid in Capital		-	-	0.1	-	-	-	-	-	-	-	-	-	-
Contributions		1.0	-	-	-	-	-	-	-	-	-	-	-	-
Withdrawals		(763.7)	-	-	-	-	-	-	-	-	-	-	-	-
Current Year Earnings		762.3	333.6	8.9	-	-	5.5	(7.2)	33.8	28.9	-	-	-	-
<b>Total Equity/Capital</b>		449.3	1,707.8	24.1	-	-	99.1	79.5	85.9	95.5	0.2	0.2	-	-
<b>Total Liabilities and Equity/Capital</b>	<b>\$</b>	<b>449.7</b>	<b>\$ 1,707.8</b>	<b>\$ 24.1</b>	<b>\$ -</b>	<b>\$ -</b>	<b>\$ 99.1</b>	<b>\$ 89.5</b>	<b>\$ 367.7</b>	<b>\$ 250.3</b>	<b>\$ 0.2</b>	<b>\$ 0.2</b>	<b>\$ -</b>	<b>\$ -</b>

The above amounts have not been consolidated.

NAS2659

PROFESSIONALS' EYES ONLY/HIGHLY CONFIDENTIAL—SUBJECT TO PROPOSED PROTECTIVE ORDER AND FRE 408

This presentation may only be viewed by the professionals identified on page 2, and it may not be shared.

# 2011 Balance Sheets

19-236248-0000 Doc 07422-0 Filed 08/05/21 Entered 08/05/21 15:25:24 Page 10 of 142  
Pg 338 of 725

(\$ in millions)	As of:	RMLP 12/31/11	74A 12/31/11	RMCI 12/31/11	74-AR 12/31/11	74-AJ 12/31/11	74B 12/31/11	Inv. Trust 12/31/11	1A Trust 12/31/11	2A Trust 12/31/11	1B Trust 12/31/11	2B Trust 12/31/11	74-AR IR 12/31/11	74-AJ IR 12/31/11
<b>Assets:</b>														
<b>Current Assets:</b>														
Cash and Cash Equivalents	\$	13.3	\$ 276.3	\$ 22.4	\$ -	\$ -	\$ 33.3	\$ 2.4	\$ 0.3	\$ 3.8	\$ 0.0	\$ 0.0	\$ -	\$ -
Accounts Receivable		9.1	0.9	0.0	-	-	-	0.1	13.4	0.2	-	-	-	-
Prepaid Expenses		-	-	-	-	-	-	-	10.0	5.0	-	-	-	-
Prepaid Investments		-	-	-	-	-	-	-	-	-	-	-	-	-
Notes Receivable Due Within One Year		-	-	-	-	-	-	-	-	-	-	-	-	-
Total current assets		22.4	277.3	22.4	-	-	33.3	2.5	23.7	9.0	0.0	0.0	-	-
<b>Noncurrent Assets:</b>														
Notes Receivable Due After One Year		-	1,125.8	-	-	-	6.4	36.8	3.0	-	-	-	-	-
Investments		433.8	670.8	9.1	-	-	54.9	54.8	583.6	518.8	0.1	0.1	-	-
Other Investments		2.3	9.1	-	-	-	0.0	-	-	66.8	-	-	-	-
Depreciable/Amorizable Property, Net		-	-	-	-	-	-	-	-	-	-	-	-	-
Total Noncurrent Assets		436.1	1,805.7	9.1	-	-	61.4	91.6	586.6	585.5	0.1	0.1	-	-
<b>Total Assets</b>	<b>\$</b>	<b>458.5</b>	<b>\$ 2,082.9</b>	<b>\$ 31.6</b>	<b>\$ -</b>	<b>\$ -</b>	<b>\$ 94.7</b>	<b>\$ 94.1</b>	<b>\$ 610.3</b>	<b>\$ 594.5</b>	<b>\$ 0.2</b>	<b>\$ 0.2</b>	<b>\$ -</b>	<b>\$ -</b>
<b>Liabilities and Equity/Capital:</b>														
<b>Current Liabilities:</b>														
Accounts Payable	\$	0.4	\$ 0.0	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Short Term Debt Due Within One Year		-	-	-	-	-	-	-	-	-	-	-	-	-
Total Current Liabilities		0.4	0.0	-	-	-	-	-	-	-	-	-	-	-
<b>Noncurrent Liabilities:</b>														
Long Term Debt Due After One Year / Deferred Liabilities - Long Term		-	-	-	-	-	-	68.0	551.2	508.9	-	-	-	-
Total Noncurrent Liabilities		-	-	-	-	-	-	68.0	551.2	508.9	-	-	-	-
<b>Total liabilities</b>		0.4	0.0	-	-	-	-	68.0	551.2	508.9	-	-	-	-
<b>Equity/Capital</b>														
Beginning Equity/Capital/Retained Earnings		449.3	1,707.8	24.0	-	-	99.1	79.5	85.9	95.5	0.2	0.2	-	-
Common Stock, @ Par Value		-	-	0.0	-	-	-	-	-	-	-	-	-	-
Paid in Capital		-	-	0.1	-	-	-	-	-	-	-	-	-	-
Contributions		1.4	-	-	-	-	-	-	-	-	-	-	-	-
Withdrawals		(554.1)	-	-	-	-	-	-	-	-	-	-	-	-
Current Year Earnings		561.4	375.1	7.5	-	-	(4.4)	(53.4)	(26.8)	(9.9)	-	-	-	-
<b>Total Equity/Capital</b>		458.0	2,082.9	31.6	-	-	94.7	26.1	59.1	85.6	0.2	0.2	-	-
<b>Total Liabilities and Equity/Capital</b>	<b>\$</b>	<b>458.5</b>	<b>\$ 2,082.9</b>	<b>\$ 31.6</b>	<b>\$ -</b>	<b>\$ -</b>	<b>\$ 94.7</b>	<b>\$ 94.1</b>	<b>\$ 610.3</b>	<b>\$ 594.5</b>	<b>\$ 0.2</b>	<b>\$ 0.2</b>	<b>\$ -</b>	<b>\$ -</b>

The above amounts have not been consolidated.

NAS2660

PROFESSIONALS' EYES ONLY/HIGHLY CONFIDENTIAL—SUBJECT TO PROPOSED PROTECTIVE ORDER AND FRE 408

This presentation may only be viewed by the professionals identified on page 2, and it may not be shared.

# 2012 Balance Sheets

19-236248-001 Doc 07422-0 Filed 08/05/21 Entered 08/05/21 15:55:11 Page 10 of 142  
Pg 339 of 725

(\$ in millions)	As of:	RMLP 12/31/12	74A 12/31/12	RMCI 12/31/12	74-AR 12/31/12	74-AJ 12/31/12	74B 12/31/12	Inv. Trust 12/31/12	1A Trust 12/31/12	2A Trust 12/31/12	1B Trust 12/31/12	2B Trust 12/31/12	74-AR IR 12/31/12	74-AJ IR 12/31/12
<b>Assets:</b>														
<b>Current Assets:</b>														
Cash and Cash Equivalents	\$	30.7	\$ 109.7	\$ 2.0	\$ -	\$ -	\$ 31.1	\$ 3.7	\$ 19.0	\$ 23.8	\$ 3.0	\$ 3.0	\$ -	\$ -
Accounts Receivable		0.2	6.7	0.0	-	-	0.0	-	4.7	34.6	-	-	-	-
Prepaid Expenses		-	-	-	-	-	-	-	-	-	-	-	-	-
Prepaid Investments		-	10.0	-	-	-	-	-	-	-	-	-	-	-
Notes Receivable Due Within One Year		-	-	-	-	-	-	-	-	-	-	-	-	-
Total current assets		30.9	126.5	2.1	-	-	31.1	3.7	23.7	58.4	3.0	3.0	-	-
<b>Noncurrent Assets:</b>														
Notes Receivable Due After One Year		-	1,535.4	-	-	-	6.4	26.9	3.0	-	-	-	-	-
Investments		583.9	919.0	12.3	-	-	61.7	172.9	685.3	692.2	0.1	0.1	-	-
Other Investments		2.3	7.5	-	-	-	0.1	-	6.1	54.3	-	-	-	-
Depreciable/Amorizable Property, Net		-	-	-	-	-	-	-	-	-	-	-	-	-
Total Noncurrent Assets		586.2	2,462.0	12.3	-	-	68.2	199.8	694.3	746.5	0.1	0.1	-	-
<b>Total Assets</b>	<b>\$</b>	<b>617.1</b>	<b>\$ 2,588.5</b>	<b>\$ 14.4</b>	<b>\$ -</b>	<b>\$ -</b>	<b>\$ 99.2</b>	<b>\$ 203.5</b>	<b>\$ 718.1</b>	<b>\$ 804.9</b>	<b>\$ 3.2</b>	<b>\$ 3.2</b>	<b>\$ -</b>	<b>\$ -</b>
<b>Liabilities and Equity/Capital:</b>														
<b>Current Liabilities:</b>														
Accounts Payable	\$	0.3	\$ 0.0	\$ -	\$ -	\$ -	\$ -	\$ 0.2	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Short Term Debt Due Within One Year		-	-	-	-	-	-	-	-	-	-	-	-	-
Total Current Liabilities		0.3	0.0	-	-	-	-	0.2	-	-	-	-	-	-
<b>Noncurrent Liabilities:</b>														
Long Term Debt Due After One Year / Deferred Liabilities - Long Term		-	-	-	-	-	-	314.0	591.2	632.6	-	-	-	-
Total Noncurrent Liabilities		-	-	-	-	-	-	314.0	591.2	632.6	-	-	-	-
<b>Total liabilities</b>		0.3	0.0	-	-	-	-	314.2	591.2	632.6	-	-	-	-
<b>Equity/Capital</b>														
Beginning Equity/Capital/Retained Earnings		458.0	2,082.9	6.5	-	-	94.7	26.1	59.2	85.6	0.2	0.2	-	-
Common Stock, @ Par Value		-	-	0.0	-	-	-	-	-	-	-	-	-	-
Paid in Capital		-	-	0.1	-	-	-	-	-	-	-	-	-	-
Contributions		-	-	-	-	-	-	-	-	-	-	-	-	-
Withdrawals		(441.8)	-	-	-	-	-	-	-	-	-	-	-	-
Current Year Earnings		600.6	505.5	7.8	-	-	4.6	(136.8)	67.7	86.8	3.0	3.0	-	-
<b>Total Equity/Capital</b>		616.9	2,588.5	14.4	-	-	99.2	(110.7)	126.9	172.4	3.2	3.2	-	-
<b>Total Liabilities and Equity/Capital</b>	<b>\$</b>	<b>617.1</b>	<b>\$ 2,588.5</b>	<b>\$ 14.4</b>	<b>\$ -</b>	<b>\$ -</b>	<b>\$ 99.2</b>	<b>\$ 203.5</b>	<b>\$ 718.1</b>	<b>\$ 804.9</b>	<b>\$ 3.2</b>	<b>\$ 3.2</b>	<b>\$ -</b>	<b>\$ -</b>

The above amounts have not been consolidated.

NAS2661

PROFESSIONALS' EYES ONLY/HIGHLY CONFIDENTIAL—SUBJECT TO PROPOSED PROTECTIVE ORDER AND FRE 408

This presentation may only be viewed by the professionals identified on page 2, and it may not be shared.

# 2013 Balance Sheets

19-23648-001 Doc 07422-0 Filed 08/05/21 Entered 08/05/21 15:28:38 Page 109 of 142  
Pg 340 of 725

(\$ in millions)	As of:	RMLP 12/31/13	74A 12/31/13	RMCI 12/31/13	74-AR 12/31/13	74-AJ 12/31/13	74B 12/31/13	Inv. Trust 12/31/13	1A Trust 12/31/13	2A Trust 12/31/13	1B Trust 12/31/13	2B Trust 12/31/13	74-AR IR 12/31/13	74-AJ IR 12/31/13
<b>Assets:</b>														
<b>Current Assets:</b>														
Cash and Cash Equivalents	\$	2.0	\$ 404.8	\$ 10.2	\$ -	\$ -	\$ 17.8	\$ 5.7	\$ 31.5	\$ 36.8	\$ 2.6	\$ 2.6	\$ -	\$ -
Accounts Receivable		0.3	0.4	0.0	-	-	0.1	0.0	6.5	0.2	-	-	-	-
Prepaid Expenses		-	-	-	-	-	-	-	-	25.0	-	-	-	-
Prepaid Investments		-	9.8	-	-	-	-	-	-	-	-	-	-	-
Notes Receivable Due Within One Year		-	-	-	-	-	-	-	-	-	-	-	-	-
Total current assets		2.4	415.0	10.3	-	-	18.0	5.7	38.1	61.9	2.6	2.6	-	-
<b>Noncurrent Assets:</b>														
Notes Receivable Due After One Year		-	1,245.4	-	-	-	6.4	26.9	-	-	-	-	-	-
Investments		365.3	1,122.9	7.3	-	-	95.1	110.5	541.8	511.5	0.1	0.1	-	-
Other Investments		0.3	20.7	-	-	-	0.1	-	42.7	78.5	-	-	-	-
Depreciable/Amorizable Property, Net		-	-	-	-	-	-	-	-	-	-	-	-	-
Total Noncurrent Assets		365.6	2,389.0	7.3	-	-	101.6	137.4	584.5	590.0	0.1	0.1	-	-
<b>Total Assets</b>	<b>\$</b>	<b>368.0</b>	<b>\$ 2,804.1</b>	<b>\$ 17.6</b>	<b>\$ -</b>	<b>\$ -</b>	<b>\$ 119.5</b>	<b>\$ 143.1</b>	<b>\$ 622.5</b>	<b>\$ 651.9</b>	<b>\$ 2.7</b>	<b>\$ 2.7</b>	<b>\$ -</b>	<b>\$ -</b>
<b>Liabilities and Equity/Capital:</b>														
<b>Current Liabilities:</b>														
Accounts Payable	\$	0.7	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 0.2	\$ 0.4	\$ -	\$ -	\$ -	\$ -
Short Term Debt Due Within One Year		-	-	-	-	-	-	-	-	-	-	-	-	-
Total Current Liabilities		0.7	-	-	-	-	-	-	0.2	0.4	-	-	-	-
<b>Noncurrent Liabilities:</b>														
Long Term Debt Due After One Year / Deferred Liabilities - Long Term		-	-	-	-	-	-	374.0	466.2	407.6	-	-	-	-
Total Noncurrent Liabilities		-	-	-	-	-	-	374.0	466.2	407.6	-	-	-	-
<b>Total liabilities</b>		<b>0.7</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>374.0</b>	<b>466.4</b>	<b>407.9</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>Equity/Capital</b>														
Beginning Equity/Capital/Retained Earnings		616.9	2,588.5	14.3	-	-	99.2	(110.7)	126.9	172.4	3.2	3.2	-	-
Common Stock, @ Par Value		-	-	0.0	-	-	-	-	-	-	-	-	-	-
Paid in Capital		-	-	0.1	-	-	-	-	-	-	-	-	-	-
Contributions		-	-	-	-	-	-	-	-	-	-	-	-	-
Withdrawals		(605.4)	-	-	-	-	-	-	(7.3)	(4.2)	-	-	-	-
Current Year Earnings		355.8	215.6	3.2	-	-	20.3	(120.2)	36.5	75.8	(0.4)	(0.4)	-	-
<b>Total Equity/Capital</b>		<b>367.3</b>	<b>2,804.1</b>	<b>17.6</b>	<b>-</b>	<b>-</b>	<b>119.5</b>	<b>(230.9)</b>	<b>156.2</b>	<b>244.0</b>	<b>2.7</b>	<b>2.7</b>	<b>-</b>	<b>-</b>
<b>Total Liabilities and Equity/Capital</b>	<b>\$</b>	<b>368.0</b>	<b>\$ 2,804.1</b>	<b>\$ 17.6</b>	<b>\$ -</b>	<b>\$ -</b>	<b>\$ 119.5</b>	<b>\$ 143.1</b>	<b>\$ 622.5</b>	<b>\$ 651.9</b>	<b>\$ 2.7</b>	<b>\$ 2.7</b>	<b>\$ -</b>	<b>\$ -</b>

The above amounts have not been consolidated.

NAS2662

PROFESSIONALS' EYES ONLY/HIGHLY CONFIDENTIAL—SUBJECT TO PROPOSED PROTECTIVE ORDER AND FRE 408

This presentation may only be viewed by the professionals identified on page 2, and it may not be shared.

# 2014 Balance Sheets

19-23628-0001 Doc 07-22 Filed 08/05/21 Entered 08/05/21 15:21:28 Page 10 of 142  
Pg 341 of 725

(\$ in millions)	As of:	RMLP 12/31/14	74A 12/31/14	RMCI 12/31/14	74-AR 12/31/14	74-AJ 12/31/14	74B 12/31/14	Inv. Trust 12/31/14	1A Trust 12/31/14	2A Trust 12/31/14	1B Trust 12/31/14	2B Trust 12/31/14	74-AR IR 12/31/14	74-AJ IR 12/31/14
<b>Assets:</b>														
<b>Current Assets:</b>														
Cash and Cash Equivalents	\$	2.7	\$ 526.5	\$ 12.7	\$ -	\$ -	\$ 32.6	\$ 4.3	\$ 14.8	\$ 18.8	\$ 2.6	\$ 2.6	\$ -	\$ -
Accounts Receivable		0.5	10.5	0.0	-	-	-	0.0	0.2	13.9	-	-	-	-
Prepaid Expenses		-	-	-	-	-	-	-	-	-	-	-	-	-
Prepaid Investments		-	-	-	-	-	-	-	-	-	-	-	-	-
Notes Receivable Due Within One Year		-	-	-	-	-	-	-	-	-	-	-	-	-
Total current assets		3.2	537.0	12.7	-	-	32.6	4.3	14.9	32.7	2.6	2.6	-	-
<b>Noncurrent Assets:</b>														
Notes Receivable Due After One Year		7.8	1,255.3	-	-	-	6.4	36.8	0.1	0.1	-	-	-	-
Investments		407.1	1,253.0	8.3	-	-	83.7	(31.7)	560.0	544.9	0.1	0.1	-	-
Other Investments		0.3	27.7	-	-	-	0.1	-	45.7	56.4	-	-	-	-
Depreciable/Amorizable Property, Net		-	-	-	-	-	-	-	-	-	-	-	-	-
Total Noncurrent Assets		415.2	2,536.1	8.3	-	-	90.2	5.1	605.8	601.4	0.1	0.1	-	-
<b>Total Assets</b>	<b>\$</b>	<b>418.4</b>	<b>\$ 3,073.2</b>	<b>\$ 21.0</b>	<b>\$ -</b>	<b>\$ -</b>	<b>\$ 122.9</b>	<b>\$ 9.4</b>	<b>\$ 620.7</b>	<b>\$ 634.1</b>	<b>\$ 2.7</b>	<b>\$ 2.7</b>	<b>\$ -</b>	<b>\$ -</b>
<b>Liabilities and Equity/Capital:</b>														
<b>Current Liabilities:</b>														
Accounts Payable	\$	0.7	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 0.0	\$ -	\$ 0.3	\$ -	\$ -	\$ -	\$ -
Short Term Debt Due Within One Year		-	-	-	-	-	-	-	-	-	-	-	-	-
Total Current Liabilities		0.7	-	-	-	-	-	0.0	-	0.3	-	-	-	-
<b>Noncurrent Liabilities:</b>														
Long Term Debt Due After One Year / Deferred Liabilities - Long Term		-	-	-	-	-	-	383.9	466.2	407.6	-	-	-	-
Total Noncurrent Liabilities		-	-	-	-	-	-	383.9	466.2	407.6	-	-	-	-
<b>Total liabilities</b>		0.7	-	-	-	-	-	383.9	466.2	407.8	-	-	-	-
<b>Equity/Capital</b>														
Beginning Equity/Capital/Retained Earnings		367.3	2,804.1	17.5	-	-	119.5	(230.9)	156.2	244.0	2.7	2.7	-	-
Common Stock, @ Par Value		-	-	0.0	-	-	-	-	-	-	-	-	-	-
Paid in Capital		-	-	0.1	-	-	-	-	-	-	-	-	-	-
Contributions		-	-	-	-	-	-	-	-	-	-	-	-	-
Withdrawals		(314.9)	-	-	-	-	-	-	-	-	-	-	-	-
Current Year Earnings		365.2	269.1	3.4	-	-	3.3	(143.6)	(1.7)	(17.7)	-	-	-	-
<b>Total Equity/Capital</b>		417.6	3,073.2	21.0	-	-	122.9	(374.5)	154.5	226.3	2.7	2.7	-	-
<b>Total Liabilities and Equity/Capital</b>	<b>\$</b>	<b>418.4</b>	<b>\$ 3,073.2</b>	<b>\$ 21.0</b>	<b>\$ -</b>	<b>\$ -</b>	<b>\$ 122.9</b>	<b>\$ 9.4</b>	<b>\$ 620.7</b>	<b>\$ 634.1</b>	<b>\$ 2.7</b>	<b>\$ 2.7</b>	<b>\$ -</b>	<b>\$ -</b>

The above amounts have not been consolidated.

NAS2663

PROFESSIONALS' EYES ONLY/HIGHLY CONFIDENTIAL—SUBJECT TO PROPOSED PROTECTIVE ORDER AND FRE 408

This presentation may only be viewed by the professionals identified on page 2, and it may not be shared.

# 2015 Balance Sheets

19-236248-001 Doc 07422-0 Filed 08/05/21 Entered 08/05/21 21:28 Page 10 of 142  
Pg 342 of 725

(\$ in millions)	As of:	RMLP 12/31/15	74A 12/31/15	RMCI 12/31/15	74-AR 12/31/15	74-AJ 12/31/15	74B 12/31/15	Inv. Trust 12/31/15	1A Trust 12/31/15	2A Trust 12/31/15	1B Trust 12/31/15	2B Trust 12/31/15	74-AR IR 12/31/15	74-AJ IR 12/31/15
<b>Assets:</b>														
<b>Current Assets:</b>														
Cash and Cash Equivalents	\$	3.2	\$ 130.3	\$ 14.4	\$ 109.4	\$ 71.0	\$ 2.7	\$ 5.9	\$ 23.0	\$ 19.9	\$ 2.6	\$ 2.6	\$ -	\$ -
Accounts Receivable		54.0	0.1	-	2.5	0.0	-	-	0.2	0.8	-	-	-	-
Prepaid Expenses		-	-	-	5.0	-	-	-	-	-	-	-	-	-
Prepaid Investments		-	-	-	-	-	-	-	-	-	-	-	-	-
Notes Receivable Due Within One Year		-	-	-	45.6	-	-	-	6.0	-	-	-	-	-
Total current assets		57.2	130.4	14.4	162.5	71.1	2.7	5.9	29.1	20.8	2.6	2.6	-	-
<b>Noncurrent Assets:</b>														
Notes Receivable Due After One Year		7.8	55.0	-	232.0	324.8	36.4	36.8	2.1	0.1	-	-	-	-
Investments		404.0	463.7	9.3	1,033.4	909.4	80.0	44.9	157.3	318.3	0.1	0.1	-	-
Other Investments		0.3	2.9	-	8.3	28.2	0.1	-	42.4	19.1	-	-	-	-
Depreciable/Amortizable Property, Net		-	-	-	-	-	-	-	-	-	-	-	-	-
Total Noncurrent Assets		412.1	521.6	9.3	1,273.7	1,262.3	116.6	81.7	201.8	337.4	0.1	0.1	-	-
<b>Total Assets</b>	<b>\$</b>	<b>469.2</b>	<b>\$ 651.9</b>	<b>\$ 23.7</b>	<b>\$ 1,436.2</b>	<b>\$ 1,333.4</b>	<b>\$ 119.2</b>	<b>\$ 87.7</b>	<b>\$ 230.9</b>	<b>\$ 358.2</b>	<b>\$ 2.7</b>	<b>\$ 2.7</b>	<b>\$ -</b>	<b>\$ -</b>
<b>Liabilities and Equity/Capital:</b>														
<b>Current Liabilities:</b>														
Accounts Payable	\$	0.7	\$ -	\$ -	\$ -	\$ 1.1	\$ -	\$ -	\$ -	\$ 0.0	\$ -	\$ -	\$ -	\$ -
Short Term Debt Due Within One Year		-	-	-	-	-	-	50.0	46.7	1.2	-	-	-	-
Total Current Liabilities		0.7	-	-	-	1.1	-	50.0	46.7	1.2	-	-	-	-
<b>Noncurrent Liabilities:</b>														
Long Term Debt Due After One Year / Deferred Liabilities - Long Term		-	-	-	95.0	20.0	-	378.9	40.0	132.8	-	-	-	-
Total Noncurrent Liabilities		-	-	-	95.0	20.0	-	378.9	40.0	132.8	-	-	-	-
<b>Total liabilities</b>		0.7	-	-	95.0	21.1	-	428.9	86.7	134.0	-	-	-	-
<b>Equity/Capital</b>														
Beginning Equity/Capital/Retained Earnings		417.6	3,073.2	20.9	-	-	122.9	(374.5)	154.5	226.3	2.7	2.7	-	-
Common Stock, @ Par Value		-	-	0.0	-	-	-	-	-	-	-	-	-	-
Paid in Capital		-	-	0.1	-	-	-	-	-	-	-	-	-	-
Contributions		-	-	-	1,261.3	1,257.9	-	-	0.0	-	-	-	-	-
Withdrawals		(283.7)	(2,519.4)	-	-	-	-	-	0.4	(0.0)	-	-	-	-
Current Year Earnings		334.6	98.2	2.7	79.8	54.3	(3.6)	33.3	(10.8)	(2.1)	-	-	-	-
<b>Total Equity/Capital</b>		468.5	651.9	23.7	1,341.2	1,312.2	119.2	(341.2)	144.2	224.2	2.7	2.7	-	-
<b>Total Liabilities and Equity/Capital</b>	<b>\$</b>	<b>469.2</b>	<b>\$ 651.9</b>	<b>\$ 23.7</b>	<b>\$ 1,436.2</b>	<b>\$ 1,333.4</b>	<b>\$ 119.2</b>	<b>\$ 87.7</b>	<b>\$ 230.9</b>	<b>\$ 358.2</b>	<b>\$ 2.7</b>	<b>\$ 2.7</b>	<b>\$ -</b>	<b>\$ -</b>

The above amounts have not been consolidated.

NAS2664

PROFESSIONALS' EYES ONLY/HIGHLY CONFIDENTIAL—SUBJECT TO PROPOSED PROTECTIVE ORDER AND FRE 408

This presentation may only be viewed by the professionals identified on page 2, and it may not be shared.

# 2016 Balance Sheets

19-236248-001 Doc 07422-0 Filed 08/05/21 Entered 08/05/21 15:21:28 Page 102 of 142  
Pg 343 of 725

(\$ in millions)	As of:	RMLP 12/31/16	74A 12/31/16	RMCI 12/31/16	74-AR 12/31/16	74-AJ 12/31/16	74B 12/31/16	Inv. Trust 12/31/16	1A Trust 12/31/16	2A Trust 12/31/16	1B Trust 12/31/16	2B Trust 12/31/16	74-AR IR 12/31/16	74-AJ IR 12/31/16
<b>Assets:</b>														
<b>Current Assets:</b>														
Cash and Cash Equivalents	\$	10.3	\$ 88.2	\$ 16.9	\$ 42.1	\$ 147.8	\$ 16.6	\$ 8.7	\$ 2.1	\$ 39.1	\$ 2.6	\$ 2.6	\$ -	\$ -
Accounts Receivable		0.4	0.0	0.0	0.0	0.1	-	-	0.2	11.2	-	-	-	-
Prepaid Expenses		-	-	-	-	-	-	-	-	-	-	-	-	-
Prepaid Investments		-	-	-	-	-	-	-	-	-	-	-	-	-
Notes Receivable Due Within One Year		-	-	-	163.0	197.2	-	-	7.0	-	-	-	-	-
Total current assets		10.8	88.2	16.9	205.1	345.1	16.6	8.7	9.2	50.4	2.6	2.6	-	-
<b>Noncurrent Assets:</b>														
Notes Receivable Due After One Year		7.8	159.8	-	96.4	127.6	36.4	61.8	2.1	0.1	-	-	-	-
Investments		543.7	555.8	11.2	1,269.1	949.0	74.7	41.7	253.5	311.5	0.2	0.2	-	-
Other Investments		0.3	-	-	11.8	30.3	0.1	-	1.4	15.9	-	-	-	-
Depreciable/Amortizable Property, Net		-	-	-	-	-	-	-	-	-	-	-	-	-
Total Noncurrent Assets		551.7	715.6	11.2	1,377.3	1,106.8	111.2	103.5	256.9	327.4	0.2	0.2	-	-
<b>Total Assets</b>	<b>\$</b>	<b>562.5</b>	<b>\$ 803.8</b>	<b>\$ 28.1</b>	<b>\$ 1,582.4</b>	<b>\$ 1,451.9</b>	<b>\$ 127.8</b>	<b>\$ 112.1</b>	<b>\$ 266.1</b>	<b>\$ 377.8</b>	<b>\$ 2.7</b>	<b>\$ 2.7</b>	<b>\$ -</b>	<b>\$ -</b>
<b>Liabilities and Equity/Capital:</b>														
<b>Current Liabilities:</b>														
Accounts Payable	\$	0.9	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Short Term Debt Due Within One Year		-	-	-	8.0	-	-	246.0	41.2	75.4	-	-	-	-
Total Current Liabilities		0.9	-	-	8.0	-	-	246.0	41.2	75.4	-	-	-	-
<b>Noncurrent Liabilities:</b>														
Long Term Debt Due After One Year / Deferred Liabilities - Long Term		-	-	-	150.0	69.8	-	207.9	16.6	58.6	-	-	-	-
Total Noncurrent Liabilities		-	-	-	150.0	69.8	-	207.9	16.6	58.6	-	-	-	-
<b>Total liabilities</b>		0.9	-	-	158.0	69.8	-	453.9	57.7	134.0	-	-	-	-
<b>Equity/Capital</b>														
Beginning Equity/Capital/Retained Earnings		468.5	651.9	23.6	1,341.2	1,312.2	119.2	(341.2)	144.2	224.2	2.7	2.7	-	-
Common Stock, @ Par Value		-	-	0.0	-	-	-	-	-	-	-	-	-	-
Paid in Capital		-	-	0.1	-	-	-	-	-	-	-	-	-	-
Contributions		-	-	-	7.5	10.4	-	-	-	-	-	-	-	-
Withdrawals		(206.0)	(17.9)	-	-	-	-	-	(0.1)	-	-	-	-	-
Current Year Earnings		299.0	169.8	4.4	75.7	59.5	8.6	(0.5)	64.3	19.6	-	-	-	-
<b>Total Equity/Capital</b>		561.6	803.8	28.1	1,424.4	1,382.1	127.8	(341.8)	208.4	243.8	2.7	2.7	-	-
<b>Total Liabilities and Equity/Capital</b>	<b>\$</b>	<b>562.5</b>	<b>\$ 803.8</b>	<b>\$ 28.1</b>	<b>\$ 1,582.4</b>	<b>\$ 1,451.9</b>	<b>\$ 127.8</b>	<b>\$ 112.1</b>	<b>\$ 266.1</b>	<b>\$ 377.8</b>	<b>\$ 2.7</b>	<b>\$ 2.7</b>	<b>\$ -</b>	<b>\$ -</b>

The above amounts have not been consolidated.

NAS2665

PROFESSIONALS' EYES ONLY/HIGHLY CONFIDENTIAL—SUBJECT TO PROPOSED PROTECTIVE ORDER AND FRE 408

This presentation may only be viewed by the professionals identified on page 2, and it may not be shared.



# 2017 Balance Sheets

19-236248-001 Doc 07422-0 Filed 08/05/21 Entered 08/05/21 22:28 Page 10 of 142  
Pg 344 of 725

(\$ in millions)	As of:	RMLP 12/31/17	74A 12/31/17	RMCI 12/31/17	74-AR 12/31/17	74-AJ 12/31/17	74B 12/31/17	Inv. Trust 12/31/17	1A Trust 12/31/17	2A Trust 12/31/17	1B Trust 12/31/17	2B Trust 12/31/17	74-AR IR 12/31/17	74-AJ IR 12/31/17
<b>Assets:</b>														
<b>Current Assets:</b>														
Cash and Cash Equivalents	\$	2.9	\$ 50.4	\$ 18.2	\$ 98.6	\$ 58.4	\$ 16.9	\$ 7.4	\$ 9.0	\$ 31.9	\$ 2.6	\$ 2.6	\$ -	\$ -
Accounts Receivable		0.6	0.0	-	0.2	20.1	0.0	0.0	0.3	15.1	0.0	0.0	-	-
Prepaid Expenses		-	-	-	-	-	-	-	0.0	-	-	-	-	-
Prepaid Investments		-	-	-	-	-	-	-	-	-	-	-	-	-
Notes Receivable Due Within One Year		-	56.1	-	4.0	0.8	-	2.0	2.0	-	-	-	-	-
Total current assets		3.5	106.5	18.2	102.8	79.3	16.9	9.4	11.4	47.0	2.6	2.6	-	-
<b>Noncurrent Assets:</b>														
Notes Receivable Due After One Year		7.8	168.8	-	188.2	210.6	36.4	94.8	13.6	5.7	-	-	-	-
Investments		558.1	564.6	11.3	1,440.7	1,131.1	81.6	(12.0)	864.5	964.0	0.2	0.2	-	-
Other Investments		0.3	-	-	12.2	55.8	0.2	-	-	28.7	-	-	-	-
Depreciable/Amortizable Property, Net		-	-	-	-	-	-	-	4.9	-	-	-	-	-
Total Noncurrent Assets		566.2	733.4	11.3	1,641.1	1,397.5	118.2	82.8	882.9	998.4	0.2	0.2	-	-
<b>Total Assets</b>	<b>\$</b>	<b>569.7</b>	<b>\$ 839.9</b>	<b>\$ 29.5</b>	<b>\$ 1,743.8</b>	<b>\$ 1,476.8</b>	<b>\$ 135.2</b>	<b>\$ 92.1</b>	<b>\$ 894.3</b>	<b>\$ 1,045.4</b>	<b>\$ 2.7</b>	<b>\$ 2.7</b>	<b>\$ -</b>	<b>\$ -</b>
<b>Liabilities and Equity/Capital:</b>														
<b>Current Liabilities:</b>														
Accounts Payable	\$	0.6	\$ -	\$ -	\$ -	\$ -	\$ 0.0	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Short Term Debt Due Within One Year		-	-	-	200.0	-	-	60.0	0.9	0.9	-	-	-	-
Total Current Liabilities		0.6	-	-	200.0	-	0.0	60.0	0.9	0.9	-	-	-	-
<b>Noncurrent Liabilities:</b>														
Long Term Debt Due After One Year / Deferred Liabilities - Long Term		-	-	-	-	-	-	428.9	60.9	103.5	-	-	-	-
Total Noncurrent Liabilities		-	-	-	-	-	-	428.9	60.9	103.5	-	-	-	-
<b>Total liabilities</b>		0.6	-	-	200.0	-	0.0	488.9	61.8	104.4	-	-	-	-
<b>Equity/Capital</b>														
Beginning Equity/Capital/Retained Earnings		561.6	803.8	28.1	1,424.4	1,382.1	127.8	(341.8)	208.4	243.8	2.7	2.7	-	-
Common Stock, @ Par Value		-	-	0.0	-	-	-	-	-	-	-	-	-	-
Paid in Capital		-	-	0.1	-	-	-	-	-	-	-	-	-	-
Contributions		-	-	-	2.5	2.5	-	-	-	-	-	-	-	-
Withdrawals		(82.3)	(5.0)	-	-	-	-	-	-	-	-	-	-	-
Current Year Earnings		89.8	41.1	1.4	117.0	92.2	7.3	(55.0)	624.0	697.2	0.0	0.0	-	-
<b>Total Equity/Capital</b>		569.1	839.9	29.5	1,543.8	1,476.8	135.2	(396.8)	832.5	941.1	2.7	2.7	-	-
<b>Total Liabilities and Equity/Capital</b>	<b>\$</b>	<b>569.7</b>	<b>\$ 839.9</b>	<b>\$ 29.5</b>	<b>\$ 1,743.8</b>	<b>\$ 1,476.8</b>	<b>\$ 135.2</b>	<b>\$ 92.1</b>	<b>\$ 894.3</b>	<b>\$ 1,045.4</b>	<b>\$ 2.7</b>	<b>\$ 2.7</b>	<b>\$ -</b>	<b>\$ -</b>

The above amounts have not been consolidated.

NAS2666

PROFESSIONALS' EYES ONLY/HIGHLY CONFIDENTIAL—SUBJECT TO PROPOSED PROTECTIVE ORDER AND FRE 408

This presentation may only be viewed by the professionals identified on page 2, and it may not be shared.

# 2018 Balance Sheets

19-236248-001 Doc 07422-0 Filed 08/05/21 Entered 08/05/21 14:28:38 Page 194 of 192  
Pg 345 of 725

(\$ in millions)	As of:	RMLP 12/31/18	74A 12/31/18	RMCI 12/31/18	74-AR 12/31/18	74-AJ 12/31/18	74B 12/31/18	Inv. Trust 12/31/18	1A Trust 12/31/18	2A Trust 12/31/18	1B Trust 12/31/18	2B Trust 12/31/18	74-AR IR 12/31/18	74-AJ IR 12/31/18
<b>Assets:</b>														
<b>Current Assets:</b>														
Cash and Cash Equivalents	\$	2.9	\$ 32.0	\$ 18.3	\$ 38.0	\$ 114.8	\$ 11.8	\$ 1.4	\$ 53.2	\$ 73.2	\$ 2.5	\$ 2.5	\$ -	\$ -
Accounts Receivable		0.1	0.1	-	0.9	0.4	0.0	0.0	0.2	0.3	0.0	0.0	-	-
Prepaid Expenses		-	-	-	-	-	-	-	-	-	-	-	-	-
Prepaid Investments		-	-	-	-	-	-	-	-	-	-	-	-	-
Notes Receivable Due Within One Year		-	-	-	0.6	-	-	4.0	-	-	-	-	-	-
Total current assets		3.0	32.1	18.3	39.4	115.3	11.8	5.5	53.4	73.6	2.5	2.5	-	-
<b>Noncurrent Assets:</b>														
Notes Receivable Due After One Year		7.8	224.8	-	136.2	107.2	36.4	92.8	17.7	5.7	-	-	-	-
Investments		560.6	584.6	11.4	1,595.8	1,218.7	89.1	(27.8)	772.5	859.9	0.2	0.2	-	-
Other Investments		0.3	-	-	5.3	28.3	0.1	-	-	6.4	-	-	-	-
Depreciable/Amortizable Property, Net		-	-	-	-	-	-	-	5.7	-	-	-	-	-
Total Noncurrent Assets		568.6	809.4	11.4	1,737.3	1,354.1	125.6	65.0	795.8	871.9	0.2	0.2	-	-
<b>Total Assets</b>	<b>\$</b>	<b>571.6</b>	<b>\$ 841.4</b>	<b>\$ 29.7</b>	<b>\$ 1,776.7</b>	<b>\$ 1,469.4</b>	<b>\$ 137.4</b>	<b>\$ 70.4</b>	<b>\$ 849.2</b>	<b>\$ 945.5</b>	<b>\$ 2.7</b>	<b>\$ 2.7</b>	<b>\$ -</b>	<b>\$ -</b>
<b>Liabilities and Equity/Capital:</b>														
<b>Current Liabilities:</b>														
Accounts Payable	\$	0.6	\$ -	\$ -	\$ -	\$ -	\$ 0.0	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Short Term Debt Due Within One Year		-	-	-	240.0	-	-	-	-	-	-	-	-	-
Total Current Liabilities		0.6	-	-	240.0	-	0.0	-	-	-	-	-	-	-
<b>Noncurrent Liabilities:</b>														
Long Term Debt Due After One Year / Deferred Liabilities - Long Term		-	-	-	-	-	-	488.9	2.4	-	-	-	-	-
Total Noncurrent Liabilities		-	-	-	-	-	-	488.9	2.4	-	-	-	-	-
<b>Total liabilities</b>		0.6	-	-	240.0	-	0.0	488.9	2.4	-	-	-	-	-
<b>Equity/Capital</b>														
Beginning Equity/Capital/Retained Earnings		569.1	839.9	29.4	1,543.8	1,476.8	135.2	(396.8)	832.5	941.1	2.7	2.7	-	-
Common Stock, @ Par Value		-	-	0.0	-	-	-	-	-	-	-	-	-	-
Paid in Capital		-	-	0.1	-	-	-	-	-	-	-	-	-	-
Contributions		-	-	-	-	-	-	-	-	-	-	-	-	-
Withdrawals		(1.6)	-	-	-	-	-	-	-	-	-	-	-	-
Current Year Earnings		3.6	1.6	0.2	(7.1)	(7.4)	2.2	(21.7)	14.3	4.4	(0.0)	(0.0)	-	-
<b>Total Equity/Capital</b>		571.0	841.4	29.7	1,536.7	1,469.4	137.4	(418.5)	846.8	945.5	2.7	2.7	-	-
<b>Total Liabilities and Equity/Capital</b>	<b>\$</b>	<b>571.6</b>	<b>\$ 841.4</b>	<b>\$ 29.7</b>	<b>\$ 1,776.7</b>	<b>\$ 1,469.4</b>	<b>\$ 137.4</b>	<b>\$ 70.4</b>	<b>\$ 849.2</b>	<b>\$ 945.5</b>	<b>\$ 2.7</b>	<b>\$ 2.7</b>	<b>\$ -</b>	<b>\$ -</b>

The above amounts have not been consolidated.

NAS2667

PROFESSIONALS' EYES ONLY/HIGHLY CONFIDENTIAL—SUBJECT TO PROPOSED PROTECTIVE ORDER AND FRE 408

This presentation may only be viewed by the professionals identified on page 2, and it may not be shared.

# 2019 Balance Sheets

19-23648-001 Doc 07422-0 Filed 08/05/21 Entered 08/05/21 15:24:28 Page 15 of 142  
Pg 346 of 725

(\$ in millions)	As of:	RMLP	74A	RMCI	74-AR	74-AJ	74B	Inv. Trust	1A Trust	2A Trust	1B Trust	2B Trust	74-AR IR	74-AJ IR												
		12/31/19	12/31/19	12/31/19	12/31/19	12/31/19	12/31/19	12/31/19	12/31/19	12/31/19	12/31/19	12/31/19	12/31/19	12/31/19												
<b>Assets:</b>																										
<b>Current Assets:</b>																										
Cash and Cash Equivalents	\$	38.8	\$	35.7	\$	0.5	\$	2.2	\$	0.6	\$	7.5	\$	0.6	\$	21.8	\$	129.1	\$	2.6	\$	2.6	\$	25.9	\$	71.2
Accounts Receivable		0.0		0.0		-		1.6		0.5		0.0		0.2		0.2		-		-		-		0.1		0.1
Prepaid Expenses		-		-		-		-		-		-		-		-		-		-		-		-		-
Prepaid Investments		-		-		-		-		-		-		-		-		-		-		-		-		-
Notes Receivable Due Within One Year		-		-		-		-		-		-		-		-		-		-		-		3.3		-
Total current assets		38.8		35.7		0.5		3.9		1.2		7.5		0.6		21.9		129.3		2.6		2.6		29.3		71.3
<b>Noncurrent Assets:</b>																										
Notes Receivable Due After One Year		7.8		245.8		18.0		-		-		36.4		92.8		17.7		5.7		-		-		137.3		107.2
Investments		622.2		640.0		11.8		162.0		13.6		101.6		(56.1)		837.0		910.6		0.2		0.2		1,496.1		1,355.5
Other Investments		0.3		1.0		-		-		4.1		0.1		-		0.0		10.0		-		-		5.7		32.0
Depreciable/Amorizable Property, Net		-		-		-		-		-		-		-		5.7		-		-		-		-		-
Total Noncurrent Assets		630.3		886.8		29.8		162.0		17.7		138.1		36.7		860.3		926.3		0.2		0.2		1,639.1		1,494.7
<b>Total Assets</b>	<b>\$</b>	<b>669.1</b>	<b>\$</b>	<b>922.4</b>	<b>\$</b>	<b>30.3</b>	<b>\$</b>	<b>165.9</b>	<b>\$</b>	<b>18.8</b>	<b>\$</b>	<b>145.7</b>	<b>\$</b>	<b>37.3</b>	<b>\$</b>	<b>882.3</b>	<b>\$</b>	<b>1,055.6</b>	<b>\$</b>	<b>2.8</b>	<b>\$</b>	<b>2.8</b>	<b>\$</b>	<b>1,668.4</b>	<b>\$</b>	<b>1,566.0</b>
<b>Liabilities and Equity/Capital:</b>																										
<b>Current Liabilities:</b>																										
Accounts Payable	\$	0.3	\$	-	\$	-	\$	-	\$	0.0	\$	-	\$	-	\$	-	\$	-	\$	-	\$	-	\$	0.2	\$	-
Short Term Debt Due Within One Year		-		-		-		-		-		-		-		-		-		-		-		140.0		-
Total Current Liabilities		0.3		-		-		-		0.0		-		-		-		-		-		-		140.2		-
<b>Noncurrent Liabilities:</b>																										
Long Term Debt Due After One Year / Deferred Liabilities - Long Term		39.0		-		-		-		-		488.9		2.4		-		-		-		-		-		-
Total Noncurrent Liabilities		39.0		-		-		-		-		488.9		2.4		-		-		-		-		-		-
<b>Total liabilities</b>		39.3		-		-		-		0.0		488.9		2.4		-		-		-		-		140.2		-
<b>Equity/Capital</b>																										
Beginning Equity/Capital/Retained Earnings		571.0		841.4		29.6		1,536.7		1,469.4		137.4		(418.5)		846.8		945.5		2.7		2.7		-		-
Common Stock, @ Par Value		-		-		0.0		-		-		-		-		-		-		-		-		-		-
Paid in Capital		-		-		0.1		-		-		-		-		-		-		-		-		-		-
Contributions		41.0		-		-		-		5.3		-		-		-		-		-		-		1,519.6		1,534.0
Withdrawals		-		-		-		(1,527.6)		(1,533.8)		-		-		-		-		-		-		(10.8)		(23.0)
Current Year Earnings		17.7		81.0		0.6		156.8		77.9		8.3		(33.1)		33.1		110.1		0.1		0.1		19.4		55.0
<b>Total Equity/Capital</b>		629.7		922.4		30.3		165.9		18.8		145.7		(451.6)		879.9		1,055.5		2.8		2.8		1,528.2		1,566.0
<b>Total Liabilities and Equity/Capital</b>	<b>\$</b>	<b>669.1</b>	<b>\$</b>	<b>922.4</b>	<b>\$</b>	<b>30.3</b>	<b>\$</b>	<b>165.9</b>	<b>\$</b>	<b>18.8</b>	<b>\$</b>	<b>145.7</b>	<b>\$</b>	<b>37.3</b>	<b>\$</b>	<b>882.3</b>	<b>\$</b>	<b>1,055.5</b>	<b>\$</b>	<b>2.8</b>	<b>\$</b>	<b>2.8</b>	<b>\$</b>	<b>1,668.4</b>	<b>\$</b>	<b>1,566.0</b>

The above amounts have not been consolidated.

NAS2668

PROFESSIONALS' EYES ONLY/HIGHLY CONFIDENTIAL—SUBJECT TO PROPOSED PROTECTIVE ORDER AND FRE 408

This presentation may only be viewed by the professionals identified on page 2, and it may not be shared.

# March 31, 2020 Balance Sheets

(\$ in millions)	As of:	RMLP 03/31/20	74A 03/31/20	RMCI 03/31/20	74-AR 03/31/20	74-AJ 03/31/20	74B 03/31/20	Inv. Trust 03/31/20	1A Trust 03/31/20	2A Trust 03/31/20	1B Trust 03/31/20	2B Trust 03/31/20	74-AR IR 03/31/20	74-AJ IR 03/31/20
<b>Assets:</b>														
<b>Current Assets:</b>														
Cash and Cash Equivalents	\$	31.2	\$ 24.7	\$ 0.3	\$ 2.2	\$ 0.5	\$ 6.2	\$ 0.6	\$ 8.1	\$ 137.2	\$ 2.6	\$ 2.6	\$ 47.5	\$ 77.1
Accounts Receivable		0.0	0.0	-	0.1	0.5	-	-	0.2	0.2	-	-	30.3	-
Prepaid Expenses		-	-	-	-	-	-	-	-	-	-	-	-	-
Prepaid Investments		-	-	-	-	-	-	-	-	-	-	-	-	-
Notes Receivable Due Within One Year		-	-	-	-	-	-	-	-	-	-	-	3.3	-
Total current assets		31.2	24.7	0.3	2.3	1.0	6.2	0.6	8.2	137.3	2.6	2.6	81.2	77.1
<b>Noncurrent Assets:</b>														
Notes Receivable Due After One Year		7.8	245.8	18.0	-	13.9	36.4	92.8	17.7	5.7	-	-	137.3	107.2
Investments		622.6	633.1	11.6	14.7	-	102.5	(79.3)	844.1	861.8	0.2	0.2	1,504.8	1,272.0
Other Investments		0.3	-	-	-	-	0.1	-	0.0	6.1	-	-	3.4	25.7
Depreciable/Amortizable Property, Net		-	-	-	-	-	-	-	5.7	-	-	-	-	-
Total Noncurrent Assets		630.6	878.9	29.6	14.7	13.9	139.1	13.5	867.5	873.6	0.2	0.2	1,645.5	1,404.9
<b>Total Assets</b>	<b>\$</b>	<b>661.9</b>	<b>\$ 903.5</b>	<b>\$ 29.9</b>	<b>\$ 17.0</b>	<b>\$ 14.9</b>	<b>\$ 145.3</b>	<b>\$ 14.2</b>	<b>\$ 875.7</b>	<b>\$ 1,011.0</b>	<b>\$ 2.8</b>	<b>\$ 2.8</b>	<b>\$ 1,726.6</b>	<b>\$ 1,482.0</b>
<b>Liabilities and Equity/Capital:</b>														
<b>Current Liabilities:</b>														
Accounts Payable	\$	0.3	\$ -	\$ -	\$ -	\$ -	\$ 0.0	\$ -	\$ 0.0	\$ -	\$ -	\$ -	\$ -	\$ -
Short Term Debt Due Within One Year		-	-	-	-	-	-	-	30.0	-	-	-	140.0	-
Total Current Liabilities		0.3	-	-	-	-	0.0	-	30.0	-	-	-	140.0	-
<b>Noncurrent Liabilities:</b>														
Long Term Debt Due After One Year / Deferred Liabilities - Long Term		39.0	-	-	-	-	-	488.9	2.4	-	-	-	-	-
Total Noncurrent Liabilities		39.0	-	-	-	-	-	488.9	2.4	-	-	-	-	-
<b>Total liabilities</b>		39.3	-	-	-	-	0.0	488.9	32.4	-	-	-	140.0	-
<b>Equity/Capital</b>														
Beginning Equity/Capital/Retained Earnings		623.2	916.0	30.1	165.9	18.8	145.7	(451.6)	879.9	1,049.3	2.8	2.8	1,526.5	1,565.7
Common Stock, @ Par Value		-	-	0.0	-	-	-	-	-	-	-	-	-	-
Paid in Capital		-	-	0.1	-	-	-	-	-	-	-	-	-	-
Contributions		12.0	-	-	25.0	10.2	-	-	-	-	-	-	144.2	4.0
Withdrawals		-	-	-	(144.2)	(4.0)	-	-	-	-	-	-	(25.0)	(10.2)
Current Period Earnings		(12.6)	(12.5)	(0.3)	(29.7)	(10.1)	(0.4)	(23.1)	(36.5)	(38.3)	(0.0)	(0.0)	(59.0)	(77.6)
<b>Total Equity/Capital</b>		622.5	903.5	29.9	17.0	14.9	145.3	(474.7)	843.3	1,011.0	2.8	2.8	1,586.6	1,482.0
<b>Total Liabilities and Equity/Capital</b>	<b>\$</b>	<b>661.9</b>	<b>\$ 903.5</b>	<b>\$ 29.9</b>	<b>\$ 17.0</b>	<b>\$ 14.9</b>	<b>\$ 145.3</b>	<b>\$ 14.2</b>	<b>\$ 875.7</b>	<b>\$ 1,011.0</b>	<b>\$ 2.8</b>	<b>\$ 2.8</b>	<b>\$ 1,726.6</b>	<b>\$ 1,482.0</b>

The above amounts have not been consolidated.

NAS2669

PROFESSIONALS' EYES ONLY/HIGHLY CONFIDENTIAL—SUBJECT TO PROPOSED PROTECTIVE ORDER AND FRE 408

This presentation may only be viewed by the professionals identified on page 2, and it may not be shared.

# Appendix E: 2008 - 2020 ICSP Sources of Wage and Consulting Income

# 2008 – 2020 IGSP Sources of Wage and Consulting Income

Jonathan D. Sackler

(Actual Dollars)	Total	Cheyenne Petroleum Co	Summer Road LLC	Purdue Pharma LP <sup>1</sup>	Mundipharma Vertriebs-GmbH & Co	Rosebay Medical Company Inc	WA Canada LP	Mundipharma AG - Switzerland	Mundipharma Lab GmbH	Napp Pharmaceutical Group	Other 3rd Party
2008	\$ 707,626	\$ 170,000	\$ -	\$ 184	\$ 99,161	\$ 100,000	\$ 1,000	\$ -	\$ 183,016	\$ 154,265	\$ -
2009	715,706	170,000	-	184	99,350	100,000	1,000	-	184,467	160,705	-
2010	929,757	192,000	-	313	96,997	290,000	1,000	-	190,862	158,585	-
2011	821,632	192,000	-	243	106,267	140,000	1,000	-	225,482	156,640	-
2012	690,830	192,000	-	202	102,676	140,000	1,000	-	214,456	40,496	-
2013	699,270	192,000	-	387	109,639	140,000	1,000	-	215,500	40,744	-
2014	703,631	192,000	-	1,263	113,555	140,000	1,000	-	216,722	39,091	-
2015	1,176,691	192,000	-	658	98,195	640,000	1,000	-	207,608	37,230	-
2016	848,421	192,000	-	363	99,537	320,000	1,000	-	203,712	31,809	-
2017	477,506	192,000	-	170	-	-	1,000	-	203,811	80,525	-
2018	473,125	192,000	-	467	-	-	1,000	-	205,880	73,778	-
2019	394,151	192,000	-	-	-	-	1,000	-	201,151	-	-
2020 (thru 3/31)	100,517	48,000	-	-	-	-	-	-	52,517	-	-
	<u>\$ 8,738,863</u>	<u>\$ 2,308,000</u>	<u>\$ -</u>	<u>\$ 4,434</u>	<u>\$ 925,377</u>	<u>\$ 2,010,000</u>	<u>\$ 12,000</u>	<u>\$ -</u>	<u>\$ 2,505,184</u>	<u>\$ 973,868</u>	<u>\$ -</u>

1 This amount differs by \$30,000 from the AlixPartners Cash Transfers of Value Analysis report primarily due to differences in accounting adjustments made by Purdue and North Bay Associates

Source: Federal Income Tax Returns (2008 - 2018) & North Bay prepared records (2019 - 2020)

Table includes amounts in addition to what is referenced in the sources and uses of cash.

**NAS2671**

PROFESSIONALS' EYES ONLY/HIGHLY CONFIDENTIAL—SUBJECT TO PROPOSED PROTECTIVE ORDER AND FRE 408

This presentation may only be viewed by the professionals identified on page 2, and it may not be shared.

# 2008 – 2020 IGSP Sources of Wage and Consulting Income

Richard S. Sackler

(Actual Dollars)	Total	Cheyenne Petroleum Co	Summer Road LLC	Purdue Pharma LP <sup>1</sup>	Mundipharma Vertriebs-GmbH & Co	Rosebay Medical Company Inc	WA Canada LP	Mundipharma AG - Switzerland	Mundipharma Lab GmbH	Napp Pharmaceutical Group	Other 3rd Party
2008	\$ 758,947	\$ 56,000	\$ -	\$ 236	\$ 336,501	\$ 75,000	\$ 1,000	\$ 137,310	\$ -	\$ 152,900	\$ -
2009	771,569	56,000	-	236	337,143	75,000	1,000	138,485	-	160,705	3,000
2010	787,797	56,000	-	15,825	329,181	75,000	1,000	143,206	-	158,585	9,000
2011	830,737	56,000	-	9,312	360,614	75,000	1,000	169,171	-	156,640	3,000
2012	672,210	56,000	-	303	348,480	75,000	1,000	160,890	-	27,537	3,000
2013	688,475	56,000	-	488	372,366	75,000	1,000	161,673	-	12,948	9,000
2014	700,642	56,000	-	1,175	385,348	75,000	1,000	162,590	-	19,529	-
2015	640,601	56,000	-	1,072	333,222	75,000	1,000	155,754	-	18,553	-
2016	691,478	56,000	90,000	433	337,809	37,500	1,000	152,832	-	15,904	-
2017	431,010	56,500	180,000	342	-	-	1,000	152,906	-	40,262	-
2018	529,976	56,500	180,000	467	-	-	1,000	255,178	-	36,831	-
2019	639,911	308,000	180,000	-	-	-	1,000	150,911	-	-	-
2020 (thru 3/31)	120,649	36,250	45,000	-	-	-	-	39,399	-	-	-
	<u>\$ 8,264,002</u>	<u>\$ 961,250</u>	<u>\$ 675,000</u>	<u>\$ 29,889</u>	<u>\$ 3,140,664</u>	<u>\$ 637,500</u>	<u>\$ 12,000</u>	<u>\$ 1,980,305</u>	<u>\$ -</u>	<u>\$ 800,394</u>	<u>\$ 27,000</u>

1 This amount differs by \$6,200 from the AlixPartners Cash Transfers of Value Analysis report primarily due to differences in accounting adjustments made by Purdue and North Bay Associates

Source: Federal Income Tax Returns (2008 - 2018) & North Bay prepared records (2019 - 2020)

Table includes amounts in addition to what is referenced in the sources and uses of cash.

**NAS2672**

PROFESSIONALS' EYES ONLY/HIGHLY CONFIDENTIAL—SUBJECT TO PROPOSED PROTECTIVE ORDER AND FRE 408

This presentation may only be viewed by the professionals identified on page 2, and it may not be shared.

# 2008 – 2020 IGSP Sources of Wage and Consulting Income

David A. Sackler

(Actual Dollars)	Total	Cheyenne Petroleum Co	Summer Road LLC	Purdue Pharma LP <sup>1</sup>	Mundipharma Vertriebs-GmbH & Co	Rosebay Medical Company Inc	WA Canada LP	Mundipharma AG - Switzerland	Mundipharma Lab GmbH	Napp Pharmaceutical Group	Other 3rd Party
2008	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
2009	1,477	-	-	1,477	-	-	-	-	-	-	-
2010	2,400	-	-	2,400	-	-	-	-	-	-	-
2011	2,400	-	-	2,400	-	-	-	-	-	-	-
2012	15,329	-	-	2,400	-	-	-	-	-	12,929	-
2013	211,988	-	183,333	981	-	-	-	-	-	27,674	-
2014	202,350	-	182,357	386	-	-	-	-	-	19,607	-
2015	3,819,478	-	3,300,285	622	-	500,000	-	-	-	18,571	-
2016	2,812,373	-	2,546,007	312	-	250,000	-	-	-	16,054	-
2017	2,602,435	-	2,562,865	21	-	-	-	-	-	39,549	-
2018	2,363,975	-	2,326,993	200	-	-	-	-	-	36,782	-
2019	3,132,037	-	3,132,037	-	-	-	-	-	-	-	-
2020 (thru 3/31)	2,761,750	-	2,761,750	-	-	-	-	-	-	-	-
	<u>\$ 17,927,992</u>	<u>\$ -</u>	<u>\$ 16,995,627</u>	<u>\$ 11,199</u>	<u>\$ -</u>	<u>\$ 750,000</u>	<u>\$ -</u>	<u>\$ -</u>	<u>\$ -</u>	<u>\$ 171,166</u>	<u>\$ -</u>

1 This amount differs by \$24,000 from the AlixPartners Cash Transfers of Value Analysis report primarily due to differences in accounting adjustments made by Purdue and North Bay Associates

Source: Federal Income Tax Returns (2008 - 2018) & North Bay prepared records (2019 - 2020)

Table includes amounts in addition to what is referenced in the sources and uses of cash.

**NAS2673**

PROFESSIONALS' EYES ONLY/HIGHLY CONFIDENTIAL—SUBJECT TO PROPOSED PROTECTIVE ORDER AND FRE 408

This presentation may only be viewed by the professionals identified on page 2, and it may not be shared.



# 2008 – 2020 IGSP Sources of Wage and Consulting Income

Raymond R. Sackler

(Actual Dollars)	Total	Cheyenne Petroleum Co	Summer Road LLC	Purdue Pharma LP <sup>1</sup>	Mundipharma Vertriebs-GmbH & Co	Rosebay Medical Company Inc	WA Canada LP	Mundipharma AG - Switzerland	Mundipharma Lab GmbH	Napp Pharmaceutical Group	Other 3rd Party
2008	\$ 866,134	\$ 115,500	\$ -	\$ 804	\$ 528,248	\$ -	\$ -	\$ 183,016	\$ -	\$ 38,566	\$ -
2009	867,380	115,500	-	804	526,333	-	-	184,567	-	40,176	-
2010	862,947	115,500	-	674	516,265	-	-	190,862	-	39,646	-
2011	949,100	115,500	-	495	568,463	-	-	225,482	-	39,160	-
2012	1,039,194	115,500	-	335	546,918	-	-	214,456	-	161,985	-
2013	1,077,734	115,500	-	158	583,601	-	-	215,500	-	162,975	-
2014	1,096,405	115,500	-	137	607,681	-	-	216,722	-	156,365	-
2015	997,553	115,500	-	319	525,206	-	-	207,608	-	148,920	-
2016	978,713	115,500	-	154	532,111	-	-	203,712	-	127,236	-
2017	238,184	63,176	-	154	-	-	-	101,061	-	73,793	-
2018	-	-	-	-	-	-	-	-	-	-	-
2019	-	-	-	-	-	-	-	-	-	-	-
2020 (thru 3/31)	-	-	-	-	-	-	-	-	-	-	-
	<u>\$ 8,973,344</u>	<u>\$ 1,102,676</u>	<u>\$ -</u>	<u>\$ 4,034</u>	<u>\$ 4,934,826</u>	<u>\$ -</u>	<u>\$ -</u>	<u>\$ 1,942,986</u>	<u>\$ -</u>	<u>\$ 988,822</u>	<u>\$ -</u>

1 This amount differs by \$20,000 from the AlixPartners Cash Transfers of Value Analysis report primarily due to differences in accounting adjustments made by Purdue and North Bay Associates

Source: Federal Income Tax Returns (2008 - 2018) & North Bay prepared records (2019 - 2020)

Table includes amounts in addition to what is referenced in the sources and uses of cash.

**NAS2674**

PROFESSIONALS' EYES ONLY/HIGHLY CONFIDENTIAL—SUBJECT TO PROPOSED PROTECTIVE ORDER AND FRE 408

This presentation may only be viewed by the professionals identified on page 2, and it may not be shared.

# 2008 – 2020 IGSP Sources of Wage and Consulting Income

Beverly Sackler

(Actual Dollars)	Total	Cheyenne Petroleum Co	Summer Road LLC	Purdue Pharma LP <sup>1</sup>	Mundipharma Vertriebs-GmbH & Co	Rosebay Medical Company Inc	WA Canada LP	Mundipharma AG - Switzerland	Mundipharma Lab GmbH	Napp Pharmaceutical Group	Other 3rd Party
2008	\$ 38,566	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 38,566	\$ -
2009	40,176	-	-	-	-	-	-	-	-	40,176	-
2010	39,646	-	-	-	-	-	-	-	-	39,646	-
2011	39,160	-	-	-	-	-	-	-	-	39,160	-
2012	161,985	-	-	-	-	-	-	-	-	161,985	-
2013	162,975	-	-	-	-	-	-	-	-	162,975	-
2014	156,365	-	-	-	-	-	-	-	-	156,365	-
2015	148,920	-	-	-	-	-	-	-	-	148,920	-
2016	127,236	-	-	-	-	-	-	-	-	127,236	-
2017	108,120	-	-	-	-	-	-	-	-	108,120	-
2018	312	312	-	-	-	-	-	-	-	-	-
2019	-	-	-	-	-	-	-	-	-	-	-
2020 (thru 3/31)	-	-	-	-	-	-	-	-	-	-	-
	<u>\$ 1,023,461</u>	<u>\$ 312</u>	<u>\$ -</u>	<u>\$ -</u>	<u>\$ -</u>	<u>\$ -</u>	<u>\$ -</u>	<u>\$ -</u>	<u>\$ -</u>	<u>\$ 1,023,149</u>	<u>\$ -</u>

1 This amount differs by \$300 from the AlixPartners Cash Transfers of Value Analysis report primarily due to differences in accounting adjustments made by Purdue and North Bay Associates

Source: Federal Income Tax Returns (2008 - 2018) & North Bay prepared records (2019 - 2020)

Table includes amounts in addition to what is referenced in the sources and uses of cash.

**NAS2675**

PROFESSIONALS' EYES ONLY/HIGHLY CONFIDENTIAL—SUBJECT TO PROPOSED PROTECTIVE ORDER AND FRE 408

This presentation may only be viewed by the professionals identified on page 2, and it may not be shared.